,ticker,content
0,TMO,more more quality stock idea be breaking upside hit new high general market power higher nasdaq be pace day streak close month august result number burgeon stock move xibd member centene cnc
1,TMO,thermo fisher scientific tmo have relative strength rs rating upgrade tuesday welcome improvement still shy higher score prefer see exclusive rating investor business daily identify share price movement worst best score score show stock price behavior trail week compare other stock database year market history reveal market biggest winner typically have rs rating early stage move see thermo fisher scientific continue show renew price strength hit benchmark thermo fisher scientific have rise more past entry first stage flat base meaning now proper buy zone look stock create new buy opportunity week tight pullback day week line company post earning growth latest quarterly report revenue increase company hold rank peer medical research equipment service industry group health science prah quintile im icon iclr be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
2,TMO,thank gilead kite merger biotechs have big week ve also rally year longer haul top health sector etfs rank year date return aug be biotech focuse accord morningstar direct top performer spdr biotech xbi post gain well ahead advance etf featured monday etf leader column break past flat base entry thursday remain buy range share run june flat base start just clear pattern fund launch january have asset bear expense ratio come second be first trust nyse arca biotech fbt ytd gain etf be buy zone past flat base entry year old fund track nyse arca biotechnology index have attract asset carry expense ratio count top holding aug kite pharma kite juno therapeutic juno illumina ilmn kite gap soar aug gilead science gild announce buy kite xbi mentioned also get boost kite ishare medical device ihi take third place ytd return etf recently regain day move average line shape flat base potential buy point fund marked anniversary track dow jone select medical equipment index ibd take gilead science have be news lately due kite pharma acquisition do rank biotechs find now ibd stock checkup top holding aug include medtronic mdt abbott laboratory thermo fisher scientific tmo ihi expense ratio be ishare nasdaq biotechnology ibb round top ytd gain price action be similar other biotech etfs buy range follow thursday flat base buy point case be etf sport expense ratio ibb oldest biotechs year have amassed asset top holding aug be gilead biogen biib celgene celg kite account position portfolio fund have beaten past year return vs gain fund have outperformed past year related gilead science buy kite pharma sector boost stock breakout put apple amazon focusretail lead broad stock sell biotechs find support celgene flirt giant soon join
3,TMO,medical related exchange trade fund have rac healthy gain year ongoing quest longer healthier life outperformer be ishare medical device ihi gain year date well ahead gain period fund boast year average annual return vs benchmark index accord morningstar inc ihi launch track dow jone select medical equipment index top holding etf include medtronic mdt abbott laboratory thermo fisher scientific tmo abbott developer generic drug disease screening system other product be buy range clear flat base entry thursday xihi be etf pick featured ibd last month oscar pursche chief executive bruderman brother bruderman asset management opposed take broad view health care sector do overall see great opportunity medical device space investor get exposure ishare medical device etf say also note fund top holding account nearly portfolio increase risk profile ihi be extend past buy point clear april ibd take find biotechs stand benefit most president trump propose tax reform recent tech column spdr health care equipment xhe return ytd year average year old fund track health care equipment select industry index have gather asset top holding include align technology algn intuitive surgical isrg edward lifescience ew account portfolio xhe be trading record high be extend recent bounce day line spdr biotech xbi year have average annual gain past year fund launch january be form flat base buy point entry still july peak vertex pharmaceutical vrtx regeneron pharmaceutical regn abbvie abbv be top name hold xbi top holding make asset related be best health care etf gop move replace etf ride industry recovery
4,TMO,here investing action plan thursday need know investor come day lull just earning season begin next week make quiet calendar be several stock near buy point include broadcom avgo thermo fisher tmo stryker syk deutsche bank db also be address major
5,TMO,ishare medical device etf ihi find high most holding participate hottest segment medical sector year most stock fund fall ibd industry group medical product medical system equipment have be top ibd group many week have best year date performance group make medical sector medical system equipment be group medical product group have climb market low june however biotechs generic drug stock have make much stronger gain still medical equipment subset be period product group be better nearly other health care group win find pharmaceutical company ishare medical device rather company provide tool develop drug help patient deal medical problem indeed company product offering span syringe heart valf robotic surgical system etf be more be try break past buy point flat base hold day move average better chance rise past entry share have best run february early august etf chart closely resemble largest hold medtronic mdt stock have be form shallow base be new high many product medtronic make insulin pump ear infection treatment coronary stent brain stimulus device treat nervous system disorder thermo fischer scientific tmo fund second largest hold rally most september also be near new high company be research equipment service industry group make medical research instrument complete acquisition fei maker high performance microscope acquisition have be part story medical device industry not always result stock gain dhr have be drag portfolio stock be base nicely high august start tumble announcement be acquire cepheid cphd make system fast genetic testing abbott laboratory nearly weighting etf also hasn be much contributor share remain lock month old consolidation ishare medical device have average annual return year year ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list related buy cepheid expand diagnostic business
6,TMO,gene sequence giant illumina ilmn touch month high intraday thursday report receive buyout offer rival thermo fisher scientific tmo wall street be skeptical street insider cite unnamed source say thermo fisher have make stock offer illumina worth be current market cap cowen analyst doug schenkel say be close probability be actually true premium be too low appeal illumina argue too expensive thermo fisher require thermo fisher issue share assume thermo fisher share continue not be pressured spite report schenkel write research note assumption render deal dilutive thermo fisher ep basis illumina stock open slightly higher then jump news break mid morning share hit month high market close be thermo fisher stock dip ibd take illumina be once top rate stock have fall hard time investor see sell signal be able get time keep money explain last fall investor corner well fargo analyst tim evan be also dubious think deal encounter significant regulatory hurdle give illumina hold monopoly high throughput sequence thermo fisher scientific be only current competitor material scale desktop sequence evan write note add overlap business lead revenue dys synergy suggest have cut back overlapping product
7,TMO,illumina ilmn rise much highest level january report thermo fisher scientific tmo make offer maker gene sequence equipment stock offer doesn include cash component streetinsider com report cite unnamed person knowledge matter san diego base illumina rise et waltham mass base thermo fisher fall less illumina reject acquisition attempt roche hold rhhby include value illumina annual revenue have more double reach representative illumina thermo fisher couldn be reach comment
8,TMO,ishare medical device etf ihi be year top etf leader ride best part mixed health care sector year medical sector have diverged industry fare much better other biotechs other drugmaker be roughly ibd medical product equipment industry group be only diversify medical company be do quite well health care much outperformance medical device owe superior result top manufacturer innovation have play key role ignite industry leader stock etf medtronic mdt be largest hold more portfolio share have climb much buy point april stock have perform decently fact earning have be basically flat quarters outlook be improve analyst expect profit rise fiscal year end april next year investor day june medtronic forecast mid single digit revenue growth develop product pipeline draw diversify market edward lifescience ew be stock have shoulder etf advance share be time high main move year be april company announce sapien transcatheter aortic valve replacement be show reduce death heart attack patient moderate risk open heart surgery share soar news medtronic corevalve compete edward heart valve replacement patient not able have open heart surgery analyst canaccord genuity remain bullish stock follow earning report say dominate market transcatheter aortic valve replacement show potential market expansion share stryker syk have broadest range orthopedic product peer have climb much year fall sharply july earning report be clear explanation slide other softness emerge market other key contributor ishare medical device be thermo fisher scientific tmo make equipment medical research zimmer biomet zbh just post strongest quarter sale growth nearly decade becton dickinson bdx have be trend higher fall sharply thursday cut full year sale forecast cite currency headwind etf be extend april pullback day move average june remain buy point week tight pattern form july ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list
9,TMO,democratic presidential candidate hillary clinton health care plan release weekend have positive impact company medical hardware development market say evercore isi analyst ross muken write research report clinton plan encourage research development spending give boost provider life science tool service used pharmaceutical development add focus generic biosimilar add additional leg growth pharma end market largely continue benefit chromatography agilent thermo fisher scientific tmo water separation player pall dhr muken write potential offset be increase scrutiny drug pricing lead fewer total dollar spend view unlikely stock be currently highly rate ibd metric especially hold highest possible composite rating be trading time high stock close stock market today touch record high friday agilent share fall thermo fisher also lose water ease clinton also want clear backlog generic drug application fda shorten year exclusivity period grant biosimilar drug muken say accelerate production company make drug drive business contract research organization cro additionally plan intention hold drug company accountable require value base study justify high drug price accelerate pharma adoption real world datum service say adoption provide cro avenue growth outside traditional clinical trial outsource be reason highlighted quintile management quintile im health im merger parexel prxl have also name real world datum service growth driver muken note quintile stock middling cr fall monday parexel hold excellent ibd ep rank dip less outlook be more mixed clinical device system hand plan succeed expand number cover life help boost demand thing orthopedic cardiovascular implant focus woman health be positive hologic holx muken write other hand increase pricing pressure already be dog industry player medtronic mdt be already shift value base business model be best position next leg evolution health care space muken write medtronic stock strong cr hit new intraday high monday close hologic stock have be consolidate company go financial turnaround fall
10,TMO,gene sequence giant illumina ilmn be slide stock market tuesday morgan stanley downgrade base negative trend key market analyst steve beuchaw cut rating underweight lower price target illumina stock also lower valuation cancer franchise cite reimbursement pressure medicare medicaid well rise immunotherapy cancer don require genetic testing beuchaw also describe trend academic research channel outsource genome sequence centralize lab reduce need locally install machine add however wasn negative call entire genomic space remain positive share gainer emerge category genomic notably natera ntra nanostring nstg market be earlier stage development write downgrade note qiagen qgen be emerge player sequence hardware expectation be likely too low genereader beuchaw add recovery genomic market seem be tie microarray be positive thermo fisher scientific tmo agilent illumina stock fall month low early trading stock market today close beuchaw positive remark rival be also sink qiagen stock fall natera lose thermo fisher retreat agilent fall nanostring rise
11,TMO,life science instrument giant thermo fisher scientific tmo agree buy electron microscope maker fei company feic cash share friday send fei share soar life science be grow adoption electron microscopy study structure protein thermo fisher ceo marc casper say statement technology gain fei complement mass spectrometry leadership putt thermo fisher best position capitalize important trend add deal be immediately accretive earning fei be profitable company ibd ep rank revenue growth have be lack last couple year casper however say thermo fisher expand fei biopharma research market evercore isi analyst ross muken describe white hot ultimately view acquisition nice tuck thermo fisher be buy electron microscopy low point cycle least hope likely help support thermo fisher core growth forecast lieu slowdown pharma spend muken write email client fei stock leap stock market today slightly offer price year high time close high thermo fisher stock climb fresh record high leerink analyst dan leonard note qiagen qgen bruker brkr agilent have be speculate buyout target thermo fisher trade news bruker perhaps suffer also feic cryo technology be view investor threat bruker nuclear magnetic resonance nmr technology comprise less bruker sale add research note qiagen bruker agilent rise less friday
12,TMO,busy morning headline fuel modest gain major average early friday even fei corp feic ulta beauty ulta veeva system veev palo alto network panw make double digit move nasdaq add dow jone industrial gain apiece stock market today volume be light ahead memorial day weekend deal news lab equipment maker thermo fisher scientific tmo agree buy fei corp maker high end electron microscope cash earlier year thermo fisher complete acquisition affymetrix just share thermo fisher edge higher news fei soar early gainer dow include nike nke share rise nearly be nowhere proper entry several week institutional selling earlier week competitor armour ua inked exclusive year sponsorship deal ucla worth estimate earning front couple ibd component make nice move ulta beauty soar report accelerate earning sale growth late thursday veeva system meanwhile jump software firm deliver second straight quarter accelerate sale growth stock be extend buy point downside former leader palo alto network plunge disappointing earning earning sale growth decelerate again prompt negative analyst commentary economic news revision gdp show growth slightly consensus estimate initial read rise new york mercantile exchange crude oil july delivery lose barrel
13,TMO,mild pullback april again mid low volatility etfs be upswing again strategy cushion portfolio big market drawdown one investor see early year powershare midcap low volatility xmlv post fresh week high stock market today bolt rs line be sign be outperform benchmark exchange trade fund invest roughly least volatile midcap stock include salvage car auctioneer copart cprt rank ibd auto part industry group stock lowest price volatility get biggest weighting xmlv portfolio however industry expert strike note caution popular asset class low volatility etfs tend be stuffed more establish dividend pay name potential fed interest rate hike june july dent high dividend sector such utility consumer staple todd rosenbluth director etf research global market intelligence write june research note precede friday dismal job report be perceive set back likelihood imminent rate hike rosenbluth suggest investor want consider small new rival hugely popular ishare edge msci minimum volatility usmv powershare low volatility splv splv powershare ex rate sensitive low volatility xrlv invest low volatility stock difference splv look stock lowest volatility past month xrlv invest stock show low volatility low interest rate risk remove stock have historically lag rate be rise xrlv have weighting utility consumer staple be rate sensitive sector comparison splv have weighting respective sector also xrlv have weighting financial sector vs splv bank other financial service tend benefit increase rate coca cola ko waste management wm pepsico pep host other stock be common portfolio medical equipment maker thermo fisher scientific tmo credit rating agency equifax efx be xrlv holding not be find splv new etf xrlv be trade care moreover low volatility stock be start look expensive more money have pile low minimum volatility etfs valuation have richen commensurately ben johnson director global etf research morningstar inc write report johnson look historical relationship begin value msci usa minimum volatility index price cash earning ratio subsequent year annualize return find richer start valuation lower ensue return current level newcomer low volatility part be set disappointing future return johnson caution year low volatility etfs focuse large cap have surge popularity ishare edge msci minimum volatility usmv absorb staggering new money more other equity exchange trade fund powershare low volatility splv soak same period smart fund investor be look large cap less risky stock xmlv powershare smallcap low volatility xslv have positive net flow year date re outperform large cap peer too xmlv be year date june vs xslv xrlv splv comparison spdr spy proxy broad market gain
14,TMO,share scientific instrument maker agilent technology pop year high early trading tuesday company beat fiscal estimate raise guidance late monday earning growth top line growth be highest vindication ceo michael mcmullen strategy attain position just year accord evercore isi analyst ross muken see mike vision superior top line growth inflection operate margin improve free cash flow deployment differentiate factor vs lst life science tool peer go forward muken write research note raise price target affirm buy rating agilent peer include thermo fisher scientific tmo dhr leerink analyst dan leonard raise price target keep outperform rating note addition lift organic growth guidance year company have offer glimpse next year management offer initial view fiscal project organic revenue growth reiterate commitment target operate margin leonard write assumption growth include continue momentum biopharma china be expect sustain second half full year chemical energy market bottom year end agilent stock early tuesday hit highest point january afternoon trading be just move break stock consolidation have be go year stock relative strength accumulation distribution rating have be improve last couple week reach respectively well average
15,TMO,do cosmetic retailer discount store software developer have common bolt new high friday follow strong quarterly earning report ulta beauty ulta sell wide range cosmetic hair care other product jump heavy volume soar week move average be
16,TMO,stock rise friday end session high investor shrug disappointing economic datum comment federal reserve chair janet yellen suggest higher interest rate be way nasdaq rise add dow jone industrial average edge volume fall nyse nasdaq compare thursday accord preliminary datum market be close monday memorial day holiday yellen say interest rate hike be possible come month improve economic growth trader put probability rate hike fed june meeting chance increase july meeting accord cme group fedwatch tool also friday gdp be revise upward less expect university michigan consumer sentiment gauge also fall short wall street consensus estimate retail stock once again outperformed stock market today discount retailer big lot big jump new high heavy volume announce profit fiscal first quarter end april jump year earlier cent share well wall street estimate revenue rise also well view stock rocket back buy point massive volume just day trigger sell signal sink entry big lot be latest discount retailer spike new high follow strong earning report dollar general dg dollar tree dltr continue rise friday follow earning inspire breakout thursday fei feic lead jump thermo fisher scientific tmo say buy maker electron microscope zoe kitchen zoe medtronic mdt yy yy workday wday be company due report quarterly earning tuesday
17,TMO,gene analysis firm affymetrix affx say wednesday engage discussion origin technology bid woo company away thermo fisher scientific tmo hold shareholder vote matter late tuesday origin technology be form former affymetrix employee specifically take affymetrix raise bid company share increase reverse termination fee last week origin have offer share affymetrix company board reject weekend ground be funded solely debt commitment wouldn be enough cover amount require be paid respect exist share employee equity arrangement exist convertible note credit facility anticipate transaction expense include termination fee payable thermo fisher scientific wednesday affymetrix leadership reluctantly admit new offer reasonably be expect lead superior proposal so company be legally require engage origin put matter shareholder vote take place march later wednesday company say board discuss proposal origin request draft merger agreement document financing deal plan obtain necessary approval board still advocate shareholder stick thermo fisher deal be share cash affymetrix stock rise wednesday share be fraction early trading stock market today thermo fisher stock be flat wednesday be fraction early thursday image provide shutterstock
18,TMO,share genetic analysis company affymetrix affx jump year high midday trading friday receive rival bid propose sale thermo fisher scientific tmo newly create company call origin technology lead group former affymetrix executive offer share cash company top share offer affymetrix accept back jan origin president wei zhou former senior vice president affymetrix also start genomic company centrillion technology back say origin have option combine centrillion acquire affymetrix origin ultimately combine centrillion origin own affymetrix centrillion offer unparalleled range microarray dna sequence technology product service customer say origin press release affymetrix stock have be trading thermo fisher deal be announce origin press release come noon friday stock pop thermo fisher stock be midday trading stock market today thermo fisher be trading time high decent relative strength rating earning sale growth shrank single digit last year affymetrix growth have also be single digit lately leerink analyst dan leonard write time deal affymetrix growth accelerate once business leverage thermo fisher broader customer geographic channel affymetrix get ibd composite rating thermo fisher
19,TMO,genetic analysis company affymetrix affx sunday reject share offer origin technology say stick plan share takeover thermo fisher scientific tmo affymetrix share dive morning trade stock market today share affymetrix hit year high friday origin offer soar affymetrix have trade just thermo fisher scientific bid affymetrix agree offer jan affymetrix say origin appear be newly form shell entity asset affymetrix be aware sole source funding propose transaction be potential debt commitment be materially short fund need actually complete deal say affymetrix cite share compensation termination fee thermo fisher scientific other item thermo fisher agree affymetrix issue statement see bid superior thermo stock fall cent origin technology be form group ex affymetrix executive purpose buy company origin president wei zhou former senior vice president affymetrix also start genomic company centrillion technology wei say origin have option combine centrillion acquire affymetrix
20,TMO,new lows have steamrolled new high so far pain continue monday new lows far outweighed new high oil stock account biggest chunk new lows wide variety group also joined dark side new high be little get excited strip thinly trade stock
21,TMO,go get tough tough build monitor etf watch list most investor be feel skittish sharp stock market sell wise focus inevitable upside smart investor also consider overall direction market make buy sell decision ibd market direction recently shift correction status again so time active etf investor be cautious even several last year etf winner have sunk day move average key support level cautious doesn mean idle several sector equity etfs track ibd be buy point buy etfs stock break buy point price chart base formation increase chance nail big gain here be etfs worth get know wait stock market trend turn bullish again spdr semiconductor xsd hold equal weight stock behemoth intel intc have roughly same stake portfolio asset smaller top notch player such monolithic power system mpwr etf have average daily trading volume roughly share ibd rs rating mean price performance have surpass most stock ibd database past month xsd be buy point cup handle base consolidated hit week high june have rally significantly interim september low last year xsd peg gain global social medium socl hold stock include linkedin lnkd facebook fb tencent holding tcehy etf have average daily volume share have rs rating socl be buy point cup handle base rally day line first second quarters then fall long consolidation full course socl jump ishare medical device ihi target niche medical device manufacturer distributor hold stock biggest position medtronic mdt abbott laboratory thermo fisher scientific tmo etf trade roughly share day average have rs rating ihi be buy point slice key day day support level broad loss stock market monday ihi bag gain
22,TMO,field biotech investing venture capitalist james blair be veteran work rothschild back blair be early investor apply biosystem now part thermo fisher scientific tmo develop gene sequencer used human genome project be also early player amgen amgn
23,TMO,gene sequence giant illumina beat analyst earning estimate tuesday miss revenue first time year send share hour trading illumina ilmn say income exclude time item amount cent share year earlier quarter beating analyst consensus cent accord thomson reuter revenue climb short consensus be third straight quarter decelerate sale growth constant currency basis sale rise company say illumina affirm full year guidance sale growth include impact foreign exchange rate firm raise full year ep range cent be still low side analyst consensus estimate expectation seem be high go stock hit new high monday tuesday grow wobbly however close just shy regular session evercore isi analyst ross muken note be first time illumina miss wall street revenue expectation management have raise revenue guidance time past report street have be widely anticipate beat raise muken write email client tuesday top line shortfall strong operate margin pull allow modest ep beat enabled slight upward tweak guidance add instrument sale vs be also first time more year instrument revenue decline sequentially muken point conference call analyst tuesday illumina president francis desouza say instrument sale overall rise year year shipment high end hiseq gene sequencer have fall compare last year product have just be rolled much fanfare other hand lower end nextseq myseq be continue grow nicely say overall sequence revenue grow ceo jay flatley say growth area be reproductive health field illumina enter acquisition few year sale ivf fertilization laboratory increase approximately sale come veriseq pgs say flatley reminder veriseq pgs be sequence base pre implantation genetic sequence solution used laboratory transition older array total nipt invasive prenatal testing revenue grow more vs second quarter last year result be due part double test send sample well increase product sale nipt provider globally flatley also praise growth shipment oncology customer customer base illumina have be try expand lately illumina have launch special cancer panel liquid biopsy program serve market revenue microarray oldest lowest end illumina business shrank volume actually grow business flatley say pricing environment be harsh illumina have be face more competition area lately player such thermo fisher scientific tmo roche rhhby
24,TMO,medical science seek uncover link genetic disease come precise treatment gene sequence make blueprint body molecular structure play critical role illumina ilmn play similarly crucial role provide researcher diagnostic company advanced tool need facilitate process tool include
25,TMO,aetna aet reportedly near deal buy humana bristol myer squibb be shuffle hundred job lululemon find midst yet recall here be today headline maker humana hum board reportedly like aetna buyout bid better cigna ci accord bloomberg cite person familiar matter
26,TMO,genomic firm illumina ilmn dip monday news compete high end gene sequencer lower end rival bio reference laboratory brli rise miss quarterly expectation european human genetic conference weekend complete genomic unit bgi formerly beij genomic institute preview revolocity sequence system supersequencer design deliver many whole genome sequence year high volume leerink analyst dan leonard say research note monday enable sequence cost genome landmark illumina first hit hiseq system rolled last year leonard note illumina have several competitor small scale target sequence such thermo fisher scientific tmo qiagen qgen bio rad laboratory bio revolocity be first high throughput rival believe biggest promise differentiate feature complete genomic system be sample answer capability leonard write bgi promise enable user input genomic dna blood saliva walk away instrument propose automate sequence process sample prep basic datum analysis variant call evercore isi analyst ross muken write note however illumina be tough competitor illumina credit have thwart most not challenger efficiently be certain have anticipate launch give constant paranoia muken write research report monday thus now view update skeptical eye do acknowledge launch have potential modestly impact term order pattern manufacturing not yet commercial scale thus complete likely hope delay purchase early reveal possibly shift small amount share customer already announce illumina stock record new high close friday late morning trading stock market today be fraction meanwhile bio reference lab stock be more even fiscal report be soft company revenue climb year earlier quarter short analyst consensus accord thomson reuter profit rise cent share miss estimate cent nonetheless statement bio reference ceo marc grodman highlighted growth firm sequence business be key selling point sale opko health opk announce last week opko stock be more late morning trading monday patient sequence test be refer bio reference genetic lab genedx requisition not include other bio reference business unit woman health oncology grodman say be increase increase have be higher have not be impact higher deductible plan impact expect lessen continue calendar year opko bio reference say ll hold conference call discuss merger thursday morning lieu earning call monday follow amy reeve twitter ibd_areeve
27,TMO,pall corp pll share jump tuesday report be final stage auction value company
28,TMO,potential buyer water air filter maker include dhr thermo fisher scientific tmo accord wall street journal
29,TMO,final bid be expect later week deal not be reach
30,TMO,pall corp share soar premarket trading stock market today share thermo fisher weren active premarket
31,TMO,follow gillian rich twitter ibd_grich pall corp pll share jump tuesday report be final stage auction value company potential buyer water air filter maker include dhr thermo fisher scientific tmo accord wall street journal final bid be expect later week deal not be reach pall corp share soar premarket trading stock market today share thermo fisher weren active premarket follow gillian rich twitter ibd_grich
32,TMO,electronic instrument giant say wednesday buy filtration separation system maker pall also split company dustrial business new publicly trade company dhr stock climb advance record intraday pall pll stock surge tuesday rumor
33,TMO,few dozen stock manage touch new high tuesday only few make strong move higher major average end red pall pll gap soar wall street journal report maker water air filter be final stage be buy
34,TMO,stock future fall hard tuesday open follow index europe be draw slide global bond market
35,TMO,dow future be point fair market value nasdaq future fall point future be point red
36,TMO,stock market today open still bound narrow range support resistance weekly close have add subtract less half percent past week trading range have be narrow
37,TMO,nasdaq have swung little wider have continually come rest week support march high distribution remain lead trait index signal investor raise cash market seize more decisive direction
38,TMO,bond europe skid monday tuesday pressure yield debt cost higher concern central bank monetary policy year yield europe hit highest close level month monday trigger response global currency market
39,TMO,europe lead index fall sharply frankfurt dax london ftse midday dollar dip vs euro yen commodity gain european oil benchmark gold add ounce
40,TMO,stock aol aol grab morning headline gain nearly premarket trade verizon communication vz say buy struggle web portal share offer be premium monday close price
41,TMO,deal bolster verizon mobile video offering advertising technology fresh content aol have be consolidate january high verizon share be fraction open
42,TMO,filtration purification specialist pall pll surge news report interested buyer be bidding port washington company wall street journal name dhr thermo fisher scientific tmo top bidder say deal value pall high final offer reportedly due end week pall have be shallow consolidation late february
43,TMO,rackspace host rax tank report late monday revenue growth revenue outlook stop short consensus expectation stock have be general uptrend past month try climb month consolidation
44,TMO,overseas market asia be mixed shanghai composite jump hong kong hang seng finished flat tokyo nikkei slip yen climb vs dollar
45,TMO,economic news labor department report march job opening labor turnover survey et treasury department turn april budget report stock future fall hard tuesday open follow index europe be draw slide global bond market dow future be point fair market value nasdaq future fall point future be point red stock market today open still bound narrow range support resistance weekly close have add subtract less half percent past week trading range have be narrow nasdaq have swung little wider have continually come rest week support march high distribution remain lead trait index signal investor raise cash market seize more decisive direction bond europe skid monday tuesday pressure yield debt cost higher concern central bank monetary policy year yield europe hit highest close level month monday trigger response global currency market europe lead index fall sharply frankfurt dax london ftse midday dollar dip vs euro yen commodity gain european oil benchmark gold add ounce stock aol aol grab morning headline gain nearly premarket trade verizon communication vz say buy struggle web portal share offer be premium monday close price deal bolster verizon mobile video offering advertising technology fresh content aol have be consolidate january high verizon share be fraction open filtration purification specialist pall pll surge news report interested buyer be bidding port washington company wall street journal name dhr thermo fisher scientific tmo top bidder say deal value pall high final offer reportedly due end week pall have be shallow consolidation late february rackspace host rax tank report late monday revenue growth revenue outlook stop short consensus expectation stock have be general uptrend past month try climb month consolidation overseas market asia be mixed shanghai composite jump hong kong hang seng finished flat tokyo nikkei slip yen climb vs dollar economic news labor department report march job opening labor turnover survey et treasury department turn april budget report
46,TMO,stock tumble hard heavy trade open tuesday
47,TMO,dow shed apiece nasdaq be retailer oil producer consumer electronic maker be worst early loss
48,TMO,volume swell unusual event week ahead labor day holiday trade rise nasdaq be higher nyse relation action same time monday
49,TMO,stock market today fall selling wash international market follow weak datum china south korea japan china manufacturing contract more expect august overall economy purchasing manager index read slip expansion contraction month south korea export drop sharply august japanese company show sharp cut capital spending plan
50,TMO,china market book uneven loss tokyo nikkei dive european stock deepen loss afternoon trade top index frankfurt paris more london ftse near decline afternoon trade
51,TMO,market early loss put less low last week dow be nasdaq be still nearly last week lows
52,TMO,august purchasing manager index researcher markit show manufacturing growth ease slightly send index vs read july be just economist expect
53,TMO,pmi institute supply management dip be july well expectation read
54,TMO,growth construction spending hold steady july commerce department say equal june improvement notch consensus forecast gain
55,TMO,stock dollar tree dltr marked worst loss nasdaq stock diving more earning revenue forecast stop short consensus expectation also nasdaq netflix nflx slump wynn resort wynn drop
56,TMO,exxon mobil xom drilled more worst decline dow oil price pull back nearly early tuesday rally day
57,TMO,leader ambarella amba tumble more stock battle hold day move average maker video process chip plan report result today close
58,TMO,nike nke gap loss heavy trade drop knock stock back week move average fifth week deep consolidation stock tumble hard heavy trade open tuesday dow shed apiece nasdaq be retailer oil producer consumer electronic maker be worst early loss volume swell unusual event week ahead labor day holiday trade rise nasdaq be higher nyse relation action same time monday stock market today fall selling wash international market follow weak datum china south korea japan china manufacturing contract more expect august overall economy purchasing manager index read slip expansion contraction month south korea export drop sharply august japanese company show sharp cut capital spending plan china market book uneven loss tokyo nikkei dive european stock deepen loss afternoon trade top index frankfurt paris more london ftse near decline afternoon trade market early loss put less low last week dow be nasdaq be still nearly last week lows august purchasing manager index researcher markit show manufacturing growth ease slightly send index vs read july be just economist expect pmi institute supply management dip be july well expectation read growth construction spending hold steady july commerce department say equal june improvement notch consensus forecast gain stock dollar tree dltr marked worst loss nasdaq stock diving more earning revenue forecast stop short consensus expectation also nasdaq netflix nflx slump wynn resort wynn drop exxon mobil xom drilled more worst decline dow oil price pull back nearly early tuesday rally day leader ambarella amba tumble more stock battle hold day move average maker video process chip plan report result today close nike nke gap loss heavy trade drop knock stock back week move average fifth week deep consolidation
59,TMO,lead medical equipment stock be thursday report strong result guidance continue season theme foreign exchange headwind life science toolmaker thermo fisher scientific tmo report earning time item share year earlier quarter beating analyst consensus cent sale rise top estimate more
60,TMO,biogen idec top estimate guide expectation thursday fellow big cap biotech alexion pharmaceutical also beat guide light stock rally strongly close biogen biib say earning time item rise share third straight quarter accelerate year year growth beat analyst consensus cent
61,TMO,several top rate stock break basis thursday new high list horton dhi break flat base entry fort worth texas base company rise volume more average homebuilder stock rally news white house be cut mortgage insurance premium charge federal housing
62,TMO,stock market have best day week thursday make straight day solid gain
63,TMO,nasdaq dow jone industrial average soar index regain day move average
64,TMO,volume rise nasdaq preliminary datum show slightly lower nyse advance stock lead decliner better
65,TMO,solar build medical energy stock lead stock market today dow transport surge
66,TMO,several breakout add positive tone include valeant pharmaceutical vrx life science equipment maker thermo fisher scientific tmo homebuilder horton dhi
67,TMO,friday government release monthly job report open economist expect new job slight dip unemployment rate accord econoday stock market have best day week thursday make straight day solid gain nasdaq dow jone industrial average soar index regain day move average volume rise nasdaq preliminary datum show slightly lower nyse advance stock lead decliner better solar build medical energy stock lead stock market today dow transport surge several breakout add positive tone include valeant pharmaceutical vrx life science equipment maker thermo fisher scientific tmo homebuilder horton dhi friday government release monthly job report open economist expect new job slight dip unemployment rate accord econoday
68,TMO,many manufacturer focus quality make scientific research instrument exactitude matter even more thermo fisher scientific tmo help customer include pharmaceutical firm hospital conduct life science research waltham mass base company have roughly employee country decade fisher scientific international make laboratory instrument scientific research
69,TMO,gene sequence company illumina late monday report blowout third quarter earning sale growth raise full year guidance send stock hour trading earning exclude time item rise vs year earlier cent share top analyst consensus cent accord thomson reuter sale rise best year year
70,TMO,big cap medical firm biogen idec abbott laboratory thermo fisher scientific underwhelm investor third quarter earning guidance wednesday biogen stock especially punish company say patient have die take lead drug biogen biib earning rise year earlier quarter share beating analyst estimate cent
71,TMO,stock future dig deeper early loss ahead thursday open follow disappointing unemployment claim datum dow future slump point moderate decline point loss hour earlier
72,TMO,nasdaq future be point fall future slip point
73,TMO,day breather stock market today jump busy day economic news start jobless claim labor department report hold steady week end nov economist consensus have project decline claim week move average rise second straight increase
74,TMO,labor department also report september job opening labor turnover survey et oil price also get attention energy information administration deliver weekly inventory datum
75,TMO,comment fed official also weigh morning action st loui federal reserve president james bullard speak just et fed chief janet yellen be deck speech washington monetary policy conference jeffrey lacker president richmond federal reserve speak follow charle evan chicago federal reserve new york federal reserve william dudley
76,TMO,stock action most dow shift lower loss be mild boee ba post widest loss unite technology utx take best gain advance open
77,TMO,wisconsin base department store chain kohl kss spiked more report bottom list fifth third bancorp fitb scrawl loss
78,TMO,also weak end advance auto part aap fall more third quarter earning revenue miss estimate guidance be weak chief executive darren jackson announce retire jan advanced share have ease slightly etching new high friday finished wednesday just buy point cup base
79,TMO,liberty medium lmca jump nearly premarket trade englewood colo base diversify medium player say divide stock separate tracking listing link company atlanta brave related asset tie stake sirius xm radio third tracking liberty portion time warner viacom livenation entertainment liberty share have trade flat month oct high
80,TMO,leader netease nte lead ibd list jump nearly late wednesday report show earning surge revenue analyst consensus have project revenue ep gain china base operation see more revenue online gaming product have advanced straight week end wednesday august low buy point cup base
81,TMO,bottom list reilly auto part orly be premarket pressure have be feel undertow selling related advance auto result reilly surge top consensus expectation positive report oct have trade sideway just high end wednesday almost cup base buy point
82,TMO,ibd weekly review list pegasystem pega marked premarket gain developer business process software financial health service company end wednesday extend nearly cup base buy point stock be thinly trade stock future dig deeper early loss ahead thursday open follow disappointing unemployment claim datum dow future slump point moderate decline point loss hour earlier nasdaq future be point fall future slip point day breather stock market today jump busy day economic news start jobless claim labor department report hold steady week end nov economist consensus have project decline claim week move average rise second straight increase labor department also report september job opening labor turnover survey et oil price also get attention energy information administration deliver weekly inventory datum comment fed official also weigh morning action st loui federal reserve president james bullard speak just et fed chief janet yellen be deck speech washington monetary policy conference jeffrey lacker president richmond federal reserve speak follow charle evan chicago federal reserve new york federal reserve william dudley stock action most dow shift lower loss be mild boee ba post widest loss unite technology utx take best gain advance open wisconsin base department store chain kohl kss spiked more report bottom list fifth third bancorp fitb scrawl loss also weak end advance auto part aap fall more third quarter earning revenue miss estimate guidance be weak chief executive darren jackson announce retire jan advanced share have ease slightly etching new high friday finished wednesday just buy point cup base liberty medium lmca jump nearly premarket trade englewood colo base diversify medium player say divide stock separate tracking listing link company atlanta brave related asset tie stake sirius xm radio third tracking liberty portion time warner viacom livenation entertainment liberty share have trade flat month oct high leader netease nte lead ibd list jump nearly late wednesday report show earning surge revenue analyst consensus have project revenue ep gain china base operation see more revenue online gaming product have advanced straight week end wednesday august low buy point cup base bottom list reilly auto part orly be premarket pressure have be feel undertow selling related advance auto result reilly surge top consensus expectation positive report oct have trade sideway just high end wednesday almost cup base buy point ibd weekly review list pegasystem pega marked premarket gain developer business process software financial health service company end wednesday extend nearly cup base buy point stock be thinly trade
83,TMO,share sigma aldrich sial major provider chemical other product life science industry jump more time high stock market today german drugmaker merck kgaa announce buy company cash merck do business emd millipore avoid confusion
84,TMO,california base stock spend long time consolidate present fresh opportunity big cap investor linkedin lnkd have headquarters mountain view calif advanced basis first january lead gain month second july lead gain month be third stage base time flat base appear be form follow sound rule sometimes seem drag linkedin punish buy base be complete buy consolidation fall week shy valid base never come instead new base linkedin action prove be start long consolidation sank september high decline be deeper bull prefer however linkedin have climb high enough form handle now likely be valid midpoint consolidation be stock be trading price volume be far neutral level accumulation distribution level be point institutional buy linkedin fundamental be improve company report pop earning well street consensus estimate less gain revenue grow vs view increase annual earning be expect rise year next year percentage represent upward revision revenue be expect jump same period concern bull be linkedin overcome remain overhead resistance refer investor buy high left side base be tempt exit stock approach break even however long deep consolidation have already scared many weak holder apple aapl begin work base september consolidated year half breaking stock sketch handle december consolidated further clear buy point april cupertino calif base company be find support first trip week move average line bounce line strong volume hasn develop yet define buy range earning growth be most recent quarter top view increase stock show positive action be massachusett base thermo fisher scientific tmo saucer handle base offer potential buy point
85,TMO,relative strength rs rating thermo fisher scientific tmo moved new percentile monday get lift look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure price action worst best score grade show stock price behavior trail week hold other stock database history reveal stock go make biggest gain tend have rs rating north early stage move see thermo fisher scientific continue show renew price strength clear threshold look winning stock try simple routinethermo fisher scientific be try complete flat base entry see break volume least average take look top bottom line number company have post quarters rise earning growth sale gain have also rise same period company earn rank peer medical research equipment service industry group medpace medp illumina ilmn luminex lmnx be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
86,TMO,next earning report schedule apr thermo fisher scientific tmo be trading entry chart pattern be first stage flat base buy stock just ahead earning be risky typically don have enough time establish profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look winning stock try simple routineregard fundamental company have post quarters increase earning growth sale growth have also increase same period analyst be look earning share growth quarter growth full year ep estimate full year be recently revise upward thermo fisher scientific have composite rating hold rank peer medical research equipment service industry group illumina ilmn be rank stock group note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
87,TMO,re try build earning season watch list look stock set base ahead next earning report here fit bill thermo fisher scientific tmo expect report apr be trading approximately entry entry be base first stage flat base buy stock just ahead earning be risky typically don have enough time establish profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure see ibd help make more money stockstaking look top bottom line number thermo fisher scientific have post quarters increase earning growth sale gain have also increase same time frame analyst expect earning share growth quarter growth full year ep estimate full year be recently revise higher company have composite rating earn rank peer medical research equipment service industry group pra health science prah be top rank stock group note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
88,TMO,myriad genetic mygn be ibd stock day break wednesday analyst upgrade note trend genetic cancer test be improve myriad stock spiked close stock market today morgan stanley analyst steve beuchaw upgrade overweight rating equal weight beuchaw also boost price target share surge past buy point cup handle base heavy volume close more extend point follow brief june cup handle myriad core business be selling test determine patient carry genetic risk develop cancer core sale stabilize myriad high return capital deployment help earning accelerate beuchaw say get newsletter deliver inbox more info product service privacy policy term use believe myriad genetic earning profile be dramatically change say report client core hereditary cancer test business be show durability bear give credit volume return growth price decline slow same time key acquisition be expand myriad total addressable market note acquisition assurex health assurex test look psychiatric condition chronic pain molecular diagnostic company announce plan acquire obstetric genetic screening outfit counsyl insurance reimbursement assurex genesight genetic test depression be become clearer beuchaw say now evidence show clinical benefit cost benefit determine medicine match specific patient depression say further investor be excited myriad plan acquisition privately hold counsyl company provide genetic screening expectant mother family counsyl beuchaw assume steady gain basis point year market share myriad fiscal year guidance be key fall likely include impact counsyl acquisition set close first quarter myriad fiscal outlook drive consensus estimate higher year beuchaw say believe buy side have also not yet incorporate dynamic view stock say company medical research equipment industry group be rank group track ibd other notable stock group include thermo fisher scientific tmo illumina ilmn term relative strength rating myriad stock land top group rs rating best possible rs rating stock price action trail week vs rest market get instant access more trading idea exclusive stock list ibd proprietary rating only related much money do need start investing long term retirement investing strategy etfssell take profit hold here be several guideline follow
89,TMO,market uptrend be pressure distribution day count be high nasdaq several large cap name week big cap be hold gain trading tightly breakout couple other health care name railroad operator be act well too bullish week end july chipotle grill cmg continue hang high tad buy range july gap july chipotle report solid earning sale customer shrug higher menu price quarterly profit rise year share sale growth accelerate third straight quarter rise same store sale exclude sale newly open store rise impressive company open new restaurant quarter focus remain growth facebook fb meanwhile have be get lot ink ibd lately rightly so stock still have look emerge leader still buy range clear third stage cup handle buy point facebook have get house order then inauspicious debut flurry better expect earning report have help july online social network report profit cent share well consensus estimate cent share increase year quarter sale rise just mobile monthly active user rise daily active user mobile device rise mobile ad revenue rise bullish last month drug distributor abc continue hold gain trade tightly share remain accumulation company july earning report earning growth accelerate third straight quarter rise share sale rise help recent pact wag long term accord announce march include year pharmacy distribution contract medical product maker thermo fisher scientific tmo meanwhile be work long saucer handle base buy point hold just week move average don forget canadian pacific railway cp be find support week move average recent support week line be good place start small position initial be miss full year profit railroad operator be expect rise year
90,TMO,most big cap stock be buy range form basis unusually good trend afford investor plenty opportunity deploy capital sluggish market pose risk new purchase willing risk today market several big cap leader be buy range latest base breakout many cyclical stock
91,TMO,build watch list focus stock higher rs rating thermo fisher scientific tmo just clear benchmark upgrade look best stock buy watch factor watch closely be relative price strength ibd unique rs rating measure market leadership show stock price action last week compare other stock major index history reveal top perform stock tend have rs rating early stage move look winning stock try simple routinethermo fisher scientific be build flat base buy point see stock break heavy trading term top bottom line number company have post rise ep growth last quarters revenue gain have also rise same time frame thermo fisher scientific hold rank peer medical research equipment service industry group pra health science prah be rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
92,TMO,thermo fisher scientific tmo see ibd smartselect composite rating rise thursday day revise score mean stock currently top other stock term key performance metric technical strength winning stock often have higher score early stage new price run thermo fisher scientific be now buy range breaking buy point flat base look best stock buy watch start stock earn ep rating mean recent quarterly longer term annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week company post ep growth mean now deliver straight quarters rise ep growth sale growth increase prior report company have now post accelerate growth last quarters thermo fisher scientific earn rank peer medical research equipment service industry group pra health science prah be rank stock group related company be now outperform stock
93,TMO,thermo fisher scientific tmo be potential buy range ahead next quarterly report expect jan trading approximately buy point first stage flat base understand buy stock just ahead earning be risky typically don have enough time build profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure see ibd help make more money stocksearning grow last quarter prior report revenue also increase analyst expect ep growth quarter growth full year annual growth estimate be recently revise upward thermo fisher scientific have composite rating hold rank peer medical research equipment service industry group pra health science prah be top rank stock group note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
94,TMO,wednesday thermo fisher scientific tmo reach noteworthy performance benchmark relative strength rs rating jump percentile improvement rise day proprietary rating identify technical performance show stock price movement last week compare other stock database decade market research show best stock often have better rs rating early stage move look winning stock try simple routinethermo fisher scientific be trading buy zone breaking past entry flat base once stock move higher initial entry consider buy range thermo fisher scientific see earning sale growth rise last quarter earning share increase revenue rise keep eye company next round number jan thermo fisher scientific earn rank peer medical research equipment service industry group pra health science prah be rank stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
95,TMO,key stock index fund rise thursday fang stock other big cap techs power big gain tech heavy powershare qqq trust powershare qqq trust qqq lead upside gain spdr spy spdr dow jone industrial average dium add respective small cap lag slightly ishare russell iwm ishare core small cap ijr climb respectively fang stock boost techs facebook fb gap soar almost retake day move average first time week close wednesday social network report result top view top bottom line amazon netflix pop stock regain day line alphabet googl advanced reclaim day line intel intc microsoft msft rise more dow stock be time high apple aapl add be tough week so far iphone maker share trade day line analyst expect apple earn share revenue report tuesday chip technology biotechs be biggest sector fund gainer stock market today vaneck vector semiconductor smh gap rise retake day line advanced micro device amd surge regain day line earning sale beat late wednesday well higher revenue outlook real estate homebuilder financial underperform stock fund be ailing volatility market health care play hold medtronic mdt abbott laboratory be find healthy support ishare medical device ihi continue consolidate mark record high late january tumble day move average stock market slump early february etf find support have be trading day line then climb back high market environment improve potential buy point be fund track dow jone select medical equipment index turn year old next month health care equipment represent biggest sector weighting tuesday nearly asset life science tool service make health care service rest top holding include medtronic abbott lab thermo fisher scientific tmo becton dickinson bdx dhr account stock portfolio get free access ibd digital april
96,TMO,get premium stock list pass fail stock rating more start herethermo fisher have produce gain wednesday close becton dickinson abbott be medtronic be medtronic have have rough start year share weaken mid february medical device maker suggest first use human hugo surgical robot be delay previously plan start operate patient end fiscal end month fund return year date tuesday accord morningstar inc far ahead loss average annual return past year have also outperformed broader index gain same period be ihi carry expense ratio wednesday pick spdr bank kbe spdr regional bank kre see mixed finish continue work right side respective shallow basis also be interested stock rise boee soar ge sink bitcoin pare lossesai robotic blockchain hot new etf industry trendshere way invest fang stock etf
97,TMO,relative strength rs rating bio rad lab bio jump new percentile tuesday increase look best stock buy watch keep close eye relative price strength exclusive rating investor business daily measure share price performance worst best score score show stock price movement trail week compare other stock database history reveal best perform stock tend have rs rating north early stage move see ibd help make more money stocksbio rad lab be build flat base buy point see clear price heavy trading keep mind later stage consolidation be riskier earlier stage pattern regard fundamental company have post rise ep growth last quarters sale gain have also moved higher same time frame company be expect release next quarterly number bio rad lab hold rank peer medical research equipment service industry group pra health science prah illumina ilmn thermo fisher scientific tmo be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
98,TMO,stock market index fund extend gain monday key dow jone industrial average etf reclaim couldn hold day move average spdr dow jone industrial average dium rally nearly inch day line then retreat gain spdr spy powershare qqq trust qqq also add stock market today foreign market trail ishare msci eafe efa ishare msci emerge market eem edge higher dow stock advanced top blue chip winner include unh merck mrk apple aapl add mark third straight advance iphone maker be work right side shallow base potential buy point raymond james warn apple get hit sell news reaction report expectation be already baked share price utility consumer staple homebuilder be top sector fund gainer spdr homebuilder xhb advanced continue trade day day line aerospace defense also show strength ishare aerospace ita lift build flat base potential buy point defense contractor include raytheon rtn northrop grumman noc dow component unite technology utx rally heel coordinate strike syrium britain france friday raytheon lift clear flat base entry average volume telecom biotech gold miner underperform most biotech health care fund get hurt past month heighten volatility broader market top performer accompany table see healthy year date gain vs wednesday accord morningstar direct first trust nyse arca biotechnology index fund fbt place first year date return even drop past month fund regain day move average thursday be form double bottom base buy point top holding thursday include avexis avxs intrexon xon nektar therapeutic nktr agio pharmaceutical agio intercept pharmaceutical icpt avexis share soar april news novartis nvs buy biotech get newsletter deliver inbox more info product service privacy policy term useark genomic revolution multus sector arkg come second year date return fund invest company involved genomic related field such gene therapy target therapeutic next generation oncology top holding intellium therapeutic ntla edita medicine edit illumina ilmn invitae nvta bluebird bio blue account third stock portfolio fund lose past month have be trading day line late march share be march intraday high third place go ishare medical device ihi gain wednesday fund track dow jone select medical equipment index sit high top holding make stock portfolio be medtronic mdt abbott laboratory thermo fisher scientific tmo becton dickinson bdx dhr alp medical breakthrough sbio spdr biotech xbi round top etfs respective year date gain also be interested stock lower big bank weigh dow apple buck declinestock market rally intel apple boost dow bitcoin biotechs drugmaker fare senate tax bill
99,TMO,icon iclr see positive improvement relative strength rs rating monday upgrade ibd proprietary rating identify market leadership worst best score grade show stock price movement trail week stack other stock database year market history reveal stock go make biggest gain tend have rs rating launch largest climb see icon continue rebound hit benchmark see ibd help make more money icon be not proper entry right now see be able form break proper base company post ep growth last quarter sale growth come keep eye company next round number feb company earn rank peer medical research equipment service industry group pra health science prah thermo fisher scientific tmo catalent ctlt be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
100,TMO,friday medpace medp earn positive adjustment relative strength rs rating proprietary rating identify technical performance used worst best score indicate stock price performance trail week match rest market decade market research show stock go make biggest gain tend have higher rs rating launch biggest climb see ibd help make more money stocksmedpace be build consolidation buy point see stock clear price heavy volume top bottom line growth moved higher last quarter earning be compare prior report revenue increase company be expect report latest earning sale number feb medpace earn rank peer medical research equipment service industry group pra health science prah thermo fisher scientific tmo catalent ctlt be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
101,TMO,welcome move bio rad lab bio see relative strength rating rise tuesday ibd unique rs rating measure technical performance show stock price action last week measure other stock database decade market research show market biggest winner tend have better rs rating begin biggest run see bio rad lab continue rebound hit benchmark look best stock buy watch start herebio rad lab be try complete cup handle entry see clear price heavy trade note fourth stage base later stage pattern work have higher failure rate point stock have already climb substantially top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase company be expect report latest number feb bio rad lab earn rank peer medical research equipment service industry group catalent ctlt pra health science prah thermo fisher scientific tmo be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
102,TMO,stock open higher tuesday dow rebound new high several china base stock post strong early move dow jone industrial average pop open bell johnson johnson jnj traveler trv lead early charge gain nasdaq composite edge less apple aapl facebook fb alphabet googl netflix nflx post early loss big retailer show early strength target tgt climb raise first quarter earning outlook high end target share include benefit much cent newly re-form tax law statement say company expect tax reform legislation create additional cash flow plan use capital investment dividend additional share repurchase target have gain june be climb right side deep month consolidation illumina spiked more announce deal market thermo fisher scientific tmo ampliseq tool exist illumina customer ampliseq work gene sequence analysis tool make illumina other limit analysis target zone genome produce result faster limit amount datum generate search illumina share be extend just buy point first stage flat base intel rival advanced micro device amd drop more early trade tuesday microsoft msft say be halter effort patch security gap amd chip set related spectre lapse operate system update be cause computer freeze amd say product be not risk meltdown vulnerability spectre threat be address operate system update microsoft share rise mazor robotic mzor be ear action maker automate surgical guidance system spiked early trade monday then narrow gain end tight week line company report sell robotic surgical system fourth quarter newly implement agreement medtronic mdt mazor be month saucer base buy point ibd stock daqo new energy dq rebound follow dive monday announce exit chief executive ibd leaderboard stock athm bolt more open trade stock be extend week advance include month base pattern national federation independent business report small business optimism index drop point december remain still record high year old survey labor department job opening labor turnover survey be due et minnesota federal reserve bank president neel kashkari be also schedule speak asia market turn strong session tuesday tokyo nikkei return holiday weekend gain hong kong hang seng index climb straight advance europe market be firmly higher afternoon trade cac paris staking high ground follow london ftse gain advance frankfurt dax related big picture bull be undefeated ready software leader boast accelerate ep estimate nvidia share break autonomous car dealsthese top china stock rocket basis breakout
103,TMO,stock be quiet ahead long weekend nike nke weigh bitcoin continue volatile week trade apple aapl be flat spdr dow jone industrial average dium powershare qqq trust qqq fall spdr spy give emerge market extend gain third straight session ishare msci emerge market eem rise stock market today nike provide biggest drag dow tumble apple meanwhile be flat enter positive territory less flat base buy point initially crossed monday telecom bank health care lead downside sector fund gold miner energy real estate be biggest gainer gold future leap ounce west texas intermediate crude price be flat barrel bitcoin crash pare loss accord coindesk earlier jump nearly level cryptocurrency have top sunday bitcoin investment trust gbtc have make double digit move past session reversed upward gain track snap session slide pare steep early loss gbtc be now tuesday intraday high look set drop week be tumultuous week cryptocurrency string decline be spark coinbase announce support bitcoin offshoot bitcoin cash subsequent probe possible insider trading grow number global central bank have issue warning potential risk bitcoin other digital currency medical stock be often consider defensive play name such abbott laboratory have also proven growth potential ishare medical device ihi have be testing support day move average month solid advance line mark opportunity buy share rise late september rebound day nov intraday high fund marked anniversary have amassed asset track dow jone select medical equipment index be make maker distributor medical device include magnetic resonance imaging scanner prosthetic pacemaker health care equipment represent lion share asset life science tool service contribute health care supply technology service make rest top holding dec include medtronic mdt abbott lab thermo fisher scientific tmo dhr stryker syk top account asset abbott share have rally year thermo fisher have rise stryker be have advanced ibd take make money catch etf uptrend require knowledge read chart learn ibd university etf ytd gain dec outpace return ihi have deliver healthy performance longer haul average annual return past year respectively have return same period ihi bear expense ratio related apple bank boost dow record bitcoin stop slump apple set sight buy point bitcoin dife nvidia gear here apple be weigh dow techs bitcoin high
104,TMO,thermo fisher scientific tmo be potential buy range next quarterly earning report due oct trading right buy point first stage flat base understand risky buy stock just report reduce risk wait see actual number market reaction way minimize risk post earning sell be use option strategy look best stock buy watch start herethermo fisher scientific post earning growth latest quarterly report revenue increase analyst expect ep growth quarter growth full year earning share estimate full year be recently revise higher company have composite rating hold rank peer medical research equipment service industry group pra health science prah be rank stock group note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
105,TMO,thermo fisher scientific tmo see welcome improvement relative strength rs rating monday upgrade exclusive rating investor business daily track share price performance worst best score rating show stock price performance last week stack other stock database history show market biggest winner tend have better rs rating early stage move look best stock buy watch start herethermo fisher scientific be buy range move past buy point flat base once stock move higher original entry consider extend buy range thermo fisher scientific report ep growth most recent report sale gain come next quarterly result be expect oct company earn rank peer medical research equipment service industry group pra health science prah be rank stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
106,TMO,indianapoli base anthem antm have be stock long run up deep plunge first debut nyse past year big cap have have share turn run up manage care provider enjoy run early mid ultimately rac gain month
107,TMO,here weekly investing action plan need know investor come week upcoming week earning give investor much broader look corporate america economy stalwart tech industrial energy medical consumer sector weigh quarterly result such amazon com amzn alphabet ticker
108,TMO,high tech instrument maker dhr report soft guidance early thursday send stock tumble nearly morning trading stock market today earning share rise year earlier quarter cent include cent tax gain sale security analyst consensus call cent sale rise
109,TMO,high tech instrument maker dhr report soft guidance early thursday send stock tumble nearly morning trading stock market today earning share rise year earlier quarter cent include cent tax gain sale security analyst consensus call cent sale rise
110,TMO,cloud base enterprise software firm health cslt vault friday pricing ipo expect range late thursday investor bet nascent information technology company promise help person navigate increasingly complex health care market price share expect range have
111,TMO,cloud base enterprise software firm health cslt vault friday pricing ipo expect range late thursday investor bet nascent information technology company promise help person navigate increasingly complex health care market price share expect range have
112,TMO,general electric ge meet earning estimate friday full year margin fall short highly tout target raise doubt conglomerate ability meet future goal focus core business industrial full year adjust profit margin widen basis point not point general electric have pledge margin rise basis point ge cite supply
113,TMO,general electric ge continue be transitional period shed asset focus industrial business analyst still expect conglomerate report sharp rise earning result come friday
114,TMO,fourth quarter earning be see climb cent share accord analyst poll thomson reuter revenue be expect rise
115,TMO,fallout financial crisis ge have look trim commercial lend business risk cost rise company also shed stake nbcuniversal comcast cmcsa february earlier expect
116,TMO,spinoff ge north american consumer lend arm be anticipate year ipo market continue power
117,TMO,retail finance unit offer private label credit card chain pep boy pby wal mart wmt la boy lzb
118,TMO,instead ge be look return root focus industrial health care segment come shale boom commercial aircraft rebound be boost demand ge industrial product help lift backlog record high
119,TMO,earlier month ge agree buy cell culture gene modulation magnetic bead business scientific instrument maker thermo fisher tmo
120,TMO,thermo hyclone cell culture business be work develop vaccine drug treat cancer arthritis similar work be be do cell biology business ge already own
121,TMO,change be expect boost ge profitability eventually earning growth slow interim
122,TMO,oppenheimer analyst recently downgrade ge perform hold outperform buy see earning rise midsingle digit percentage range next year slower high single digit growth anticipate double digit gain reach past few year
123,TMO,follow gillian rich twitter ibd_grich general electric ge continue be transitional period shed asset focus industrial business analyst still expect conglomerate report sharp rise earning result come friday fourth quarter earning be see climb cent share accord analyst poll thomson reuter revenue be expect rise fallout financial crisis ge have look trim commercial lend business risk cost rise company also shed stake nbcuniversal comcast cmcsa february earlier expect spinoff ge north american consumer lend arm be anticipate year ipo market continue power retail finance unit offer private label credit card chain pep boy pby wal mart wmt la boy lzb instead ge be look return root focus industrial health care segment come shale boom commercial aircraft rebound be boost demand ge industrial product help lift backlog record high earlier month ge agree buy cell culture gene modulation magnetic bead business scientific instrument maker thermo fisher tmo thermo hyclone cell culture business be work develop vaccine drug treat cancer arthritis similar work be be do cell biology business ge already own change be expect boost ge profitability eventually earning growth slow interim oppenheimer analyst recently downgrade ge perform hold outperform buy see earning rise midsingle digit percentage range next year slower high single digit growth anticipate double digit gain reach past few year follow gillian rich twitter ibd_grich
124,TMO,general electric ge agree buy multiple division scientific instrument maker thermo fisher tmo ge look expand health care unit
125,TMO,industrial conglomerate buy cell culture gene modulation magnetic bead business thermo fisher
126,TMO,acquisition generate combine revenue last year become part ge healthcare life science unit deal be expect close begin year
127,TMO,thermo hyclone cell culture business be work develop vaccine drug treat cancer arthritis similar work be be do cell biology business ge already own
128,TMO,ge share be flat thestock market today thermo share rise
129,TMO,thermo fisher say be selling business ge effort get approval european commission buy life technology life approval deal be still pending federal trade commission
130,TMO,ge be look expand industrial health care field shrink financial service division focus get back core offering
131,TMO,follow gillian rich twitter ibd_grich general electric ge agree buy multiple division scientific instrument maker thermo fisher tmo ge look expand health care unit industrial conglomerate buy cell culture gene modulation magnetic bead business thermo fisher acquisition generate combine revenue last year become part ge healthcare life science unit deal be expect close begin year thermo hyclone cell culture business be work develop vaccine drug treat cancer arthritis similar work be be do cell biology business ge already own ge share be flat thestock market today thermo share rise thermo fisher say be selling business ge effort get approval european commission buy life technology life approval deal be still pending federal trade commission ge be look expand industrial health care field shrink financial service division focus get back core offering follow gillian rich twitter ibd_grich
132,TMO,mfs growth be batten hatch brace economic environment earning growth be more scarce borrow cost inch dec translate key bet often overweight vs russell growth index health care financial service leisure stock health care manager eric fischman like thermo fisher
133,TMO,new analyst report cowen co offer upbeat assessment medical research equipment stock ahead first quarter earning thank improve end market
134,TMO,report life science diagnostic tool sector tuesday analyst doug schenkel write most company be poise meet beat expectation
135,TMO,expectation combine confidence build forward look commentary positive update end market help share price sector recover recent slump schenkel add
136,TMO,company reckon be best position beat estimate be fluidigm fldm illumina ilmn myriad genetic mygn orasure technology osur perkinelmer pki thermo fisher scientific tmo
137,TMO,fluidigm belong ibd medical system equipment group rank industry track illumina myriad perkinelmer thermo fisher be ibd medical research equipment service group rank orasure be medical product group rank
138,TMO,stock myriad have highest ibd composite rating be follow illumina perkinelmer thermo fisher orasure fluidigm
139,TMO,myriad have have best stock action late reach year high friday share be more begin year
140,TMO,company life science diagnostic tool benefit growth most end market schenkel say
141,TMO,coverage universe include major customer end market academic government industrial apply biopharma healthcare hospital
142,TMO,have be show improvement say
143,TMO,base check management commentary past few month continue believe academic government end market be stable improve schenkel note
144,TMO,industrial cyclical end market not be improve quickly hope say be encourage sign
145,TMO,remain enthused outlook improve end market favorable comparison drive continue relative outperformance schenkel write
146,TMO,related myriad tata motor rs leader correction new analyst report cowen co offer upbeat assessment medical research equipment stock ahead first quarter earning thank improve end market report life science diagnostic tool sector tuesday analyst doug schenkel write most company be poise meet beat expectation expectation combine confidence build forward look commentary positive update end market help share price sector recover recent slump schenkel add company reckon be best position beat estimate be fluidigm fldm illumina ilmn myriad genetic mygn orasure technology osur perkinelmer pki thermo fisher scientific tmo fluidigm belong ibd medical system equipment group rank industry track illumina myriad perkinelmer thermo fisher be ibd medical research equipment service group rank orasure be medical product group rank stock myriad have highest ibd composite rating be follow illumina perkinelmer thermo fisher orasure fluidigm myriad have have best stock action late reach year high friday share be more begin year company life science diagnostic tool benefit growth most end market schenkel say coverage universe include major customer end market academic government industrial apply biopharma healthcare hospital have be show improvement say base check management commentary past few month continue believe academic government end market be stable improve schenkel note industrial cyclical end market not be improve quickly hope say be encourage sign remain enthused outlook improve end market favorable comparison drive continue relative outperformance schenkel write related myriad tata motor rs leader correction
147,TMO,marc casper leadership listen go hand hand learn more interrupt less
148,TMO,mentor be always datum gathering mode say casper president chief executive thermo fisher scientific tmo waltham mass part be discipline let person go thought cut
149,TMO,company bill world leader serve science provide product service scientific analysis lab research customer include pharmaceutical firm hospital university
150,TMO,merger thermo electron fisher scientific create firm announce stock deal company be perform well respective stock be hit new high combine firm continue grow report strong result
151,TMO,casper characterize integration company incredibly seamless credit transition management team determination stay focuse external customer rather get divert internal issue
152,TMO,decade growth
153,TMO,casper become chief executive say company leader set pretty ambitious goal year example declare want separate competitor emerge industry leader
154,TMO,ve do say casper ve go revenue time thermo fisher scientific have employee
155,TMO,attribute company success scale depth capability position largest player field aid merger provide wide range product service thermo fisher scientific gain strategic advantage rival say
156,TMO,customer lay goal look help achieve goal say help manage supply chain reduce inventory select right product application
157,TMO,company launch practical process improvement ppi program spur continuous improvement business used ppi method team employee explore way streamline operation cut waste adopt green initiative such used less paper electricity
158,TMO,now ingrained culture casper say help get comfort zone
159,TMO,tour facility casper say site manager let see ppi board huddle bulletin board review status various project design improve efficiency
160,TMO,also enjoy meeting customer get call unfiltered feedback re do translate action step often ask customer be worry so identify concern then explore company address concern marc casper leadership listen go hand hand learn more interrupt less mentor be always datum gathering mode say casper president chief executive thermo fisher scientific tmo waltham mass part be discipline let person go thought cut company bill world leader serve science provide product service scientific analysis lab research customer include pharmaceutical firm hospital university merger thermo electron fisher scientific create firm announce stock deal company be perform well respective stock be hit new high combine firm continue grow report strong result casper characterize integration company incredibly seamless credit transition management team determination stay focuse external customer rather get divert internal issue decade growthcasper become chief executive say company leader set pretty ambitious goal year example declare want separate competitor emerge industry leader ve do say casper ve go revenue time thermo fisher scientific have employee attribute company success scale depth capability position largest player field aid merger provide wide range product service thermo fisher scientific gain strategic advantage rival say customer lay goal look help achieve goal say help manage supply chain reduce inventory select right product application company launch practical process improvement ppi program spur continuous improvement business used ppi method team employee explore way streamline operation cut waste adopt green initiative such used less paper electricity now ingrained culture casper say help get comfort zone tour facility casper say site manager let see ppi board huddle bulletin board review status various project design improve efficiency also enjoy meeting customer get call unfiltered feedback re do translate action step often ask customer be worry so identify concern then explore company address concern
161,TMO,scientific instrument maker bruker brkr boost restructure effort friday result guidance miss estimate send bruker stock tumble midday trading market
162,TMO,bruker say sale fall year earlier quarter miss analyst consensus profit drop cent share company press release ceo frank laukien say also be softer expect lead company ramp restructure effort
163,TMO,have be make organizational system operational change better position bruker sustainable profitable growth cash flow generation laukien say continue weakness industrial market update view be fourth quarter not be strong originally expect result be take additional term action reduce headcount lower expense base analyze restructure opportunity
164,TMO,firm be now guide full year revenue flat slightly lower ep range cent vs cent last year
165,TMO,isi group analyst ross muken shave dollar price target now reiterate buy rating give significant ep fcf free cash flow power potential business confidence improve execution underlie market demand dynamic improve add research note friday
166,TMO,bruker stock open thursday close midday be trading have be do fairly well ibd relative strength rating
167,TMO,difficult industrial market have affected bruker peer earning season well thermo fisher scientific tmo also suffer weak industrial market report last week make health care diagnostic side be similar story dhr life science performance be so good lift share new high water other hand see most trouble drug market many big pharmas have be restructure cost cut water stock dove last week be still depress scientific instrument maker bruker brkr boost restructure effort friday result guidance miss estimate send bruker stock tumble midday trading market bruker say sale fall year earlier quarter miss analyst consensus profit drop cent share company press release ceo frank laukien say also be softer expect lead company ramp restructure effort have be make organizational system operational change better position bruker sustainable profitable growth cash flow generation laukien say continue weakness industrial market update view be fourth quarter not be strong originally expect result be take additional term action reduce headcount lower expense base analyze restructure opportunity firm be now guide full year revenue flat slightly lower ep range cent vs cent last year isi group analyst ross muken shave dollar price target now reiterate buy rating give significant ep fcf free cash flow power potential business confidence improve execution underlie market demand dynamic improve add research note friday bruker stock open thursday close midday be trading have be do fairly well ibd relative strength rating difficult industrial market have affected bruker peer earning season well thermo fisher scientific tmo also suffer weak industrial market report last week make health care diagnostic side be similar story dhr life science performance be so good lift share new high water other hand see most trouble drug market many big pharmas have be restructure cost cut water stock dove last week be still depress
168,TMO,involved scientific research then have hear base thermo fisher scientific inc tmo free report lead scientific instrument manufacturer world interestingly acquisition friendly company latest buy life technology be expect give birth unrivaled market leader serve research specialty diagnostic apply market currently thermo fisher have zack rank hold change follow promising first quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning current zack consensus estimate be peg share thermo fisher adjust earning share be year year report quarter revenue thermo fisher post first quarter revenue have also surpass zack consensus estimate revenue thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotekey stat business segment report quarter thermo fisher deliver revenue life science solution analytical instrument specialty diagnostic laboratory product service respectively major factor management be pleased way company have start year company launch innovative new product key technology platform enabled breakthrough proteomic genetic analysis structural biology company also gain high growth emerge market particularly china india south korea stock price follow earning release share price gain pre market trading session check back later full thermo fisher earning report later investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
169,TMO,first quarter earning season see starry start most member beating earning maintain revenue momentum apr however number positive revenue surprise be lag precede year number be par sequential figure latest earning preview total earning company have report so far be year year higher revenue total beat earning surpass revenue estimate week member be line release quarterly result expect get clearer picture first quarter earning season have offing end week medical sector snapshotmedical zack sector be expect stand quarter sector benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model broadly speaking latest tax cut job act many other change slash corporate tax rate earlier have also buoy optimism inventor medical product space be part broader medical sector have be hog lot limelight certain favorable development consider favorable demographic change market dynamic artificial intelligence ai big datum application upbeat consumer sentiment increase business investment sector have be go strong further senate decision defer implementation industry wide excise tax couple year know medical device tax have instilled confidence investor tax be put effect jan bill also delay so call cadillac tax tax employer insurance moreover medtech company have be ride high innovation grow consolidation focus emerge market backdrop let take look major medical product stock schedule release result apr quantitative zack model stock advantageous combination solid zack rank strong buy buy hold positive earning esp have higher chance beating estimate uncover best stock buy sell re report earning esp filter laboratory corporation america holding lh free report labcorp first quarter result be expect reflect gain strong labcorp diagnostic segment favorable price mix tuck acquisition organic volume zack consensus estimate earning be peg indicate year year growth further predict earning beat quarter labcorp have zack rank earning esp read more launchpad aid labcorp covance arm earning see complete list today zack rank stock here stock surpass zack consensus estimate trail quarters average beat reflect chart laboratory corporation america holding price ep surprise laboratory corporation america holding price ep surprise laboratory corporation america holding quotethermo fisher scientific inc tmo free report have be progress well analytical instrument business rise global demand company focus growth implementation strategy consolidation product offering be encourage initiative be likely reflect first quarter result zack consensus estimate earning be peg show year year growth however be difficult conclusively predict earning beat thermo fisher have zack rank earning esp read more offing thermo fisher earning stock surpass zack consensus estimate last quarters average beat be see chart thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quoteboston scientific corporation bsx free report have be gradually witness improve performance interventional cardiology ic lead innovative portfolio efficient commercial team globally watchman platform be set see stellar first quarter consistent global momentum boston scientific effort continue drive growth zack consensus estimate be peg cent indicate year year growth model show earning beat boston scientific have zack rank earning esp read more watchman aid boston scientific earning wo stock beat zack consensus estimate trail quarters average beat be negative show chart boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quotealign technology inc algn free report first quarter result be likely reflect gain continue adoption invisalign technology strong scanner service business zack consensus estimate earning be peg cent reflect year year improvement foresee beat align technology have zack rank earning esp read more steady overall growth drive align earning stock trump zack consensus estimate trail quarters average beat be see chart align technology inc price ep surprise align technology inc price ep surprise align technology inc quotevarian medical system inc var free report favorable revenue opportunity various oncology imaging component product grow adoption proton therapy strong overseas presence be likely have influenced company second quarter fiscal result zack consensus estimate earning be pin highlight year year rise however don see beat varian have zack rank earning esp read more varian medical earning be surprise store stock beat zack consensus estimate trail quarters average beat demonstrated chart varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quote make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
170,TMO,thermo fisher scientific inc tmo free report be slate report first quarter result market open apr last quarter company deliver positive earning surprise moreover thermo fisher have surpass estimate trail quarters average beat let see thing be shape announcement key catalyststhermo fisher have be go strong analytical instrument business increase global demand particularly company acquisition fei have be largely contribute analytical instrument portfolio past year buyout have enabled thermo fisher access fei industry lead high performance electron microscopy platform used protein study well facilitate life science research be also vital highlight quarter be report thermo fisher anticipate realize total synergy approximately end year follow deal closure cost synergy roughly adjust operate income benefit revenue related synergy thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quote follow completion deal company have launch host product expand thermo scientific helio dualbeam platform scope material science application also get reflect first quarter performance apart fei related development notable unveil company analytical instrument business be new line thermo scientific air quality monitor call iq series platform include mobile application remote monitoring control well wireless connectivity enhance service turn be likely contribute company top line yet be report quarter overall waltham base company be gear yet quarter strong analytical instrument segmental growth period be report thermo fisher expect see positive impact electron microscopy business well robust volume expansion productivity zack consensus estimate analytical instrument revenue be peg higher year figure here be other factor influence thermo fisher first quarter result company focus boost growth implementation strategy consolidate product offering be encourage initiative be likely help post impressive result first quarter company have spend research development same trend be continue expect innovation product introduction substantially drive company top line first quarter company aim expand capability fast grow asia pacific zone well emerge market also lead solid result recent standout contributor be china india south korea strategic investment support key customer application thermo fisher forecast maintain bullish momentum moreover growth be estimate apply market such environmental food safety apart life science addition company be bet key area focus enormous opportunity disposal include advance precision medicine mass spectrometry target gene sequence structural biology however be apprehensive thermo fisher face foreign exchange headwind revenue adjust ep also hostile macroeconomic condition continue weigh heavily stock stiff competition consistently pose challenge stock value here quantitative model predict proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp thermo fisher have zack rank increase predictive power esp earning esp leave surprise prediction inconclusive be company need positive esp be confident earning surprise thus combination do not suggest stock be likely beat earning quarter caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter stock considerhere be few medical stock worth consider right combination element outpace expectation time myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp be zack rank player investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
171,TMO,mar issue update research report thermo fisher scientific inc tmo free report company boast strong international operation have witness consistent growth asia pacific emerge market however company earning have be affected unfavorable foreign exchange last few quarters stock carry zack rank hold lead scientific instrument maker have be outperform industry past year stock have rally compare gain industry meanwhile thermo fisher have be witness solid growth globally strong expansion company plan continue strengthen foothold emerge market such china india other region such south korea russia brazil fourth quarter standout contributor be china india south korea china lead way growth high teen company open customer demo center region reflect company lead position electron microscopy precision medicine space company have also invest significantly digital capability india company be currently work tap growth opportunity biopharma healthcare food safety market part strategy effectively deploy capital thermo fisher have undertake several acquisition recent past apart boost revenue deal have drive operate margin also result tax synergy regard thermo fisher acquisition fei company have start boost analytical instrument portfolio also company spend acquisition add lead biopharma contract development manufacturing service patheon buyout significantly enhance company value proposition biopharma customer patheon have start contribute thermo fisher laboratory product service segment flip side thermo fisher derive huge portion revenue international market expose fluctuation foreign currency past several year company earning be affected adverse currency movement great extent apart competitive headwind rise operate cost threat zack rank key pickssome better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
172,TMO,last few day laboratory corporation americas holding lh free report popularly know labcorp have be dominate headline several strategic development follow extend alliance interpace diagnostic idxg free report announce earlier week labcorp have form more joint venture time appalachian regional healthcare multus year comprehensive laboratory collaboration help labcorp provide high quality high value standardized laboratory diagnostic appalachian regional healthcare hospital base lab apart technical service labcorp aid reference testing appalachian regional healthcare entire network facility clinician make enhance information technology datum analytic accessible help improve delivery patient care alliance be expect strengthen labcorp diagnostic testing foothold eastern kentucky southern west virginia progress strategic collaboration note labcorp have fortify footprint diagnostic space organic inorganic mean plan collaborate lead company academic institution build wider portfolio test company continue increase scale competency clinical laboratory medicine acquisition range routine capability highly esoteric testing recent alliance new agreement interpace diagnostic dianon pathology member labcorp specialty testing group perform thyroid biopsy analysis apart worth mention be company major health system partnership mount sinai health system paml market lead reference outreach laboratory base pacific northwest labcorp anchor health system gradually emerge research hub improve access trial well covance site activation investigator patient recruitment capability other recent collaboration include strategic partnership thermo fisher tmo free report thermo fisher oncomine dx target panel be launch small cell lung cancer patient also ride partnership drug retailer walgreen wba free report company work develop operate patient service center select walgreen store significant be tie japan base sysmex corporation foremost clinical laboratory service provider roche world repute biotech company share price performance past month share labcorp have outperformed industry stock have gain industry decline labcorp carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
173,TMO,thermo fisher scientific inc tmo free report bid broaden human identification hide portfolio recently announce buyout integenx inc notably integenx be developer rapid dna platform use law enforcement forensic forensic application however financial detail deal have be keep wrapped company integenx rapidhit platform software analysis tool related consumable highly complement thermo fisher short tandem repeat str chemistry human identification qpcr capillary electrophoresis system encouragingly note integenx have widespread presence country provide assistance prosecutor law enforcement application generate forensic dna profile sample very short process time believe addition integenx tech platform aid thermo fisher boost top line contribution hide portfolio human identification portfolio glancethermo fisher robust hide portfolio encompass dna quantification kit pcr amplification kit human identification professional service next generation sequence ngs solution apply biosystem product such quantifile trio globalfiler yfiler kit apply biosystem genemapper id software copan nucleic card floqswab collection system cater kind demand niche market develop portfolio last september thermo fisher announce receipt approval unite state federal bureau investigation fbi authorize usage company apply biosystem yfiler pcr amplification kit generate genetic profile uploading combine dna index system market potentialper report global human identification market be anticipate value see cagr thus latest development have come opportune time company cash bountiful opportunity high potential niche market price performanceover past year thermo fisher share have outperformed industry belong stock have gain compare industry rise zack rank key picksthermo fisher carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank stock company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
174,TMO,feb issue update research report thermo fisher scientific inc tmo free report lead scientific instrument maker stock have zack rank hold thermo fisher end fourth quarter promising note adjust earning revenue beating zack consensus estimate be encourage company solid international performance strong year year growth asia pacific emerge market china south korea middle east also series product launch major progress precision medicine initiative have benefit company performance thermo fisher acquisition fei company have already start boost analytical instrument portfolio thermo fisher scientific inc price thermo fisher scientific inc price thermo fisher scientific inc quote also company deploy strategic acquisition add lead biopharma contract development manufacturing service patheon significantly enhance company value proposition biopharma customer patheon have start contribute company laboratory product service segment additional good news be thermo fisher have strong cash balance enable provide solid return investor past month thermo fisher have successfully trade broader industry stock have rally surpass broader industry gain period promising guidance be more encourage indicate overall bullish trend continue year ahead last quarter company business segment be impact strategic investment unfavorable business mix also competitive headwind rise operate cost persistently threat apart thermo fisher derive majority revenue international market expose foreign currency fluctuation key pickssome better rank stock broader medical space be abiom abmd free report athenahealth athn free report cardinal health cah free report sporting zack rank strong buy see complete list today zack rank stock here abiom have expect long term growth rate stock have soar last month ahead broader industry performance athenahealth have project long term growth rate stock have climb last month industry gain cardinal health have expect long term growth rate last month stock have gain higher industry rise today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
175,TMO,roper technology inc rop free report recently inked definitive agreement thermo fisher scientific inc tmo free report divest wholly own subsidiary gatan inc cash amount roughly deal currently subject customary close condition be expect be accomplish end year gatan be premium manufacturer software instrumentation used extend improve performance operation electronic microscope premium technology company be used domain electronic life science material science support electron microscopy workflow imaging analysis specimen manipulation preparation gatan be headquarter pleasanton major facility be locate warrendale pa gatan be predict generate roughly revenue gatan reinforce thermo fisher exist electron microscopy portfolio post buyout business be include latter analytical instrument segment divestment gatan be sync roper technology inorganic growth strategy company streamline business back business acquisition divestiture first quarter end march acquisition divestment contribute top line growth roper technology currently carry zack rank buy past month share company have rally loss record industry company pull average positive earning surprise past quarters company zack consensus estimate reflect year year growth respectively other key pickssome other top rank stock same space be list chart industry inc gtls free report sport zack rank strong buy company earning share ep be predict grow next year see complete list today zack rank stock here idex corporation iex free report carry zack rank company ep be estimate rise next year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
176,TMO,thermo fisher scientific inc tmo free report recently announce signing agreement buy gatan inc wholly own subsidiary roper technology inc rop free report company have agree pay cash buyout transaction be expect be complete end be subject certain customary close condition glimpse gatangatan be lead manufacturer well supplier instrumentation software electron microscopy industry technology be utilize electronic life science material science enable electron microscopy workflow further subsidiary be expect generate revenue thermo fisher plan integrate gatan technology analytical instrument business further company aim build integrate system consistently connect microscope hardware software accessory combine gatan technology electron microscopy portfolio strategic buyout major growth drivera part strategy effectively deploy capital thermo fisher have undertake several acquisition recent past boost revenue accretion deal have historically benefit company operate margin result tax synergy notably patheon buyout have substantially add impetus company value proposition biopharma customer further have already start prove accretive laboratory product service segment recent development be company takeover affymetrix work multiplex simultaneous analysis biological system cell protein gene level facilitate transition research tool clinical apply market have start boost thermo fisher offer fast grow flow cytometry market advanced antibody portfolio also take consideration other strategic acquisition thermo fisher company complete buyout desktop scanning electron microscopy sem solution provider phenom world financial term transaction remain undisclosed further thermo fisher announce buyout integenx inc broaden human identification hide portfolio market potentialper report publish financial report global market electron microscope be expect see cagr consider bountiful opportunity niche company latest development seem be strategically align price performanceover past year thermo fisher share have outperformed industry stock have gain industry fall zack rank key picksthermo fisher carry zack rank hold better rank stock broader medical space be genomic health ghdx free report abiom abmd free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
177,TMO,thermo fisher scientific inc tmo free report report better expect performance fourth quarter adjust ep come beating zack consensus estimate year quarter figure report basis fourth quarter ep marked decline year year bottom line figure include time tax provision associate recent enactment tax reform legislation unite state full year adjust ep come year period ahead zack consensus estimate quarter ep also exceed company provide guidance range revenue quarter come year year top line also outpaced zack consensus estimate full year revenue be year period surpass zack consensus estimate moreover revenue count stand company guide band quarter detailorganic revenue fourth quarter grow year year acquisition increase revenue currency translation positively impact total revenue thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc quote thermo fisher currently operate business segment life science solution analytical instrument specialty diagnostic laboratory product service revenue life science solution segment total revenue improve year year analytical instrument segment sale rise represent acquisition fei company revenue laboratory product service segment surge reflect buyout patheon august specialty diagnostic segment record rise gross margin fourth quarter be basis point bps year year improvement gross profit adjust operate margin contract bps rise selling general administrative expense increase research development expense company exit year cash cash equivalent compare end full year net cash provide operate activity be compare year period company provide financial outlook earning conference call bottom linethermo fisher end fourth quarter promising note adjust earning revenue beating zack consensus estimate be encourage company solid international performance strong year year growth asia pacific emerge market china south korea middle east also series product launch major progress precision medicine initiative benefit company performance thermo fisher acquisition fei company have already start boost analytical instrument portfolio also company deploy strategic acquisition add lead biopharma contract development manufacturing service patheon significantly enhance company value proposition biopharma customer patheon have start contribute company laboratory product service segment zack rank key picksthermo fisher have zack rank hold better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning prior year quarter revenue report quarter increase year year constant exchange rate cer perkinelmer release fourth quarter adjust earning cent company report adjust revenue approximately top year quarter accuray announce loss cent second quarter fiscal cent narrower year figure total revenue gain year year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
178,TMO,decode mystery human dna genomic sequence be far fetch idea just decade not forget take year investment more first human genomic sequence now genome be sequence just couple day cost lesser latest iphone healthcare news analyst believe grow demand personalize medicine solid investment rise research activity have propel growth buoy trend genomic have receive warm response medtech investment space healthcare market market global genomic market be worth be expect reach cagr fact zack medical biomedical genetic industry rise month time compare index return so here discuss genomic have be create opportunity medtech investor be keen putt money healthcare space solid gain favorable trend drive genomic marketsthe global genomic market have be favore streak solid development sequence microarray pcr polymerase chain reaction nucleic acid extraction purification technique further implication artificial intelligence ai cloud base technology increase focus have provide company significant exposure genomic lend competitive edge medtech space late gene editing synthetic dna production already vogue be not very far era gene be customize requirement research report techcrunch suggest highly advanced crispr technology be capable splice editing gene lung cancer leukemia regard pacific bioscience california pacb free report single molecule real time smrt sequence technology deserve mention technology help scientist observe dna synthesis real time harness natural process replication start enzyme dna polymerase lead medical instrument company have strong exposure genomic carry zack rank hold pacific bioscience flagship platform sequel system have be fortify company international footprint system be nucleic acid sequence platform base smrt technology other company be also poise gain rise influence genomic medtech stock have vgm style score carry zack rank higher illumina inc ilmn free report illumina portfolio sequence platform comprise system be design meet output accuracy demand full range sequence application company miseq sequence system be low cost desktop sequence platform provide individual researcher rapid turnaround time high accuracy streamline illumina new product launch genomic portfolio consistently contribute top line management be optimistic recently launch novaseq flow cell reagent kit company also receive product approval certificate nextseq dx instrument ministry food drug safety mfds south korea past year illumina have outperformed industry stock have gain stock have zack rank buy thermo fisher scientific inc tmo free report thermo fisher offer comprehensive portfolio genotyp solution snp indel cnv analysis buyout affymetrix be worth mention discuss genomic portfolio affymetrix work multiplex simultaneous analysis biological system cell protein gene level facilitate transition research tool clinical apply market have start boost thermo fisher offer fast grow flow cytometry market advanced antibody portfolio moreover genetic analysis affymetrix technology complement thermo fisher product target clinical apply market total synergy value be peg third year post completion deal comprise cost synergy adjust operate income benefit past year thermo fisher have successfully outperformed industry stock have gain company have zack rank qiagen qgen free report various analyst opine qiagen currently offer broadest portfolio molecular technology human healthcare company announce lab develop test woman man health feature gene panel get know individual risk hereditary cancer type company also provide service pharmacogenomic first quarter company announce receipt japan ministry health labor welfare approval quantiferon tb gold qft diagnostic detect tuberculosis tb infection past year qiagen have be outperform industry stock have gain company have zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
179,TMO,oct issue update research report henry schein inc hsic free report lead distributor health care product service globe company carry zack rank hold term price return performance past month stock remain line broader industry expect trend improve balanced growth operate segment henry schein be also encourage company effort grow internationally apart north america europe have presence australia new well emerge nation china brazil israel czech republic poland also company continue ride high dental business majorly accretive strategic merger integration colossal merger field be poland base dental cremer henry schein animal health revenue growth have be consistently support niche acquisition begin company have make foray brazilian animal health market investment tecnew same time company announce decision acquire southern sas turn benefit dental business controlled controlled pharmaceutical well surgical supply also henry schein gain several trend end market customer demographic increase number life cover follow healthcare reform unite state be likely boost company additionally henry schein gain traction animal health business back tailwind north america well overseas market burgeon demand animal health product unite state further drive company growth flip side escalate cost expense continue be drag company margin bottom line tough competitive landscape pricing pressure also weigh henry schein stock key better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have surge last year thermo fisher have long term expect earning growth rate stock have gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
180,TMO,involved scientific research then have hear base thermo fisher scientific inc tmo free report lead scientific instrument manufacturer world interestingly acquisition friendly company latest buy life technology be expect give birth unrivaled market leader serve research specialty diagnostic apply market currently thermo fisher have zack rank hold change follow promising fourth quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning current zack consensus estimate be peg share thermo fisher adjust earning share be year year report quarter thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quote revenue thermo fisher post fourth quarter revenue have also surpass zack consensus estimate revenue key stat business segment report quarter thermo fisher deliver revenue life science solution analytical instrument specialty diagnostic laboratory product service respectively major factor management be pleased performance company launch innovative new product key technology platform enabled breakthrough proteomic genetic analysis structural biology company also gain high growth emerge market particularly china india south korea be also very active year strategic stock price follow earning release share price gain pre market trading session check back later full thermo fisher earning report later hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
181,TMO,pacific bioscience california pacb free report recently announce feature new multiplexing sequence tool upcoming american society microbiology asm annual meeting atlanta make process obtain microbial genome highly accurate faster more affordable additionally result genome sequence more dangerous bacterium pacific bioscience house uk national collection type culture also be showcased meeting upgrade sequel system also know pacbio sequel system have increase throughput enable multiple microbe be sequence single smrt single molecule real time sequence cell day thereby reduce cost microbe have unique barcode be incorporate smrtbell adapter help multiplexing pacbio sequel system drive top linepacbio include pacbio rs pacbio rs ii system be nucleic acid sequence platform base smrt technology have be significant contributor company top line stiff competition medtech bigwig illumina inc ilmn free report thermo fisher scientific tmo free report begin company release latest sequence enzyme software sequel system fact first quarter sequel booking have be strong largest number instrument order largest multus unit sequel order come china drive plan animal sequence project moreover al base hudsonalpha institute biotechnology be currently used pacbio sequel study more child parent read more pacific bioscience gain hudsonalpha pick sequel system other recent development pacbio platform radboud university medical center netherlands purchase second sequel instrument market prospectsper study global genomic market have be value be expect grow cagr reach grow demand personalize medicine grow investment rise research activity field genomic propel growth market hence conclude latest move be beneficial pacific bioscience price performancein past month share pacific bioscience have rally outperform industry return zack rank key pickpacific bioscience currently carry zack rank hold better rank stock broader medical sector be abiom inc abmd free report abiom have expect long term earning growth rate stock currently sport zack rank strong buy see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
182,TMO,jun initiate research report bio rad laboratory inc bio free report be upbeat company deliver robust performance overseas tough competitive landscape be concern stock carry zack rank hold california base manufacturer global supplier clinical diagnostic life science research product have be outperform industry past year stock have gain versus industry rise bio rad kick start solid note earning revenue rise year year first quarter company have be strongly progress effort strengthen hold other geography first quarter bio rad derive net sale globally company deliver robust performance primarily north america china asia pacific region further constant currency sale life science segment be particularly strong north america china europe currency neutral sale company clinical diagnostic segment see strength china asia pacific north america be encourage company active portfolio expansion blood typing market january bio rad announce receipt clearance fda ih incubator ih centrifuge instrument be used complete range bio rad ih system gel reagent manual blood typing method meanwhile bio rad operate highly competitive environment dominate firm vary large multinational corporation start up also competitive regulatory condition market company operate limit ability switch strategy price increase other driver cost increase life science segment bio rad primarily compete like becton dickinson thermo fisher scientific tmo free report other again prominent competitor clinical diagnostic segment be abbott laboratory free report diasorin further bio rad be expose risk associate weaker global economy lower reimbursement rate key picksa better rank stock broader medical sector be intuitive surgical isrg free report sporting zack rank strong buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
183,TMO,investor be always look stock be poise beat earning season thermo fisher scientific inc tmo free report be such company firm have earning come pretty soon event be shape quite nicely report be thermo fisher be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface tmo report fact most accurate estimate current quarter be currently share tmo compare broader zack consensus estimate share suggest analyst have very recently bump estimate tmo give stock zack earning esp head earning season thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give tmo have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead thermo fisher beat be card upcoming report don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
184,TMO,thermo fisher scientific inc tmo free report be slate report fourth quarter result market open jan last quarter company deliver positive earning surprise moreover thermo fisher have surpass estimate trail quarters average beat let see thing be shape announcement key catalystthermo fisher have be go strong analytical instrument business increase global demand particularly company acquisition fei have already start generate synergy largely contribute analytical instrument portfolio last quarters buyout have enabled thermo fisher access fei industry lead high performance electron microscopy platform used protein study facilitate life science research be also vital highlight quarter be report thermo fisher anticipate realize total synergy approximately end year follow deal closure cost synergy roughly adjust operate income benefit revenue related synergy get reflect fourth quarter performance thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quote apart fei related development notable launch company analytical instrument business be new line thermo scientific air quality monitor call iq series platform include mobile application remote monitoring control well wireless connectivity enhance service turn be likely contribute company top line yet be report quarter last not least worth mention be company recent completion take desktop scanning electron microscopy sem solution provider phenom world thermo fisher plan integrate business analytical instrument segment management addition phenom world desktop sem platform be project leverage position electron microscopy space expand entry level desktop sem offering customer work material science industrial manufacturing life science electronic industry overall waltham base company be gear yet quarter strong analytical instrument segmental growth period be report thermo fisher expect see positive impact electron microscopy business well robust volume expansion productivity zack consensus estimate analytical instrument revenue be peg higher sequentially last quarter report figure total revenue estimate segment also remain impressive level here be other factor influence thermo fisher fourth quarter result company focus boost growth implementation strategy consolidate product offering be encourage initiative be likely help post impressive result fourth quarter company have spend research development same trend be continue expect innovation product launch significantly contribute company top line fourth quarter company aim expand capability fast grow asia pacific zone well emerge market also lead solid result recent standout contributor be china india south korea strategic investment support key customer application thermo fisher forecast maintain bullish momentum rest growth be also estimate apply market such environmental food safety apart life science addition company be bet key area focus enormous opportunity disposal include advance precision medicine mass spectrometry target gene sequence structural biology however be apprehensive thermo fisher cite foreign exchange headwind revenue adjust ep also hostile macroeconomic condition continue weigh heavily stock stiff competition consistently impose challenge stock value here quantitative model predict thermo fisher do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat quarter zack esp thermo fisher have earning esp uncover best stock buy sell re report earning esp filter zack rank thermo fisher zack rank increase predictive power esp however need positive esp be confident earning surprise hence combination leave surprise prediction inconclusive zack consensus estimate fourth quarter earning share reflect rise year year basis stock considerhere be few medical stock worth consider right combination element beat estimate time bio rad laboratory inc bio free report have earning esp zack rank strong buy see complete list today zack rank stock here myriad genetic inc mygn free report have earning esp be zack rank player henry schein inc hsic free report have earning esp be rank player make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
185,TMO,illumina inc ilmn free report have sign commercial agreement distribute thermo fisher scientific inc tmo free report ion ampliseq technology researcher conduct study illumina next generation sequence ngs platform term agreement thermo fisher provide illumina ion ampliseq technology research use notably amplicon technology be highly effective capture dna rna very limit amount sample application range research area ion ampliseq technology be develop facilitate amplicon sequence ion torrent ngs system illumina now distribute product directly customer brand ampliseq meanwhile thermo fisher continue sell ion ampliseq chemistry ivd ruo application ion torrent ngs customer furthermore thermo fisher retain right make technology available other next generation sequence platform next generation sequence platform focusillumina be consistently work enhance next generation sequence platform illumina recently introduce second fda regulate ce ivd marked next generation sequence system nextseq dx august illumina partner telegraph hill partner set independent company verogen inc entity be expect strengthen illumina ngs business forensic genomic market accord market market global next generation sequence market be estimate reach worth cagr last month illumina have gain broader industry decline estimate revision current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share same period zack rank key picksillumina carry zack rank hold couple better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
186,TMO,laboratory corporation americas holding lh free report popularly know labcorp recently collaborate unilab lead european provider clinical laboratory testing medical diagnostic imaging service term deal have be keep wrapped labcorp company start assay have be design test analytically clinically labcorp covance drug development business collaboration labcorp unilab aim increase access channel companion diagnostic north america europe company also intend drive uptake companion diagnostic widening laboratory network access company start oncology particularly immuno oncology labcorp unilab work simplify technical regulatory clinical complexity related critical assay collaboration tracklabcorp have strengthen foothold diagnostic space organic inorganic mean plan collaborate lead company academic institution offer wider portfolio test recent alliance company have announce extension exist partnership agreement aetna aet free report late company have be dominate headline announcement expand partnership business unitedhealth group unh free report continue serve exclusive national laboratory provider jan further company comprehensive laboratory collaboration appalachian regional healthcare hospital health system kentucky west virginia be worth mention apart company have expand relationship mount sinai consolidate latter reference work streamline inpatient lab also labcorp covance business recently enter strategic technology agreement glaxosmithkline plc gsk free report term agreement glaxosmithkline use covance xcellerate monitoring xcellerate insight xcellerate clinical datum hub solution software service model other recent partnership include thermo fisher tmo free report enabled launch thermo fisher oncomine dx target panel small cell lung cancer patient also labcorp work develop operate patient service center select walgreen store drug retailer walgreen wba free report share price performanceover past month share zack rank hold company have outperformed industry stock have gain compare industry gain see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
187,TMO,nuvasive inc nuva free report have be news late receipt expand fda approval advanced magnetic invasive limb lengthen technology precice fall nuvasive specialize orthopedic nso precice now be used treat open close fracture fixation pseudoarthrosis malunion nonunion bone transport notably product be earlier allow use limb lengthen procedure elongate femur tibia approval be expect considerably drive nuvasive customer base precice platform comprise intramedullary device be implanted used external remote controller order invasively compress distract long bone company key precice platform be magnetic interaction external remote control precice intramedullary nail notably nso operate wholly own subsidiary nuvasive acquisition ellipse technology nuvasive continue gain share nso portfolio include magnetic external control magec early onset scoliosis precice technology build magec technology platform latest development nuvasive expect gain traction fast grow limb reconstruction trauma market report ally market research publish ortho spine news global extremity reconstruction market substantiate view report global extremity reconstruction market be expect reach value cagr believe unhealthy lifestyle result several joint disorder rapidly agee population rise awareness technological advancement increase spending healthcare government individual continue drive limb reconstruction trauma market thus nuvasive latest fda approval likely help cash bountiful opportunity niche market share price have be trading broader industry last stock have lose comparison broader industry decline believe latest development help company boost investor sentiment reverse downtrend zack rank key picksnuvasive currently carry zack rank sell few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
188,TMO,laboratory corporation americas holding lh free report popularly know labcorp have announce extension exist partnership agreement aetna aet free report late company have be dominate headline announcement expand partnership business unitedhealth group unh free report continue serve exclusive national laboratory provider jan expand agreement aetna labcorp serve prefer national laboratory almost company member start jan extend agreement provide network access labcorp complete portfolio laboratory service eligible member collaboration play big rolelabcorp have strengthen foothold diagnostic space organic inorganic mean plan collaborate lead company academic institution offer wider portfolio test company continue increase scale competency clinical laboratory medicine acquisition range routine capability highly esoteric testing recent alliance company comprehensive laboratory collaboration appalachian regional healthcare hospital health system kentucky west virginia be worth mention apart company have expand relationship mount sinai consolidate latter reference work streamline inpatient lab also labcorp covance business recently enter strategic technology agreement glaxosmithkline plc gsk free report term agreement glaxosmithkline use covance xcellerate monitoring xcellerate insight xcellerate clinical datum hub solution software service model other recent partnership include thermo fisher tmo free report enabled launch thermo fisher oncomine dx target panel small cell lung cancer patient also labcorp work develop operate patient service center select walgreen store drug retailer walgreen wba free report apart company have important tie japan base sysmex corporation foremost clinical laboratory service provider roche world repute biotech company share price performanceover past month share labcorp have outperformed industry stock have gain compare industry gain zack ranklabcorp carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
189,TMO,last few month laboratory corporation americas holding lh free report popularly know labcorp have be dominate headline several development include strategic partnership divestment follow company laboratory collaboration appalachian regional healthcare mount sinai have form more joint venture time business unitedhealth group unh free report fact be renewal entity long term strategic partnership create more simplified personalize care recommendation person enrolled plan unitedhealth labcorp continue serve exclusive national laboratory provider jan however financial term deal have be keep wrapped notably part expand relationship company be go join force variety value base program alliance help bring advanced lab service accountable care arrangement more hospital physician progress strategic labcorp have fortify footprint diagnostic space organic inorganic mean plan coordinate lead company academic institution build wider portfolio test company continue increase scale competency clinical laboratory medicine acquisition range routine capability highly esoteric testing recent association labcorp have form multus year comprehensive laboratory teamwork appalachian regional healthcare also new agreement interpace diagnostic dianon pathology member labcorp specialty testing group company perform thyroid biopsy analysis additionally worth mention be company major health system partnership mount sinai health system paml respectively paml be pacific northwest base market lead reference outreach laboratory labcorp anchor health system gradually emerge research hub improve access trial well covance site activation investigator patient recruitment capability other recent coalition include strategic partnership thermo fisher tmo free report enabled launch thermo fisher oncomine dx target panel small cell lung cancer patient also labcorp work develop operate patient service center select walgreen store courtesy drug retailer walgreen wba free report apart company have important tie japan base sysmex corporation foremost clinical laboratory service provider roche world repute biotech company share price performanceover past month share labcorp have outperformed industry stock have gain industry decline labcorp carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
190,TMO,issue update research report thermo fisher scientific inc tmo free report banking several takeover include patheon fei acquisition lead scientific instrument maker be rapidly ramp inorganic growth profile company strong focus emerge market be also encourage stock have zack rank hold thermo fisher end first quarter promising note adjust earning revenue surpass zack consensus estimate be also impressed company solid international performance back strong growth emerge market china south korea india thermo fisher scientific inc price thermo fisher scientific inc price thermo fisher scientific inc quote also series product launch major progress precision medicine initiative aid thermo fisher performance moreover patheon buyout have substantially add impetus company value proposition biopharma customer notably integration have already start prove accretive thermo fisher laboratory product service segment past year thermo fisher have successfully outperformed industry stock have rally versus industry decline promising guidance also uplift mood indicate stock continuous bull run remainder year flip side company business segment have be impact unfavorable business mix past few quarters also competitive headwind rise operate cost persistently threat apart thermo fisher derive majority revenue international market expose currency volatility zack rank other key picksthermo fisher currently carry zack rank buy other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate zack rank varian medical have project long term growth rate stock hold zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
191,TMO,thermo fisher scientific inc tmo free report report better expect performance first quarter adjust ep come beating zack consensus estimate year quarter figure report basis ep marked increase year year revenue quarter logged year year top line also outpaced zack consensus estimate quarter detailorganic revenue report quarter grow year year acquisition increase revenue currency translation positively impact total revenue thermo fisher operate business segment life science solution analytical instrument specialty diagnostic laboratory product service thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc quote revenue life science solution segment total revenue improve year year analytical instrument segment sale rise revenue laboratory product service segment surge reflect buyout patheon august specialty diagnostic segment record rise gross margin first quarter be basis point bps year year improvement gross profit adjust operate margin however expand bps rise operate profit company exit first quarter cash cash equivalent compare end mar net cash provide operate activity be compare year period guidancebase solid first quarter performance more significant impact acquisition more favorable foreign exchange environment thermo fisher have raise revenue earning guidance revenue be expect range compare company earlier project band enhance revenue growth year period zack consensus estimate remain guide range adjust ep view have be lift new range compare previous forecast reflect growth year earlier period zack consensus estimate share fall company prediction bottom linethermo fisher end first quarter promising note adjust earning revenue surpass consensus mark be encourage company solid international performance strong year year growth emerge market china south korea india also series product launch major progress precision medicine initiative aid company performance quarter review company have launch vanquish duo uhplc system pharma qa qc chromeleon xtr laboratory management system ion genestudio series next generation sequence instrument moreover substantially add impetus company value proposition biopharma customer patheon buyout have already start prove accretive company laboratory product service segment zack rank key picksthermo fisher have zack rank hold better rank stock broader medical sector be abaxis inc abax free report bio rad laboratory inc bio free report resm inc rmd free report abaxis bio rad sport zack rank strong buy resm carry zack rank buy see complete list today zack rank stock here abaxis be expect release fourth quarter fiscal result apr zack consensus estimate adjust ep be cent revenue same stand bio rad be expect report first quarter result zack consensus estimate adjust ep be cent revenue resm be slate release third quarter fiscal result apr consensus mark adjust ep be cent same revenue be peg investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
192,TMO,hologic inc holx free report be slate report third quarter fiscal financial result aug close bell last quarter company deliver positive earning surprise notably hologic earning surpass zack consensus estimate past quarters average beat let see thing be shape prior announcement factor playhologic witness lackluster performance diagnostic segment last report quarter poor cytology perinatal sale particularly longer cervical cancer screening guideline interval be play spoilsport here issue still factor company performance expect segment continue perform dull upcoming quarter be also worry fact hologic blood screening divestiture be expect impede company growth momentum day ahead expect get reflect company financial performance yet be report quarter hologic have face several challenge owing unfavorable foreign currency impact have be affect company overall performance past few quarters foreign exchange headwind be expect result reduction escalate operate expense intense competition particularly tomosynthesis market continue be concern hologic quite time now company witness several challenge such restrict capital spending environment economic uncertainty europe slower sale cycle increase pricing pressure expect problem linger upcoming quarters well company get significant synergy benefit third quarter integration cynosure inc medical aesthetic system technology company hologic acquire mar mention fda have recently grant expand clearance cynosure invasive body contour product sculpture treat back inner outer thigh come product launch third quarter company receive european ce mark new panther fusion system panther fusion assay flu respiratory testing also company announce fda approval itsgenius mammography exam several other product launch also boost upcoming quarterly result overall third quarter fiscal hologic expect revenue compare prior guidance current zack consensus estimate third quarter revenue be company expectation adjust ep be project cent cent high end previous cent cent range current zack consensus estimate third quarter adjust ep be peg cent company guidance earning whispersour proven model do not conclusively show hologic be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp hologic have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank hologic have zack rank note caution sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company want consider model show have right combination element come earning beat quarter dextera surgical inc have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here idexx laboratory inc idxx free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
193,TMO,illumina inc ilmn free report lead provider tool integrate system analysis genetic variation function be schedule report second quarter result aug close bell last quarter company earning be line zack consensus estimate however illumina earning outpaced zack consensus estimate past quarters average let take look thing be shape prior announcement factor playin last report first quarter illumina witness robust revenue growth account consistent improvement sequence consumable strong demand microarray management be still emphasize portfolio sequence platform fortify market position expect company maintain top line growth second quarter management top line growth first quarter also be attribute strong uptake novaseq platform more order place period moreover active hiseq customer base roughly customer company expect replacement older generation instrument novaseq trend continue yet be report quarter illumina inc price ep surprise illumina inc price ep surprise illumina inc quotefurther company recently launch veriseq nipt solution europe ce ivd marked next generation sequence base approach noninvasive prenatal testing notably outside rate nipt adoption be increase netherlands denmark begin cover test first quarter same be expect shortly france company continue see positive reimbursement trend europe well also illumina have be forge ahead nipt expansion plan china believe development boost company top line upcoming quarter flip side weak margin owing introduction novaseq higher array service revenue product mix sequence consumable continue act deterrent company also tough competitive landscape challenge company be also apprehensive issue pertain nih funding illumina have be face quite time now overall second quarter illumina project revenue growth approximately current zack consensus estimate second quarter revenue be peg company expect adjust ep range cent however zack consensus estimate be stable cent guide range earning whispersour proven model do not conclusively show illumina be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp illumina have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank illumina zack rank increase predictive power esp however company earning esp make surprise prediction difficult meanwhile caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
194,TMO,stryker corporation syk free report lead player medical technology space be set report second quarter result jul bell last quarter company post earning share surpass zack consensus estimate cent notably average stryker beat zack consensus estimate almost last quarters let see thing be shape prior release likely positive surprise proven model show stryker be likely beat estimate have right combination key ingredient zack esp stryker earning esp be most accurate estimate be higher zack consensus estimate favorable esp serve meaningful indicator likely positive surprise uncover best stock buy sell re report earning esp filter zack rank stryker currently have zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely sell rate stock zack rank never be consider go earning announcement combination stryker favorable zack rank positive esp make reasonably confident beat stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quotefactor second quarter stryker expect adjust earning share range notably indicate rise year year basis believe grow adoption mako robot drive sale orthopedic reconstructive surgery market additionally stryker be well poise acquisition sage physio control past full year company expect adjust earning band stryker expect organic sale growth full year tie indo uk institute health medicity program be important factor well notably be year partnership aim offer primary joint replacement orthopedic area hip knee trauma product healthcare service india low cost company estimate revision trend be encourage current quarter stryker see upward estimate movement movement opposite direction last month current quarter estimate earning share be peg stock warrant lookhere be company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
195,TMO,resm inc rmd free report be slate report fourth quarter fiscal result market close aug last quarter company deliver positive earning surprise quarter average earning beat be let see thing be shape announcement factor playmanagement expect sg expense margin band yet be report quarter be third quarter also expense margin be project fourth quarter compare precede quarter hence expect bottom line drag continue yet be report quarter resm inc price ep surprise resm inc price ep surprise resm inc quotemeanwhile company generate significant portion revenue international market notably last report quarter currency impact resm combine emea asia pacific revenue be likely dent result fourth quarter well moreover overall macroeconomic uncertainty be major obstacle come company international operation also market sleep disordered breathe sdb product be highly competitive respect product price feature reliability other challenge competitive bidding reimbursement pressure continue hurt stock brighter side expand chronic obstructive pulmonary disease copd market be huge opportunity resm line company release positive datum pertain clinical trial related home oxygen therapy home mechanical ventilation hot hmv result demonstrated copd patient receive invasive ventilation niv home oxygen therapy have decrease risk re hospitalization death stay hospital more time longer compare receive oxygen alone company current endeavor gain traction copd market be expect boost revenue further major breakthrough treatment sleep apnea resm introduce airtouch full face mask ultrasoft memory foam keep patient cpap therapy comfortable night airtouch be available canada now be expect drive company top line yet be report quarter resm effort expand business internationally be encourage company revenue performance segment report third quarter be impressive expect company maintain similar trend quarter resm estimate revision trend be also encourage current year company see estimate move north movement opposite direction last month have take current year estimate same period earning whispersour proven model do not conclusively show earning beat resm quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp resm have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank resm have zack rank increase predictive power esp however company esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
196,TMO,jan issue update research report pacific bioscience california inc pacb free report solid contribution instrument consumable revenue platform have be boost pacific bioscience growth trajectory however cutthroat competition niche space have be hamper pacific bioscience revenue stock have zack rank sell pacific bioscience be lead player dna sequence market however niche space be highly competitive owing presence establish player illumina ilmn free report thermo fisher scientific inc tmo free report low cost sequence product illumina continue gain traction be headwind company moreover pacific bioscience be relatively small company compare second generation sequence technology firm moreover product launch like oxford nanopore dovetail genomic be expect intensify competition genome assembly market increase pricing pressure pacific bioscience long term other major concern pacific bioscience sale europe have decline substantially year year basis lag company target number customer europe have be slow initiate usage sequel system result company product witness poor adoption european market recent past further management forecast rise operate expense full year year year basis operate expense third quarter totale compare year quarter cash investment end third quarter be compare end second quarter positive note pacific bioscience flagship platform sequel system have be fortify company footprint worldwide sequel system be nucleic acid sequence platform base smrt technology be develop partnership roche however pacific bioscience agreement roche terminate earlier sequel system have be persistent contributor pacific bioscience top line price price movement pacific bioscience have be unfavorable last month notably stock have lose almost compare unfavorably industry rally roughly further current level compare unfavorably index return ongoing sluggishness european market be principal cause dismal price performance further company terminate year long agreement roche diagnostic collaboration provide way generate million long single molecule barcode dna fragment average kilobasis originated much longer fragment kilobasis key picka better rank stock broader medical sector be bio rad laboratory inc bio free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
197,TMO,oct issue update research report abbott free report global healthcare company dedicate improve life development product technology stock carry zack rank hold last month abbott have be trading broader industry stock have gain industry decline market be upbeat several new initiative adopt abbott latest buyout company be alere oct abbott have also announce receipt fda approval freestyle libre flash glucose monitoring system unite state moreover company announce receipt fda approval magnetic resonance mr conditional labele ellipse implantable cardioverter defibrillator icd apart fda approval buyout be upbeat abbott freestyle libre flash glucose monitoring system prospect post receipt full partial reimbursement french health ministry platform company announce health canada license freestyle libre june abbott also announce freestyle libre system be now available reimbursement flip side abbott sluggish pediatric business china continue mar growth management be concern economic problem venezuela be expect remain unresolved time also foreign exchange be major headwind abbott considerable portion revenue come outside unite state key stocksa few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
198,TMO,bruker corporation brkr free report scale new week high oct eventually close bit lower zack rank hold stock have market cap comparison broader majority last month company share price have considerably outperformed broader industry stock have rally last month outshine industry return company have also outperformed gain last month company year historical growth rate be also favorable compare broader industry index take stable stock performance consideration expect bruker gain ground come quarters growth week high come back several new development most recent be introduction new ce ivd marked fungiplex candida fast diagnostic assay multiplex real time pcr test rapid identification most common pathogen associate invasive candidiasis company also introduce ce ivd marked micronaut be antimycotic test plate automate manual antifungal susceptibility testing afst yeast culture recently bruker introduce timstof pro system pasef mass spectrometry annual world congress human proteome organization hupo also bruker announce new ray diffraction xrd system japan analytical scientific instrument show jasis bruker recently complete buyout merlin gmbh locate germany merlin have specialize skill product service consult field antibiotic resistance testing art antibiotic susceptibility testing ast acquisition have also play pivotal role drive company share price new week high key stocksa few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
199,TMO,few month line republican complete full year power unfortunately political power change healthcare community hasn have many opportunity rejoice survey report gallup analytic last month reveal adult cite healthcare second major problem face country new presidential administration fact debate repeal affordable care act aca obamacare have be rage now report peaked reach congress august consider prevailing uncertainty implementation health policy respite term seem unlikely medtech unite state blur pictureneedless say current crisis medtech industry integral part broader healthcare space show sign abate few month back company space be hopeful promise cancellation medtech tax obamacare new government unquestionably latest political development have land medtech space uncertain territory investor be mull retain exist medtech stock forego holding favor company other industry boost financial resource say spite future hold believe investor stick medtech space have show sign prosperity recent time globally yes read right even consider dull performance medical device market still hold lead position almost third world market share rise regulatory legislative uncertainty global growth have be quite encourage industry grow pace last see financial crisis emerge market hold immense uncertainty unite state worsening economic condition europe automatically shift focus emerge geography china india latin america other emerge economy be see rise uptake medical device largely due grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage make market happy hunting ground global medical device player add rise healthcare spending improve healthcare infrastructure growth continue go recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india medtech market fifth largest world be currently demonstrate annual growth continue india give good competition japan germany other emerge geography latin america even face general economic stagnation hold enormous potential january report medtech intelligence central south american nation significantly increase capita spending healthcare period accord world bank datum guatemala increase spending brazil chile colombia uruguay paraguay ecuador lower domestic production latin america have make open market exporter investment emerge market player look sensiblein such scenario believe be wise investor be keen medtech stock keep eye company have turn emerge market happy hunting ground expertise network wonder stock cash enormous growth potential emerge geography have perfectly shield political turmoil unite state let look few medtech player significant emerge market presence give huge potential region long back johnson johnson jnj free report have set manufacturing center brazil china india company medical device segment emerge market be grow time faster develop market have be do business china nearly year be expand further here back synthe acquisition johnson johnson price consensus johnson johnson price consensus chart johnson johnson quote abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina abbott laboratory price consensus abbott laboratory price consensus chart abbott laboratory quote medtronic mdt free report last report first quarter fiscal business china latin america southeast asia show sustain strength grow double digit overall medtronic remain confident long term outlook emerge market company be focuse develop new public private partnership well execute channel optimization strategy medtronic plc price consensus medtronic plc price consensus chart medtronic plc quote boston scientific bsx free report emerge market business register organic growth second quarter significant increase growth business china be once again remarkable year year company be currently look forward much better performance ahead china banking recent approval synergy china boston scientific corporation price consensus boston scientific corporation price consensus chart boston scientific corporation quote thermo fisher tmo free report too be leave stone unturned expand presence emerge market company garner total revenue high growth asia pacific emerge market thermo fisher scientific inc price consensus thermo fisher scientific inc price consensus chart thermo fisher scientific inc quote wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
200,TMO,oct issue update research report laboratory corporation america holding lh free report popularly know labcorp stock currently carry zack rank buy last month burlington nc base healthcare diagnostic company provide comprehensive clinical laboratory service end end drug development support have be outperform broader industry stock have lose compare industry decline period market seem be upbeat diagnostic business have deliver promising performance recent past spite persistent softness company covance drug development business be also encourage successful closure acquisition chiltern international group specialty contract research organization chiltern be major partner serve top biopharma segment help company focus high growth emerge mid market biopharma segment notably labcorp be steadily progress prong strategy drive growth first company be focuse research development collaboration academic institution order gain traction grow lab testing market second labcorp be increasingly deploy integrate testing capability industry lead science innovative technology offering establish strategic partnership provider moreover investor be look forward long standing strategic collaboration andme have already demonstrated impressive growth trajectory third labcorp core diagnostic strategy be base innovation datum integration tool support enhance connectivity report decision support company be also focuse extend core testing capability traditional health care set flip side unfavorable foreign exchange be threat moreover company operate tough competitive landscape meanwhile apprehension tough reimbursement scenario intensify concern company other key picksother top rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
201,TMO,oct issue update research report new york base dentsply sirona inc xray free report global leader design development manufacture marketing dental consumable dental laboratory product dentsply recently announce renewal exist distribution agreement henry schein canada inc continue dec henry schein agreement dentsply be initiate august feel deal extension be smart move dentsply preexist agreement do not include cerec cad cam restoration system schick line imaging sensor include aforementioned line product company benefit henry schein distribution network canada recent development dentsply announce renewal partnership pacific dental service duo latest agreement extend period year be sign move be also strategic pacific dental network consist center state tenure present agreement management expect number such office utilize dentsply technology exceed dentsply dual brand strategy product innovation growth opportunity emerge market especially asia pacific middle east africa diversify product portfolio recur revenue base be key catalyst company expect solid guidance full year project adjust ep range flip side apart series macroeconomic headwind currency fluctuation continue be major dampener fact strengthen dollar euro other emerge market currency have dent company growth trajectory furthermore higher capital expenditure product development be expect keep margin pressure share price estimate revision lack lusterdentsply estimate revision trend look unfavorable moment third quarter analyst moved south compare upward revision last month notably current quarter estimate drop cent share last day dentsply share price movement have be unfavorable last month company shed much higher industry decline zack rank key picksdentsply currently carry zack rank hold few better rank stock broader medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock have rally roughly year idexx laboratory have long term expect earning growth rate stock have gain year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
202,TMO,henry schein inc hsic free report recently complete earlier announce buyout merritt veterinary supply certain undisclosed financial term merritt be part veterinary business henry schein namely henry schein animal health merritt be independent family own supplier animal health product merritt have veterinary clinic eastern unite state strong presence southeastern part nation company offer comprehensive line product include pharmaceutical diagnostic equipment merritt generate revenue approximately accord henry schein acquisition drive earning share henry schein have be consistently try expand animal health business company global animal health segment witness improvement revenue last report second quarter recently henry schein animal health announce open new national distribution service center columbus brookhollow neighborhood expand presence central ohio begin henry schein have enter brazilian animal health market investment tecnew privately hold distributor animal health product prior company have acquire rxwork lead provider veterinary practice management software primarily customer australia new netherlands other country accord report grand view research global animal health market be expect reach value consider huge potential market believe latest development be strategic past year henry schein have underperform broader industry stock have gain compare broader industry rise estimate revision trend estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate current quarter have increase cent share cent zack rank key pickshenry schein currently carry zack rank hold few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
203,TMO,gnc holding inc gnc free report specialty retailer health nutrition related product be schedule report third quarter result oct open bell last quarter company post positive earning surprise however gnc holding trail quarter earning average miss stand let see thing be shape prior announcement factor playgnc holding last report second quarter revenue drop year year apart lower sale canada international manufacturing wholesale segment decline revenue be attribute overall drop sale protein vitamin weight management food drink category absence catalyst drive growth expect similar trend third quarter well moreover gnc holding have number competitor market include large international pharmacy chain supermarket firm big base company global operation thus expect company slash product price face stiff competition turn hurt margin gnc holding inc price ep surprise gnc holding inc price ep surprise gnc holding inc quote also currency headwind continue be grow concern gnc holding management also expect failure comply ftc regulation change consumer preference hamper business however bright side performance new gnc be improve gradually also last report quarter pro access member double visit purchase double product spend significantly more second quarter banking factor expect company continue gain yet be report quarter well meanwhile new consumer enrolment mygnc reward program launch gnc storefront amazon buoy optimism earning whisper proven model do not conclusively show earning beat gnc holding quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp gnc holding be uncover best stock buy sell re report earning esp filter zack rank gnc holding carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise stock considerhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank strong buy stock here henry schein inc hsic free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
204,TMO,future healthcare space be mired uncertainty president trump effort revoke affordable care act aca obamacare fall flat be fact republican be go end policy fiasco investment world be equally baffle chance stability anytime soon majority healthcare space have heaved sigh relief recent failure graham cassidy bill thank congressional budget office cbo latest warning report anticipate health coverage loss million american due reduction federal spending medicaid report be considerable decrease number person enrolling medicaid period primary reason expansion program establish aca be repeal start federal reimbursement state medicaid be capped en rollee basis begin individual mandate penalty induce person enroll medicaid be repeal legislation enactment president latest action plan indicate respite graham cassidy failure be short live thing be pretty clear entire pandemonium effort bring major change exist health insurance policy again turn be futile republican be undying effort fully repeal replace obamacare republican have never achieve majority related article do round report kimberly amadeo publish balance state trump want congress replace affordable care act september last day senate republican pass bill just vote majority include vice president mike pence cast final vote never get vote economist be once again dissect fact try come probable way ruling party turn be hard investor keen medical space settle investment strategy earn concrete pay investing strategy bet onamid such political conundrum ponder several investment mantra majority investor prefer bet stock have ability brave situation rock solid fundamental however sometimes think box create wonder find more logical ask investor consider investment option be not dependent political twist turn be talk momentum investing believe investor earn handsome profit extrapolate current bullish trend market future banking momentum investment strategy be worthwhile moment however pick right momentum stock be challenge task even seasoned investor be plan enter uncharted world jam packed trade zack screening guidewe be used zack style score system single stock yield favorable return be not affected market condition momentum style score indicate best time buy stock take advantage momentum highest probability success research show stock momentum score combine zack rank strong buy buy offer best upside potential short term see complete list today zack rank stock here picksthermo fisher scientific inc tmo free report thermo fisher post earning share most recent quarter surpass zack consensus estimate then company have see positive estimate revision company current year zack consensus estimate have increase cent past month revision activity have propel stock zack rank recent gain have help earn momentum score thermo fisher share have increase more last month way ahead market gain company impressive growth prospect continue push stock higher look ahead thermo fisher be poise benefit lead position market life science solution analytical instrument laboratory product service seaspine holding corp spne free report lead name field surgical solution related spinal disorder report loss cent share last quarter narrower zack consensus estimate loss cent then company have see positive estimate revision zack consensus estimate current year improve cent past couple month have propel stock zack rank have momentum score last month company make full commercial launch shoreline anterior cervical standalone system feature truprofile technology believe several new development further drive stock seaspine share have increase nearly last month way ahead market gain period veru inc veru free report company focuse urology oncology have benefit steady growth space company report loss cent share narrower zack consensus estimate loss cent last month veru stock have improve cent current fiscal company stock price have increase more last month veru be now zack rank strong buy stock have momentum growth score enteromedic inc enteromedic be also prove be investor favorite recent time company deliver loss cent share most recent quarter narrower zack consensus estimate loss then have see positive estimate revision last month enteromedic estimate have improve share current fiscal revision activity have propel stock zack rank recent gain have help earn momentum score company impressive growth prospect continue push stock higher look ahead enteromedic be poise benefit latest acquisition reshape medical privately hold medical technology company provider reshape dual weight loss balloon fda approve minimally invasive intragastric balloon enteromedic share have gain last month ahead gain trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
205,TMO,vwr corporation announce open new kit center skalice czech republic eve company be take avantor vwr new square foot facility be strategically locate be helpful company business high prospect emea europe middle east africa region notably new center particularly help expand therapak acquire vwr exist footprint europe advanced facility comprehensive kit service regional well global customer location wise new center assist company vwrcatalyst offer grow apart proximity site major industrial freight carrier hub enhance service level compare vwr current model facility be fully operational oct notably vwrcatalyst clinical biorepository service lend complete solution global regulate research product development client pharma biopharma manufacturing clinical trial industry earlier vwrcatalyst acquire laboratory medical equipment ancillary supplier mesm international biorepository service organization epl archive regard note last couple year vwr emea apac asia pacific segment have be experience increase comparable net sale backed several strategic initiative implement recent time include series plan significantly upgrade information technology infrastructure optimize distribution network modify marketing scheme recently report second quarter organic basis net sale emea apac improve go forward management expect emea apac segment continue run strong historical progress however presence large number player have make medical device market intensely competitive general vwr compete player thermo fisher scientific tmo free report agilent technology inc free report perkinelmer inc pki free report make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
206,TMO,bio techne corporation tech free report brand proteinsimple recently expand ella immunoassay platform launch simple plex cartridge cartridge provide more accurate result lower cost notably proteinsimple fall protein platform division bio techne simple plex immunoassay have same feature gold standard elisa run fully automate ella platform simple plex cartridge combination automate ella platform have help skip manual step provide more accurate dynamic log traditional elisas hour management combination deliver solution enable higher throughput immunoassay last report fourth quarter bio techne witness year year revenue growth organically protein platform division notably quarter marked sixth straight quarter double digit organic growth management growth be drive new product introduction application company be presently focuse strengthen position segment banking solid prospect accord report market market global immunoassay market be expect reach value cagr consider opportunity see latest development strategic however company face tough competition industry well establish player thermo fisher scientific inc tmo free report luminex corporation lmnx free report bio rad laboratory inc bio free report more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
207,TMO,boston scientific corporation bsx free report be schedule report second quarter result open bell jul last quarter company earning miss zack consensus estimate however post average beat trail quarters let see thing be shape prior announcement factor playahead boston scientific earning release believe quarter performance be grossly impact company product recall issue europe notably earlier year news surface boston scientific be recall prime product lotus range heart device europe device malfunction abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory company also delay submission marketing application lotus edge device lotus remediation work be currently track product line have little hope return european other market fourth quarter lead major setback company fast grow transcatheter aortic valve replacement tavr business interventional cardiology have high chance severely weigh company second quarter revenue result apart severe currency headwind boston scientific have be face lately remain concern note company record sale international market remain highly expose currency fluctuation boston scientific expect unfavorable foreign exchange headwind tune revenue bps cent share earning adjust gross margin full year assume negative foreign exchange impact bps positive angle company downbeat interventional cardiology business get sort boost company acquisition switzerland base symetis sa privately hold structural heart company completion acquisition back boston scientific have already begin selling valve system europe other geography outside company believe symetis acurate group valve product strongly complement aortic valve platform integrate technology not only diversify boston scientific structural heart portfolio also provide cardiac surgeon multiple tavi offering vary patient pathology anatomy expect see contribution development second quarter revenue subsegment namely medsurg be expect demonstrate consistent performance lead endoscopy urology woman health be also estimate grow market level drive investment strategy key international geography state earlier company overall second quarter adjust earning be expect band cent share revenue zack consensus estimate ep stand cent revenue be earning whispersour proven model do not conclusively show boston scientific be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp boston scientific earning esp be most accurate estimate zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank boston scientific currently have zack rank sell please note caution sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be better rank company want consider proven model show have right combination element post earning beat quarter thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here dextera surgical inc have earning esp zack rank telefex inc tfx free report have earning esp zack rank more stock news company verge apple run do miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
208,TMO,mckesson corporation mck free report largest healthcare service provider be schedule report first quarter fiscal result jul last report quarter company earning surpass zack consensus estimate also last quarters mckesson earning beat zack consensus estimate average let see thing be shape prior announcement likely positive surprise proven model show mckesson be likely beat earning have perfect combination key ingredient zack esp mckesson have earning esp most accurate estimate be peg zack consensus estimate be favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank mckesson currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination mckesson zack rank esp make reasonably confident earning beat drive better expect earning mckesson be major player pharmaceutical medical supply distribution market management expect gain gradually stabilize generic brand market company distribution solution segment perform favorably fiscal weak pricing trend customer consolidation also mckesson expect earning share range fiscal distribution solution business revenue growth be expect increase mid single digit year year keep mind last quarter performance promising guidance expect similar trend yet be report quarter mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation mckesson be likely benefit acquisition covermymed llc quarter be report regard note acquisition be complete fourth quarter fiscal international segment management expect percentage revenue growth mid single digit constant currency basis management international business be likely be impact additional reimbursement cut incremental cut impact fiscal be significantly smaller fiscal however continue volatility unfavorable pricing trend reimbursement generic drug significant fluctuation nature frequency magnitude generic pharmaceutical launch have adverse impact mckesson also competitive landscape add wo other stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
209,TMO,expect idexx laboratory inc idxx free report beat expectation report second quarter result aug open bell last quarter company beat zack consensus estimate cent deliver positive earning surprise be worth note idexx have outperformed zack consensus estimate precede quarters average let take look thing be shape prior announcement likely positive surprise proven model show idexx be likely beat earning have perfect combination key ingredient zack esp idexx have earning esp most accurate estimate be cent zack consensus estimate be lower cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank idexx currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination idexx zack rank esp make reasonably confident earning beat drive better expect earning idexx achieve strong organic growth international region last report first quarter drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab rapid assay revenue well continue expansion idexx premium instrument install base company expect bullish trend continue upcoming quarters well overall idexx raise revenue outlook range reflect organic revenue growth expectation zack consensus estimate revenue be peg guide range idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quoteon bottom line front company raise ep guidance share earlier range support continue operate margin expansion align long term goal update outlook represent ep growth report basis zack consensus estimate ep be peg be guide range be upbeat company innovation base global strategy be lead cag diagnostic growth june idexx announce addition rvetlink portfolio technology application notably rvetlink be advanced inclusive referral management solution design specialty care hospital simplify referral procedure primary care specialty care veterinarian apart idexx continue display solid growth respect international expansion company have be significantly benefitting companion animal market emerge nation demonstrate bountiful opportunity further management consistent share buyback reflect strong free cash flow reserve believe outcome endeavor be reflect second quarter performance flip side foreign currency fluctuation be major headwind company concern be company high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also company be expose higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion internationally portfolio expansion also competitive landscape domestic overseas market weigh idexx performance struggle gain market share also prove be drag second quarter result other stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
210,TMO,thermo fisher scientific inc tmo free report have recently complete acquisition desktop scanning electron microscopy sem solution provider phenom world financial term transaction remain undisclosed acquire company deliver advanced desktop sem imaging analysis package research industrial market company aim make imaging analysis nanoscale available scientist lab company so far have put effort develop high quality electron microscope solution be functionally rich simple handle close phenom world purchase base eindhoven netherlands thermo fisher plan integrate business analytical instrument segment company addition phenom world desktop sem platform be likely strengthen position electron microscopy expand entry level desktop sem offering customer work material science industrial manufacturing life science electronic industry positive note thermo fisher have undertake several acquisition late deploy capital effectively boost revenue accretion strategic deal have historically benefit company operate margin also result tax synergy takeover fei have already start contribute thermo fisher analytical instrument portfolio last acquisition pantheon be also line plan expand biopharma service europe company other recent strategic purchase be finesse solution alfa aesar past month thermo fisher have be trading broader industry stock have gain higher broader industry gain same time frame key picksthermo fisher carry zack rank hold better rank stock broader medical space be akari therapeutic plc aktx free report protagonist therapeutic inc ptgx free report xoma corp xoma free report sporting zack rank strong buy see complete list today zack rank stock here akari have project growth rate next quarter earning surprise deliver company have be positive last quarters average beat protagonist have expect earning growth rate stock have soar impressive last month xoma be expect score impressive earning growth rate stock have sky-rocket whopping last month loss incur broader industry investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
211,TMO,angiodynamic inc ango free report be set report second quarter fiscal result jan market open last quarter company report adjust earning cent share miss zack consensus estimate cent average angiodynamic deliver positive earning surprise trail quarters however lackluster price performance last year high debt level continue hinder company angiodynamic share have return mere compare industry rally let see thing be shape prior announcement factor playstrong product portfolio angiodynamic wide array product angiovac bioflo nanoknife enhance market opportunity notably pv business peripheral vascular sale have also build strong momentum angiodynamic have be experience growth other product family food management thrombus management bioflo product nanoknife disposable oncology section solero mta system drive growth company ride market solid response solero microwave tissue ablation mta system especially microwave ablation space platform be intend be used ablation soft tissue open procedure management solero be primary driver whopping year year increase oncology surgery sale last quarter robust fundamental growth story last year company sale witness cagr earning share see cagr company expect benefit ongoing market transition less invasive interventional procedure upcoming year unfavorable estimate revision trend estimate revision trend current quarter have be unfavorable angiodynamic current quarter zack consensus estimate revenue fall year year further zack consensus estimate earning decline cent share year year basis angiodynamic inc price ep surprise angiodynamic inc price ep surprise angiodynamic inc quoteearning quantitative model do not conclusively show earning beat angiodynamic quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp angiodynamic currently have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank angiodynamic currently carry zack rank increase predictive power esp however esp make surprise prediction difficult caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision momentum stock considerhere be company want consider model show have right combination element post earning beat quarter edward lifescience corp ew free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank medtronic plc mdt free report have earning esp zack rank investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
212,TMO,cryolife inc cry free report recently enter definitive agreement buy german base jotec ag jotec privately hold maker technologically advanced endovascular stent graft cardiac vascular surgical graft focuse aortic repair company have be record revenue cagr last year financial term agreement cryolife pay aggregate deal cash share cryolife common stock issue jotec shareholder buyout be slate complete later subject customary close condition deal cryolife aim expand exist portfolio product focuse aortic surgery thereby solidify footprint fast grow endovascular surgical market management deal help cryolife diversify business gain access global market stent graft used endovascular open repair aortic disease market be project value interestingly cryolife aim deliver consistent high single digit revenue growth deal deal be also line company strategy directly sell eliminate distributor europe create cross selling opportunity company product portfolio last report quarter cryolife begin process direct selling canada belgium netherlands luxembourg expand direct operation europe same time management expect newly add product continue post double digit growth outside unite state least next year moreover deal be expect prove accretive company gaap ep cagr not less next year contribute gross operate margin cryolife expect gain access stent graft market be project value roughly newly gain highly competitive product portfolio advanced research development platform thus company expect deal drive growth well cryolife also provide sneak peek preliminary third quarter result company have record revenue consider negative impact hurricane delay receipt re certification ascend aortic prosthesis reversal record revenue repurchase inventory third party distributor order sell directly believe unhealthy lifestyle favorable demographic rise expenditure healthcare government technological development continue drive growth aortic aneurysm market fact be further substantiated research market report publish nasdaq report global aortic aneurysm market be estimate witness cagr thus acquisition deal be expect boost top line cryolife share price performanceover last month cryolife have be trading broader industry stock have gain compare broader industry rise zack rank key pickscryolife currently carry zack rank hold few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
213,TMO,laboratory corp america holding lh free report labcorp be schedule report second quarter result market open jul last quarter company report positive earning surprise average beat trail quarters let see thing be shape prior announcement factor play last report first quarter dent labcorp overall top line performance heavily dull number register covance drug development business be due sluggish early development central lab business affected slower revenue conversion backlog cancellation sponsor large clinical study abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quoteright now company be try execute strategy focus more higher value therapeutic area such oncology cns central nervous system disorder procedure be tie complex study take time generate revenue believe covance drug development continue remain drag labcorp overall business earlier company note timing perspective covance drug development revenue margin be year year basis second quarter show favorable growth second half apart unfavorable foreign exchange remain previously company view expect impact approximately basis point negative currency revenue covance drug development net revenue be estimate feel impact approximately basis point negative currency labcorp diagnostic segment be affected approximately basis point negative currency be reflect number quarter yet be report be also highly disappoint cms proposal related protect access medicare act positive note be upbeat company ongoing cost reduction initiative related project launchpad currently have project various stage implementation recently company have expand launchpad initiative now include covance drug development initiative be year program covance consist phase company have already initiate first phase right size covance drug development resource primarily head count facility footprint phase be project generate pre tax saving approximately approximately annualize basis thereafter pre tax cost achieve saving be estimate be approximately be presume be cash expenditure get reflect second quarter result well company companion diagnostic portfolio grow robust last couple year also maintain momentum notably immuno oncology drug development double number study award also perform number pd test diagnostic drug development segment earning whispersour proven model do not conclusively show labcorp be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp labcorp have earning esp be most accurate estimate zack consensus estimate stand uncover best stock buy sell re report earning esp filter zack rank labcorp have zack rank lower predictive power esp note caution sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here dextera surgical inc have earning esp zack rank telefex inc tfx free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
214,TMO,quest diagnostic inc dgx free report third quarter adjust earning share ep beat zack consensus estimate year number adjust ep report quarter exclude charge related restructure integration retirement debt gain disposition business well amortization expense report ep come slip year quarter figure report revenue third quarter inched year year quarter number however remain line zack consensus estimate accord company spite weather challenge year year improvement come back successful execution point strategy accelerate growth drive operational excellence quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate quote volume measure number requisition increase year year third quarter also revenue requisition increase diagnostic information service revenue quarter rise year year basis cost service report quarter be year year gross margin come reflect basis point bps contraction year year operate expense selling general administrative expense increase report quarter accordingly adjust operate margin show contraction bps quest diagnostic exit third quarter cash cash equivalent marked rise precede quarter year date net cash provide operate activity be compare year period third quarter company repurchase share sep quest diagnostic be left authorization previous share repurchase plan impact hurricane third quarter especially company operation florida texas puerto rico well recently close acquisition quest diagnostic have update full year guidance company now expect full year report revenue approximately annualize growth approximately compare earlier state range annualize growth current zack consensus estimate revenue be peg lower company project number addition upper end company earlier provide adjust ep range have be reduce currently quest diagnostic expect earning full year remain band earlier forecast zack consensus estimate fall lower end project band operate cash flow be expect unchanged previous guidance current estimate capital expenditure be peg unchanged takequest diagnostic third quarter earning exceed zack consensus estimate revenue remain line same positive note company be currently refocusing core diagnostic information service business work discipline capital deployment be also highly optimistic company focus point strategy company several new collaboration hospital integrate delivery network continue act major growth driver be currently look forward company recently announce strategic relationship cleveland clinic include acquisition cleveland heartlab flip side quest diagnostic face major sale disruption due hurricane florida texas company have significant presence also hurricane puerto rico earthquake mexico affected quest diagnostic overall performance report quarter company have reduce upper end earlier provide full year earning guidance range be disappointing notably company have not positively take latest center medicare medicaid service cms publication propose medicare reimbursement rate clinical laboratory test clinical lab fee schedule clf be currently request cms delay implementation pama protect access medicare act zack rank key pickscurrently quest diagnostic carry zack rank sell few better rank stock broader medical sector be integra lifescience holding corp iart free report abbott free report thermo fisher scientific inc tmo free report stock carry zack rank buy see complete list today zack rank strong buy stock here integra lifescience have long term expect earning growth rate stock rally roughly last month abbott have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
215,TMO,strengthen focus image guide volumetric intensity modulate radiotherapy cancer patient varian medical system inc var free report announce have initiate treatment latest halcyon radiotherapy treatment system europe notably treatment be provide year old male head neck cancer belgium base university hospital leuven uz leuven just month hospital have order new system halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide platform receive clearance ce mark european directive allow varian start selling system unite state europe company unveil halcyon radiotherapy treatment system astro conference vienna third quarter notably treatment used halcyon platform be cost effective short duration system have be ergonomically design provide user friendly platform clinical staff patient halcyon fortify varian global footholdvarian have long term goal treat cancer patient year highly exclusive radiotherapy treatment end third quarter management varian announce halcyon have receive order country north america varian strike strategic deal petcure deliver halcyon unit veterinary oncology network management regulatory clearance china japan follow next year furthermore varian receive order halcyon system icon group australia company book several order country india morocco romania russia turkey market prospectsvarian have be take initiative gain customer broad spectrum product especially target emerge market strong revenue opportunity oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership deal be positive varian datum market market reveal global radiotherapy market be project reach worth cagr other company eyee emerge marketsthe ongoing political uncertainty unite state deteriorate economic condition europe automatically shift focus several medtech player emerge geography china india latin america other johnson johnson jnj free report have set manufacturing center brazil china india have be do business china nearly year be expand further back synthe acquisition thermo fisher tmo free report be also leave stone unturned expand presence emerge market company garner total revenue high growth asia pacific emerge market abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strong growth country colombia mexico peru argentina today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
216,TMO,abbott lab free report report third quarter adjust earning continue operation cent share ahead zack consensus estimate penny year year adjust quarterly number also remain upper end company guidance range cent cent report earning quarter come cent share compare year loss cent share third quarter worldwide sale come year year report basis quarterly figure also remain slightly ahead zack consensus estimate abbott laboratory price consensus ep surprise abbott laboratory price consensus ep surprise chart abbott laboratory quoteon comparable operational basis adjust impact foreign exchange certain acquisition divestment sale increase year year report quarter quarter detailabbott operate segment establish pharmaceutical division epd medical device nutrition diagnostic epd sale be report basis comparable operational basis be positive impact back currency fluctuation sale key emerge market increase drive double digit growth brazil russia india china expect sale india be positively impact purchasing pattern follow implementation new good service tax system lower second quarter sale country medical device business sale spiked report basis comparable operational basis sale increase cardiovascular neuromodulation sale soar report basis comparable operational basis double digit growth structural heart heart failure neuromodulation vascular product sale growth however be sluggish comparable operational basis rhythm management company register loss comparable operational basis sale be impact continue competitive dynamic magnetic resonance mr conditional category product diabetes care sale improve comparable operational basis drive double digit international sale growth lead continue consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott nutrition sale be year year report basis same comparable operational basis foreign exchange favorably affected sale marginal pediatric nutrition sale increase comparable operational basis adult nutrition sale be comparable operational basis diagnostic sale rise year year report basis comparable operational basis core laboratory point care diagnostic sale grow comparable operational basis molecular diagnostic sale be strong growth infectious disease testing business be partially offset plan scale genetic business guidanceabbott have narrow full year guidance adjust certain net specify item full year adjust earning share continue operation be now expect stay band earlier guidance be current zack consensus estimate be peg midpoint project range company have also provide fourth quarter adjust earning share guidance expect report adjust earning continue operation range cent cent quarter current zack consensus estimate cent fall midpoint project range takeone more time abbott have successfully exceed zack consensus estimate earning sale front be optimistic company strong consistent epd medical device performance however strong performance be extent offset sluggish nutrition business company continue benefit recently complete acquisition st jude medical have start offer industry lead pipeline cardiovascular neuromodulation diabetes vision care company be effectively execute exist operate model focus selling portfolio core therapeutic area also emerge market performance remain extremely promising several new strategic development abbott currently carry zack rank buy stock considera few other top rank stock medical sector be integra lifescience holding corp iart free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report integra lifescience sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here integra lifescience have long term expect earning growth rate stock rally roughly last month idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
217,TMO,boston scientific corporation bsx free report be schedule report third quarter result open bell oct last quarter company deliver positive earning surprise trail quarter average beat be peg let see thing be shape prior announcement key catalystswe be optimistic company gradually improve performance interventional cardiology ic lead innovative portfolio robust commercial team globally company gain share number cardiovascular segment de drug eluting stent continue build momentum globally boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote however ahead earning release believe quarter ic business be grossly impact company product recall issue europe notably last february company recall prime product lotus range heart device europe due device malfunction company also delay submission marketing application lotus edge device product line have little hope return european other market fourth quarter lead major setback company fast grow transcatheter aortic valve replacement tavr business ic soon be report quarter believe downbeat ic business earn boost company recent acquisition switzerland base symetis sa full recovery take time accordingly zack consensus estimate third quarter ic revenue be currently peg lower sequentially last quarter report number other factor playamong segment medsurg be expect demonstrate consistent performance lead endoscopy urology woman health be also estimate grow market level drive investment strategy key international geography zack consensus estimate third quarter endoscopy revenue be peg significantly higher year quarter report figure urology woman health current zack consensus estimate remain ahead year report tally flip side severe currency headwind boston scientific have be face late remain concern fact company record sale international market remain highly expose currency fluctuation boston scientific expect unfavorable foreign exchange challenge tune revenue bps cent share earning overall boston scientific third quarter adjust earning be expect band cent share revenue here quantitative model predict boston scientific do not have right combination main ingredient positive earning esp favorable zack rank strong buy buy hold increase odd earning beat see complete list today zack rank stock here zack esp boston scientific have earning esp uncover best stock buy sell re report earning esp filter zack rank boston scientific carry zack rank sell fail increase predictive power esp stock considerhere be few medical stock worth consider right combination element beat estimate quarter thermo fisher scientific tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp also carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
218,TMO,developer robotic technology product mazor robotic ltd mzor free report recently announce expect report third quarter revenue approximately compare year quarter bullishness come strength mazor system sale increase procedure volume stock price performance israel base company have be encourage last month stock have return outperform industry gain roughly stock current return be higher return same time frame bullish price trend estimate revision stock have be quite disappointing full year see estimate move south last month compare movement opposite direction result estimate contract loss cent share loss cent aforementioned period factor mazor strengthdure third quarter company receive purchase order mazor system unite state addition mazor receive purchase order renaissance system chinese market mazor be guidance system simplify spine surgery advanced feature sophisticated integrative ability strong demand mazor system third quarter reach backlog introduction second half company be slate report financial result third quarter end sep november bottom linewe be hopeful encourage global spine surgery market research report market market suggest niche market be estimate reach cagr fact increase utilization rate mazor be quite compelling company believe cycle mazor platform be progress plan grow customer base zack rank other key pickscurrently mazor have zack rank strong buy few other top rank stock broader medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here abbott have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
219,TMO,oct issue update research report netherlands base molecular diagnostic provider qiagen qgen free report company offer innovative technology product pre analytical sample preparation molecular diagnostic solution be upbeat qiagen partnership co marketing agreement centogene ag boost bioinformatic portfolio also be encourage note post receipt fda approval june qiagen announce complete launch fourth generation blood test tuberculosis tb infection quantiferon tb gold qft unite state moreover company strategic focus drive growth sample insight offering buoy optimism qiagen be form collaboration personalize homecare space well qiagen currently market product more country last report second quarter company witness growth international region include top emerge market flip side last month qiagen have be trading broader industry latest share price company have gain compare gain broader industry moreover adverse currency translation continue be drag overall sale furthermore decline hpv sale unite state continue be drag competitive landscape heavy dependence collaboration continue be concern zack rank other key picksqiagen currently carry zack rank buy other top rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank stock here abbott have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
220,TMO,sep issue update research report thermo fisher scientific inc tmo free report lead scientific instrument maker stock currently carry zack rank buy past month thermo fisher have be trading broader industry last trading price stock have gain higher broader market gain time frame company continue see strong growth pharma biotech backed solid market fundamental plan growth strategy raise guidance be also encourage company acquisition activity drive growth inorganically also raise hope be particularly upbeat company foray high potential contract development manufacturing organization cdmo space recent acquisition patheon moreover takeover fei company have start contribute thermo fisher analytical instrument portfolio few company other strategic purchase be finesse solution alfa aesar meanwhile waltham base company plan continue strengthen foothold emerge market such china india translate success other high priority opportunity region such south korea russia brazil second quarter company record solid contribution china india middle east be also upbeat company recent open center excellence electron microscopy saudi arabia additionally thermo fisher have strong cash balance enable adopt attractive share repurchase program turn provide solid return investor flip side thermo fisher derive majority revenue international market expose fluctuation foreign currency management currently estimate unfavorable foreign exchange have negative impact top line landscape have become intensely competitive thank change technology customer demand require continual research development other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
221,TMO,third quarter earning season have commence encourage note most sector release participant total market cap october latest earning preview total earning member rise higher revenue member line release quarterly result week be decidedly bullish equity market be gradually demonstrate sequential improvement medical broader sector zack sector be expect put impressive show quarter expect earning growth rate sector be revenue growth comparison report earning growth rate second quarter be quite impressive revenue growth medical product political medical product space broader medical universe have be precarious game republican day courtesy president trump repeat failure repeal replace obamacare however major medtech player have be pin hope abolition infamous medical device sale tax elimination tax be far be achieve consider tax issue investor interested medical product space likely keenly await earning report medtech bigwig baxter international inc bax free report varian medical var free report thermo fisher scientific inc tmo free report laboratory corporation america holding lh free report notably company be expect release earning result oct third quarter baxter anticipate sale growth constant currency cc adjust earning share be forecast range cent versus year figure cent believe company solid sale medical product segment be key driver third quarter notably zack consensus estimate segment stand year year basis read more baxter international earning store solid prospect quantitative model do not conclusively show beat company give combination zack rank buy earning esp be model stock need have positive earning esp zack rank strong buy hold beat earning baxter international inc price consensus baxter international inc price consensus baxter international inc quotewe be upbeat varian medical oncology business be estimate account company total revenue fourth quarter fiscal company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space fourth quarter fiscal varian expect adjust earning share range revenue be likely increase year year basis read more varian medical earning be surprise store contrary zack consensus estimate varian medical revenue stand year year consensus estimate earning be peg year year proven model do not predict earning beat company season thank earning esp zack rank see complete list today zack rank stock here varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotelaboratory corporation also know labcorp continue face softness covance drug development business third quarter however be upbeat company expectation improvement covance drug development arm start second half be reflect third quarter performance read more card labcorp earning season zack consensus estimate labcorp third quarter revenue stand year year labcorp be concern cms center medicare medicaid service proposal related protect access medicare act pama believe reimbursement pressure affect company performance third quarter well fact proven model do not predict earning beat company season be labcorp have zack rank earning esp uncover best stock buy sell re report earning esp filter laboratory corporation america holding price consensus laboratory corporation america holding price consensus laboratory corporation america holding quotethermo fisher be gear solid third quarter result primarily drive analytical instrument segmental growth third quarter company expect see positive impact electron microscopy business well strong volume leverage productivity zack consensus estimate analytical instrument operate income be peg line last quarter report number total revenue estimate segment be impressive level read more expect thermo fisher earning quantitative model predict earning beat thermo fisher stock currently have zack rank earning esp zack consensus estimate revenue be third quarter year year basis thermo fisher scientific inc price consensus thermo fisher scientific inc price consensus thermo fisher scientific inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
222,TMO,petm express inc pet free report announce earning share ep cent second quarter fiscal year quarter cent also earning surpass zack consensus estimate year year rise earning be drive increase sale improve margin net sale report quarter rise year year outpace zack consensus estimate petm express inc price consensus ep surprise petm express inc price consensus ep surprise petm express inc quote lead pet pharmacy americas upside sale be result increase new order reorder quarter report quarter reorder sale increase year year basis new order sale rise average order value be approximately quarter compare year quarter note variation average order value be mainly drive shift sale higher price item company seasonality business be mainly proportion flea tick heartworm medication product mix spring summer be consider peak season fall winter represent season quarter review petm acquire new customer year roughly order be generate versus prior year quarter gross margin expand basis point bps year year report quarter general administrative expense be year year also advertising expense rise lead increase adjust operate expense depreciation expense amount nevertheless adjust operate margin quarter rise bps year quarter petm exit fiscal second quarter cash cash equivalent compare end first quarter fiscal company also announce quarterly dividend cent share payable shareholder record nov takepetm successfully deliver yet quarter solid result fiscal second quarter company once again top zack consensus estimate revenue earning be also encourage note stellar increase reorder new order sale quarter company be also strive implement several strategy revitalize top line include increase focus advertising efficiency boost new order sale shift sale higher margin item also expand product offering petm currently offer wide range product cater dog cat horse work upgrading exist portfolio zack rank key pickspetm currently have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock surge last year thermo fisher have long term expect earning growth rate stock gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
223,TMO,corp abc free report be set report third quarter fiscal result aug open bell track record have be quite impressive company comfortably beating estimate trail quarters last report quarter deliver positive earning surprise bring quarter average let see thing be shape prior release factor pharmaceutical distribution segment continue face headwind form contract renewal lower generic inflation drug corporation abdc business be also be hurt several factor include accelerate deflation generic drug lower contribution generic launch generic inflation have be nominal rate deflation be rise gradually factor combine anticipate shift product mix lower margin higher price specialty brand drug lack generic inflation adversely impact bottom line however company renew relationship largest health system customer have be make persistent effort address headwind abdc segment boost top line extent fiscal third quarter company estimate revision trend be mixed current quarter see upward downward estimate movement last month current quarter estimate earning share be peg also company be apprehensive earning revenue growth expectation fiscal due uncertainty surround drug pricing trend company currently expect revenue growth range company expect adjust diluted earning share range meanwhile expect brand drug inflation range corporation hold co price ep surprise corporation hold co price ep surprise corporation hold co quoteearning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank carry zack rank sell caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considerhere be company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank thermo fisher scientific inc tmo free report have earning esp hold zack rank more stock news company verge apple run do miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
224,TMO,quest diagnostic inc dgx free report second quarter adjust earning share ep beat zack consensus estimate year number adjust ep report quarter exclude charge related restructure integration retirement debt well amortization expense report ep come line year figure report revenue second quarter inched year year however lag zack consensus estimate accord company year year improvement come back extend tie up hospital health system strength several company advanced diagnostic offering quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate quotevolume measure number requisition increase year year second quarter also revenue requisition increase diagnostic information service revenue quarter rise year year basis cost service report quarter be year year gross margin come reflect rise basis point bps year year operate expense selling general administrative expense increase report quarter adjust operate margin show improvement bps quest diagnostic exit second quarter cash cash equivalent marked fall precede quarter year date net cash provide operate activity be compare year period second quarter company repurchase share jun quest diagnostic be left authorization previous share repurchase plan outlookquest diagnostic raise full year revenue guidance company now expect full year revenue range annualize growth earlier state range annualize growth current zack consensus estimate revenue be peg par lower end company update guide range addition company adjust ep range have be raise earlier forecast zack consensus estimate be range operate cash flow be expect previous guidance current estimate capital expenditure be peg unchanged takequest diagnostic second quarter earning exceed zack consensus estimate revenue lag same positive note company be currently refocusing core diagnostic information service business work discipline capital deployment also raise guidance adjust earning revenue net cash operate activity buoy optimism company performance be also highly optimistic company focus new point strategy accord quest diagnostic plan divestiture focus diagnostic product business be part strategy refocu diagnostic information service addition several new collaboration hospital integrate delivery network be major growth driver regard be look forward company deal walmart particularly company be positive recent agreement peacehealth pacific northwest be expect bolster growth also management be upbeat latest acquisition med fusion clearpoint advance diagnostic space however past several quarters overall soft industry trend lead low volume environment act dampener company zack rank key pickscurrently quest diagnostic carry zack rank hold few better rank stock broader medical sector be petm express inc pet free report becton dickinson company bdx free report thermo fisher scientific inc tmo free report notably petm sport zack rank strong buy becton dickinson company thermo fisher scientific carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have gain last month becton dickinson company have long term expect earning growth rate stock have gain last month thermo fisher scientific have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
225,TMO,medical instrument manufacturer thermo fisher scientific inc tmo free report be slate release third quarter result oct market open last quarter company post earning share surpass zack consensus estimate fact thermo fisher earning outpaced zack consensus estimate past quarters average beat let see thing be shape prior announcement key acquisition fei have already start generate synergy largely contribute waltham base company analytical instrument portfolio last quarters acquisition have enabled thermo fisher access fei industry lead high performance electron microscopy platform used protein study facilitate life science research be also vital highlight quarter be report thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotethermo fisher anticipate realize total synergy approximately end year follow deal closure cost synergy roughly adjust operate income benefit revenue related synergy get reflect third quarter performance overall company be gear yet quarter strong analytical instrument segmental growth third quarter thermo fisher expect see positive impact electron microscopy business well strong volume leverage productivity zack consensus estimate analytical instrument operate income be peg line sequentially last quarter report number total revenue estimate segment also remain impressive level here be other factor influence thermo fisher third quarter result company focus boost growth implementation strategy strengthen product offering be encourage initiative be likely help post solid result third quarter company have spend research development same trend be continue last couple quarters major development field be novartis chimeric antigen receptor cell car therapy kymriah first fda approve cell therapy leukemia utilize thermo fisher ct dynabead technology expect innovation product launch significantly contribute company top line third quarter company aim expand capability fast grow asia pacific zone well emerge market also lead impressive result standout contributor recent time be china india south korea strategic investment support key customer application thermo fisher hope maintain bullish momentum rest growth be also likely be see apply market such environmental food safety apart life science addition company be currently bet key area focus enormous opportunity be advance precision medicine mass spectrometry target gene sequence structural biology however be apprehensive thermo fisher cite foreign exchange headwind revenue adjust ep also unfavorable macroeconomic condition continue weigh heavily stock stiff competition continue impose challenge stock value here quantitative model predict thermo fisher have right combination main ingredient positive earning esp favorable zack rank strong buy buy hold earning beat see complete list today zack rank stock here zack esp thermo fisher have earning esp uncover best stock buy sell re report earning esp filter zack rank thermo fisher carry zack rank buy increase predictive power esp other stock considerhere be few medical stock worth consider model indicate consist right combination element post earning beat quarter abbott free report have earning esp zack rank align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp aslo carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
226,TMO,oct issue update research report phibro animal health corporation pahc free report nj base company be lead global diversify animal health mineral nutrition company last month phibro have be trading broader industry currently stock have gain compare broader industry animal health be key contributor deliver positive growth last few quarters accord phibro animal health product be excellent prevent control treat disease animal well improve nutrition improve health believe diverse portfolio allow company address distinct grow condition livestock different region world outside unite state phibro have extend reach brazil other country south america china india asia pacific russia africa feel help company counter competition company continue invest far east asia poultry dairy industry be expect grow exponentially currently company be expand dairy business market australia brazil mexico believe turmoil economy russia greece brazil china phibro have perform quite well have potential maintain performance flip side phibro operate highly competitive industry respect major product face threat substantial number global regional player furthermore withdrawal approval mecadox carbadox fda be concern additionally phibro conduct operation globally entail transaction variety currency result currency fluctuation be major issue company zack rank key picksphibro carry zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
227,TMO,baxter international inc bax free report be schedule report second quarter earning jul open bell last report quarter company record positive earning surprise reach quarter average let see thing be shape prior release factor playwe be encourage company guidance second quarter full year second quarter baxter estimate sale growth constant currency adjust earning share be forecast range cent cent versus year figure cent also full year company project earning band share continue operation special item full year earning late baxter have accelerate pace acquisition strategic collaboration enhance product portfolio thereby open significant long term opportunity also several recent fda approval be likely boost growth yet be report second quarter baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc company estimate revision trend be also encourage current year baxter see upward estimate revision movement opposite direction last month however lower sale threat company integrate pharmacy solution franchise second quarter decline sale be expect impact top line low single digit also foray group purchasing organization gpos intensify competition company earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp baxter international be be most accurate estimate zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank baxter international carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
228,TMO,second quarter earning season commence last week index have good start respect earning revenue growth latest earning preview jul member total market cap have report quarterly number total earning member have go higher revenue week member be line report quarterly result time be bullish equity market be gradually demonstrate sequential improvement store medical space overall growth be steadily accelerate few precede quarters performance investor be concern healthcare space sector have be see struggle lot past half year thank political power change ongoing policy restructure related battle president donald trump finally amend earlier propose american health care act ahca totally repeal replace obamacare uncertainty medical space be towering high investor be currently adopt see policy space lack visibility befuddle bullish trend medical sector broader zack sector be maintain past few quarters accordingly second quarter expect earning growth rate stand break even level revenue growth projection compare unfavorably first quarter report earning growth rate revenue growth let take sneak peek performance major medical instrument company broader medical space expect jul edward lifescience corporation ew free report lead cardiovascular product maker be schedule report second quarter result market close jul edward lifescience post strong global sale last report quarter primarily buoy strength transcatheter heart valve tavr banking continue therapy adoption geography notable strength company be expect maintain bullish trend second quarter well edward lifescience currently carry zack rank buy have earning esp be most accurate estimate zack consensus estimate be par cent note positive zack esp serve lead indicator likely positive earning surprise bullish zack rank increase predictive power esp read more edward lifescience earning surprise store edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotethermo fisher scientific inc tmo free report base medical instrument manufacturer focus boost growth implementation strategy strengthen product offering be encourage initiative be likely help post solid result second quarter company have already spend research development same trend be expect year too thermo fisher be expect beat expectation report second quarter result market open have right combination key ingredient stock currently carry zack rank buy have earning esp be most accurate estimate be zack consensus estimate be lower uncover best stock buy sell re report earning esp filter read more thermo fisher earning surpass expectation thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotevarian medical system inc var free report lead provider radiotherapy radiosurgery proton therapy brachytherapy treat cancer be schedule report third quarter fiscal earning market close strengthen foothold oncology business company launch fda approve product halcyon also june company sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient proven model do not conclusively show varian medical be likely beat earning quarter varian currently carry zack rank hold have earning esp be most accurate estimate zack consensus estimate be par cent see complete list today zack rank stock here read more varian medical earning be surprise store varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quotemore stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
229,TMO,expect align technology inc algn free report beat expectation report second quarter earning jul market close last quarter company have post positive earning surprise be worth note align technology have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement likely positive surprise proven model show align technology be likely beat earning have perfect combination key ingredient zack esp align technology have earning esp most accurate estimate be cent zack consensus estimate be peg lower cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank align technology currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination align technology zack rank esp make reasonably confident earning beat drive better expect earning be upbeat align technology execution strategic initiative international expansion thereby ensure invisalign treatment grow base patient context company strengthen foothold internationally acquire invisalign distributor highly lucrative europe middle east africa emea region well brazil feb be likely drive company result be report quarter company announce receipt patent align smarttrack aligner material be exclusively used invisalign aligner treatment moreover bid gain traction invisalign platform align collaborate digital design march post collaboration align invisalign clear aligner treatment be used dentist tooth alignment procedure design protocol align technology inc price ep surprise align technology inc price ep surprise align technology inc quotenotably expand invisalign brand offering align technology introduce patient friendly solution invisalign mandibular advancement teen march accord company advancement help offer more option treatment boost top line yet be report quarter recently company expand work flow option lead itero scanner context align collaborate exocad gmbh march integrate portfolio result high tech solution efficient scanning design manufacturing house dental prosthesis february company have announce addition digital nobel biocare implant itero intraoral scanner portfolio moreover company see increase adoption itero scanner invisalign case submission instead pvs impression especially north america thereby drive invisalign utilization management expect bullish trend likely continue yet be report quarter notably second quarter company project earning share cent revenue company also expect invisalign case shipment band year flip side unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion portfolio stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
230,TMO,henry schein medical subsidiary henry schein inc hsic free report announce exclusive distribution agreement terason distribute latter usmart nexgen development remain part henry schein medical emergency medical service em business terason division teratech corporation be manufacturer portable ultrasound machine usmart be portable ultrasound device allow emergency responder carry exam emergency medical transport vehicle aircraft reduce need speculate em professional usmart nexgen be portable light weight ultrasound tablet easy transport operate terason usmart feature many advanced feature include customize preset fast boot grab go portability wi fi capability responder recognize issue point care transportation also alert emergency room staff important vital usmart accord company access patient vital help emergency responder make more inform decision treatment also help emergency room staff prepare ahead patient arrival henry schein be consistently work boost medical segment notably worldwide medical revenue rise year year last report second quarter henry schein medical recently inked agreement cerebral assessment system cas distribute cognivue be first computerize cognitive assessment screening device clear fda detection early sign dementia moreover henry schein announce partnership simplifeye create mobile platform health care provider use practice management electronic health record software micromd accord report market market ultrasound market be expect reach value cagr consider substantial potential market believe latest development be strategic past year henry schein have underperform broader industry stock have gain compare gain broader industry estimate revision estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate current quarter earning share have increase cent cent zack rank key pickshenry schein have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
231,TMO,thermo fisher scientific inc tmo free report have be gain investor confidence consistently positive result stock have rally last month ahead gain broader industry rise moreover massachusett base medical instrument manufacturer have market cap company year historical growth rate be favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company have impressive earning surprise history have surpass zack consensus estimate trail quarters average beat company estimate revision trend current year have be positive last day analyst revise estimate upward movement opposite direction magnitude estimate revision earning increase share same time frame let find recent positive trend be sustainable company have be steadily add capacity enhance exist one acquisition regard acquisition fei have already start generate synergy contribute largely company analytical instrument portfolio have turn boost market optimism surround stock moreover be look forward company latest patheon buyout thermo fisher forayed high potential contract development manufacturing organization cdmo space moreover company plan continue strengthen foothold emerge market such china india translate success other high priority opportunity region such south korea russia brazil second quarter company record solid contribution china india middle east be also upbeat company recent open center excellence electron microscopy saudi arabia additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor moreover believe company strong cash balance enable carry strategy inorganic expansion flip side thermo fisher derive majority revenue international market expose fluctuation foreign currency management currently estimate unfavorable foreign exchange have negative impact top line also tough competitive landscape continue challenge company other key picksother top rank stock medical sector be abbott free report idexx laboratory inc idxx free report integra lifescience holding corporation iart free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year integra lifescience have long term expect earning growth rate stock gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
232,TMO,agilent technology inc free report have claim former employee form shanghai electronic technology co ltd have adopt not so honest way get information replicate agilent gas chromatograph lead provider application focuse solution sue shanghai number former employee allege intellectual property theft suit seek ban use agilent proprietary technology compensation loss company senior vice president general counsel michael tang state agilent be determine protect ip take appropriate legal action infringement worldwide observe agilent share have rally year date outperform industry gain ip protection property ip right protection law encourage company better production commitment additional resource enhance consumer confidence counterfeit hold key survival multibillion dollar firm give way legally fight competition be more important agilent face fierce competition like veeco instrument veco free report abbott laboratory free report thermo fisher scientific tmo free report agilent technology inc revenue ttm agilent technology inc revenue ttm agilent technology inc truth be bitterat end day employee do switch job more profitable allow liberty aren available sticking big corporate house agilent process ip also change hand illegally have be instance employee leave company form new one get sue intellectual property infringement past happen future too so agilent battle war go agilent have zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
233,TMO,thermo fisher scientific tmo free report have recently obtain require antitrust clearance related earlier announce purchase outstanding ordinary share patheon aug competition authority brazil approve transaction initiate day comment period expire aug additionally european commission sanction takeover aug notably thermo fisher cn luxembourg wholly own subsidiary lead scientific instrument maker agree acquire netherlands base patheon latter be global provider high quality drug solution pharmaceutical biopharma sector completion deal patheon become part thermo fisher laboratory product service segment total transaction value be fix include assumption approximately net debt acquisition be expect wrap end subject customary close condition basically patheon offer comprehensive highly customizable solution well expertise help company satisfy complex development manufacturing need be leader high growth contract development manufacturing organization cdmo market company extensive network north america europe have generate revenue approximately notably thermo fisher have be do well quite time last month company have be trading industry stock have inched industry decline period latest report second quarter revenue laboratory product service segment grow year year segment serve laboratory customer equipment consumable improve productivity range biopharma outsource service also include company research safety market customer channel thermo fisher consider patheon purchase strategic fit expand biopharma service europe management combine entity significantly strengthen acquirer unique value proposition pharmaceutical biotech customer add highly complementary service consolidation be also expect prove accretive thermo fisher adjust earning share first full year post merger completion management also expect realize total synergy approximately third year follow closure deal consist roughly cost synergy adjust operate income benefit revenue related synergy recent report global laboratory equipment service market be project reach worth cagr forecast period growth market be primarily lead increase research pharmaceutical biotechnology industry urgent need timely effective diagnosis disease expect thermo fisher cash opportunity order gain traction potentially strong new market zack rank key picksthermo fisher currently have zack rank hold better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally last month lantheus holding have long term expect earning growth rate stock have surge last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
234,TMO,express script hold company esrx free report recently inked agreement acquire privately hold evicore healthcare investor include general atlantic ta associate ridgemont equity partner transaction be expect close fourth quarter evicore provide evidence base integrate medical benefit management service mbm solution drive cost reduction quality care outcome notably evicore operate standalone business unit express script express script pharmacy benefit management couple evicore complementary medical benefit management be likely build comprehensive patient benefit management pbm solution buyout provide express cross sell client basis financial acquisition be expect prove accretive express script adjust diluted earning share first full year operation exclude transaction related expense amortization intangible accord company deal be likely take care be spend healthcare annually industry pbm be highly competitive industry report market research project pharmacy benefit management market see cagr accord market market report global healthcare provider network management market value cagr period take account express script have be consistently try expand core pbm business company recently announce plan expand customize worker compensation pharmacy solution acquisition mymatrixx pharmacy benefit solution provider worker compensation industry furthermore company anticipate compound annual ebitda growth rate core pbm business however express script announce biggest customer lead health insurer anthem inc antm be not likely extend pharmacy benefit management agreement be slate expiration end price script stock have underperform broader industry last year specifically stock have lose period industry gain zack rank key picksexpress script currently carry zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
235,TMO,integra lifescience holding corporation iart free report develop manufacture market medical device implant biomaterial primarily used treatment burn skin defect spinal cranial disorder orthopedic other surgical application company have rally last month better gain broader industry stock have market cap company year historical growth rate be also favorable compare index solid prospect zack rank buy stock be attractive pick present let find recent positive trend be sustainable integra lifescience have positive earning surprise last quarters also have long term expect earning growth rate market be upbeat integra lifescience latest development most recent be launch collagen matrix revize revize plastic reconstructive surgery expand tissue technology portfolio also follow ce mark approval integra lifescience recently announce launch mesh acellular dermal tissue matrix adm surgimend prs mesh pre sub pectoral breast reconstruction europe moreover integra lifescience have finally complete codman neurosurgery business acquisition johnson johnson expand neurosurgery business latest development indicate company have capability sustain momentum other key picksother top rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
236,TMO,transenterix inc trxc free report announce receipt fda clearance senhance surgical robotic system senhance be multiport surgical robotic system help perform minimally invasive surgery be first fda approve entrant field abdominal surgical robotic development be go fortify transenterix medical device robotic segment business accord company senhance surgical robotic system help surgeon direct small surgical instrument camera robotic precision also offer security haptic feedback eye sense camera control first time robotic surgery platform minimize procedural cost senhance enable hospital surgeon leverage technology investment operate room ecosystem system make robotic surgery cost effective procedure basis used fully reusable instrument recently transenterix sell senhance robotic surgery system japanese customer be sell saitama medical university international medical center locate saitama prefecture greater tokyo region moreover system get install imperial college london notably senhance be ce marked use general gynecology urology thoracic surgery accord report market market minimally invasive surgical instrument market be forecast reach value cagr consider substantial potential market believe latest development be strategic transenterix share have outperformed industry past month stock have sky-rocket compare industry gain same period current level be better return estimate revision trend estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate current year have narrow loss cent share loss cent zack rank key have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
237,TMO,athenahealth inc athn free report be set report second quarter result jul last quarter company post earning cent share miss zack consensus estimate cent average athenahealth beat zack consensus estimate almost last quarters let take look thing be shape company prior announcement factor playwe believe strong product portfolio expand physician base continue drive athenahealth top line application athenaclinical athenaclinical streamline athenainsight athenaone athenacollector hospital health system be fortify market position however flip side lack enterprise size deal wind government funded stimulus increase competition healthcare market be major dampener fiscal company expect revenue band adjust operate income be project range annual booking be expect question linger investor mind now be athenahealth be able deliver positive earning surprise quarter be report zack consensus estimate quarter review be cent reflect year year increase note zack consensus estimate have be stable ahead earning release analyst poll zack expect revenue year quarter athenahealth inc price consensus ep surprise athenahealth inc price consensus ep surprise athenahealth inc quoteearning whisper proven model do not conclusively show athenahealth be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp athenahealth earning esp be most accurate estimate zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank athenahealth have zack rank favorable zack rank increase predictive power esp company esp make surprise prediction difficult also caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter thermo fisher scientific inc tmo free report have earning esp carry zack rank see complete list today zack rank stock here dextera surgical inc have earning esp carry zack rank telefex inc tfx free report have earning esp hold zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
238,TMO,intuitive surgical inc isrg free report be schedule report second quarter result close bell jul last quarter company earning exceed zack consensus estimate also company deliver average beat trail quarters let see thing be shape intuitive surgical prior announcement factor playwe believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be key catalyst earlier da vinci procedure increase approximately year year first quarter second quarter company expect procedure growth rate slow bit outside company anticipate full year procedure growth full year gross profit margin be expect upper end range net revenue moreover rise procedural volume outside particularly europe fortify company market position fact integrate table motion product line have gain significant traction short span time be likely boost company top line be report quarter meanwhile increase spending product development higher investment expand company footprint international market be prudent move drive long term growth view note intuitive surgical outperformed zack medical instrument sub industry last year stock have return sub industry have gain only intuitive surgical inc price consensus ep surprise intuitive surgical inc price consensus ep surprise intuitive surgical inc quoteearning whisper proven model do not conclusively show intuitive surgical be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp intuitive surgical earning esp be most accurate estimate zack consensus estimate stand uncover best stock buy sell re report earning esp filter zack rank intuitive surgical have zack rank favorable zack rank increase predictive power esp company esp make surprise prediction difficult also caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here dextera surgical inc have earning esp hold zack rank telefex incorporate tfx free report have earning esp carry zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
239,TMO,zimmer biomet holding inc zbh free report report second quarter adjust earning share ep year year adjust earning be also ahead zack consensus estimate cent reportedly net earning come cent share mark massive increase year loss cent share revenue detailszimmer biomet second quarter net revenue come mark rise constant exchange rate cer year year recently include ldr hold contribute basis point bps top line exclude contribution ldr hold quarter revenue decline year year revenue however remain line zack consensus estimate revenue generate americas quarter touch year year cer same emea europe middle east africa gross asia pacific figure be zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc derive knee be year year cer hip record sale prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf record improvement dental be quarter other revenue drop marginswith reduction cost product sell zimmer biomet gross margin expand bps second quarter selling general administrative expense be research development expense increase however adjust operate margin expand bps surge operate profit quarter cash positionzimmer biomet exit second quarter cash cash equivalent first quarter end total long term debt be compare end first quarter year date operate cash flow be compare year period company also paid dividend second quarter outlook base dull topline show zimmer biomet have lower full year guidance company currently expect register revenue growth cer range earlier prediction be include contribution approximately bps ldr transaction current zack consensus estimate revenue be peg adjust ep expectation have be forecast range lower earlier range year current zack consensus estimate ep be peg much ahead current guidance takezimmer biomet end quarter mixed note earning top zack consensus estimate revenue remain line same be disappoint company decline sale performance several core segment trimemd guidance also add concern indicate little chance recovery ahead nevertheless improve gross operate margin performance be encourage look forward expect synergy ldr hold acquisition broaden complement company musculoskeletal offer be also impressed strong strategic financial goal combine entity expect reach now deal have be close zack rank other key pickscurrently zimmer biomet carry zack rank hold better rank stock broader medical sector be petm express inc pet free report becton dickinson company bdx free report thermo fisher scientific inc tmo free report notably petm sport zack rank strong buy becton dickinson company thermo fisher scientific carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have soar last month becton dickinson company have long term expect earning growth rate stock have rally last month thermo fisher scientific have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
240,TMO,boston scientific corporation bsx free report post adjust earning share ep consider certain time adjustment other amortization expense cent second quarter year quarter consider amortize expense adjustment quarter adjust ep come cent year adjust number figure remain penny ahead zack consensus estimate fall company adjust ep guidance range cent adjustment company report earning cent share comparison loss cent share year period boston scientific corporation price consensus ep surprise boston scientific corporation price consensus ep surprise boston scientific corporation quoterevenue detailrevenue second quarter be year year report basis operational basis constant exchange rate cer figure top company guidance also exceed zack consensus estimate organic revenue growth second quarter exclude impact change foreign currency exchange rate sale acquisition endochoice holding symetis sa be year year geographically second quarter company achieve operational growth organically europe asia middle east africa region emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm management medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year cer respectively second quarter second largest contributor boston scientific top line be rhythm management include cardiac rhythm management crm crm reflect year year increase sale cer report quarter worldwide sale pacemaker crm increase defibrillator be sale go year year cer other segment endoscopy urology pelvic health neuromodulation medsurg broader group record sale cer respectively marginsgross margin expand basis point bps year year fall cost product sell adjust operate margin also expand bps report quarter quarter selling general administrative expense go research development expense increase royalty expense reduce quarter balance sheetboston scientific exit second quarter cash cash equivalent end sequential last quarter end second quarter company have total long term debt marginal increase end first quarter guidanceboston scientific have provide update full year guidance company raise revenue guidance range annualize growth report basis growth operational basis include contribution approximately bps endochoice symetis earlier band annualize growth report basis growth operational basis current zack consensus estimate revenue be guide range adjust ep guidance range have be slightly increase earlier range zack consensus estimate be guide range company also provide third quarter financial guidance adjust earning be expect band cent share revenue zack consensus estimate ep stand cent revenue be takeeven challenge economic condition competitive environment severe currency headwind boston scientific post better expect second quarter earning miss zack consensus estimate revenue ahead mark foreign exchange headwind continue challenge be concern company recent recall prime product lotus range heart device also unimpressive defibrillator performance company core crm segment continue remain drag overall growth nevertheless boston scientific be leave stone unturned strengthen core business invest new technology global market account higher sale geography second quarter be also encourage company gain number approval product domestic overseas market recent development worth mention be company recent acquisition switzerland base symetis sa bid fortify structural heart business europe apart company receive fda approval resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system also receive ce mark vercise gevia deep brain stimulation dbs system first mr conditional directional dbs system treatment movement disorder symptom patient parkinson disease dystonia essential tremor zack rank other key pickscurrently boston scientific carry zack rank sell other better rank stock broader medical sector be petm express inc pet free report becton dickinson company bdx free report thermo fisher scientific inc tmo free report notably petm sport zack rank strong buy becton dickinson company thermo fisher scientific carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have soar last month becton dickinson company have long term expect earning growth rate stock have rally last month thermo fisher scientific have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
241,TMO,zimmer biomet holding inc zbh free report be expect beat earning report third quarter result nov open bell last quarter company earning miss zack consensus estimate however report average beat trail quarters let see thing be shape prior announcement key prior quarter company be expect gain strength surgical sport medicine foot ankle extremity trauma arm revenue be drive surgical business sport medicine offering such gel quattro link last report quarter moreover solid uptake plate system foot ankle portfolio boost segment performance zack consensus estimate revenue reflect increase year quarter zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quote be also upbeat spine thoracic spine cmf segment be expect deliver quarter promising performance spine category zimmer biomet continue gain strong uptake mobi cervical disc moreover initial phase integration ldr holding acquisition be expect contribute approximately basis point company top line be report quarter also management be hopeful gain significant cross selling opportunity ldr acquisition provide back integrate spine sale force unite state also continue solid uptake sternalock blu sternalock primary closure system well ribfix blu thoracic fixation system thoracic arm buoy optimism zack consensus estimate spine cmf revenue indicate rise year quarter here be other factor influence zimmer biomet third quarter result look focuse execution zimmer biomet sale team expect global adoption rate company flagship personalize knee system persona be impressive regard september company announce launch persona partial knee system be latest addition portfolio personalize anatomically design knee implant system also june zimmer biomet announce release ray base patient specific instrument psi knee system be world first ce marked surgical plan system allow patient specific implant position solely utilize ray technology development be expect boost top line third quarter emerge market have always be significant revenue generate source zimmer biomet recent economic downturn affected zimmer biomet business latin america company manage drive growth operation other part emerge market especially asia pacific emea europe middle east africa zack consensus estimate third quarter revenue emea indicate improvement year quarter overall zimmer biomet expect third quarter revenue range reflect negative impact foreign exchange zack consensus estimate third quarter total revenue be peg however factor macroeconomic uncertainty unfavorable currency fluctuation have be adversely dent zimmer biomet sale past few quarters moreover company have also be deal pricing pressure issue regard zimmer biomet face negative pricing pressure approximately second quarter thus absence favorable change line company continue face headwind be report quarter well meanwhile second half management continue expect adverse impact reduce sale expectation continue spending critical program rise manufacturing cost warsaw north campus facility persist here be quantitative model predict zimmer biomet do not have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp zimmer biomet be uncover best stock buy sell re report earning esp filter zack rank zimmer biomet carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise zack consensus estimate earning reflect decline year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank buy see complete list today zack rank strong buy stock here thermo fisher scientific inc tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
242,TMO,investor be always look stock be poise beat earning season thermo fisher scientific inc tmo free report be such company firm have earning come pretty soon event be shape quite nicely report be thermo fisheris see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface tmo report fact most accurate estimate current quarter be currently share tmo compare broader zack consensus estimate share suggest analyst have very recently bump estimate tmo give stock zack earning esp head earning season thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give tmo have zack rank buy esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead thermo fisher beat be card upcoming report today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
243,TMO,henry schein inc hsic free report be expect report third quarter result nov last quarter company deliver positive earning surprise encouragingly henry schein earning surpass zack consensus estimate past quarters average let see thing be shape prior announcement likely positive surprise proven model show henry schein be likely beat earning have perfect combination key ingredient zack esp henry schein have earning esp most accurate estimate be cent zack consensus estimate be lower cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank henry schein currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination henry schein zack rank esp make reasonably confident earning beat henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quotefactor playhenry schein second quarter result be quite impressive record growth segment dental animal health medical technology value add service geographically company gain traction north america overseas expect similar trend third quarter well company strategy expand digital dentistry globally be also encourage be also upbeat management expectation witness least low single digit growth north america dental consumable merchandise market second half zack consensus estimate third quarter total revenue reflect increase year quarter company be currently banking digital dentistry be part strategic plan henry schein be busy promote digital workflow general dentistry well dental specialty begin sep company start selling full range dentsply sirona dental equipment north america include lead cerec cad cam restoration system be expect boost top line extent notably second quarter henry schein animal health open new national distribution service center ndsc columbus brookhollow neighborhood have help company operate complete solution provider veterinary practice country expect boost top line yet be report quarter flip side henry schein disappointing gross operate margin past few quarters due higher cost sale expense be matter concern apart currency fluctuation tough competitive landscape add wo also entry group purchasing organization gpos unite state have intensified competition overall henry schein expect ep range reflect growth ep figure stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
244,TMO,penumbra inc pen free report be expect report third quarter fiscal result nov company deliver positive earning surprise trail quarters let see thing be shape announcement catalystsover past few quarters penumbra showcased strong top line performance consistent growth neuro peripheral vascular arm company be presently focuse drive innovation product development geographic expansion be expect help penumbra maintain bullish growth trend be report quarter be be note neuro growth be mainly drive sale penumbra system ischemic stroke company witness increase sequential growth higher procedural volume however company expect see seasonality neuro business third quarter also peripheral vascular growth be drive indigo family peripheral thrombectomy coil portfolio peripheral embolization zack consensus estimate neuro revenue reflect increase year quarter zack consensus estimate peripheral vascular revenue show rise year earlier quarter penumbra inc price ep surprise penumbra inc price ep surprise penumbra inc quote overall fiscal third quarter total revenue be project prior year quarter here be other factor influence penumbra third quarter result penumbra have be deliver strong performance domestic international market back solid contribution neuro business expect trend continue yet be report quarter second quarter gross margin deteriorate operate expense increase accord company increase compensation expense related growth headcount higher clinical trial expense result operate loss quarter expect escalate cost expense continue keep margin pressure third quarter meanwhile research development expense increase second quarter company remain focuse product launch expect expense remain high third quarter further foreign exchange fluctuation stiff competition major commercial laboratory hospital continue raise caution overall company expect revenue decline sequentially third quarter owing seasonality summer company expect report revenue band here be quantitative model predict penumbra have right combination main ingredient positive earning esp favorable zack rank strong buy buy hold increase odd earning beat see complete list today zack rank stock here zack esp earning esp penumbra be uncover best stock buy sell re report earning esp filter zack rank penumbra zack rank increase predictive power esp however zack consensus estimate loss cent be wider loss cent report year quarter stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank buy see complete list today zack rank strong buy stock here thermo fisher scientific inc tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
245,TMO,expect idexx laboratory inc idxx free report beat expectation report third quarter result oct open bell last quarter company deliver positive earning surprise be worth note idexx have outperformed zack consensus estimate precede quarters average let take look thing be shape prior announcement key catalystsimilar prior quarter idexx be expect gain strong global growth companion animal group cag diagnostic recur revenue growth cag diagnostic be lead double digit organic revenue gain consumable reference lab rapid assay revenue well continue expansion idexx premium instrument install base be upbeat year year rise uptake snap pro unit north america last quarter management expect solid performance continue be report quarter well zack consensus estimate cag diagnostic revenue reflect increase year quarter here be other factor influence idexx third quarter result idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quoteidexx expect livestock poultry dairy lpd business witness flat modest growth second half segment have be see continue strength china also expansion recur pregnancy testing franchise buoy optimism zack consensus estimate lpd business third quarter reflect increase year quarter company continue expand globally have be significantly benefitting bountiful opportunity companion animal market emerge nation further management consistent share buyback reflect strong free cash flow reserve believe outcome endeavor be reflect company third quarter performance encourage factor idexx expect revenue range reflect organic revenue growth expectation zack consensus estimate third quarter total revenue be project prior year also estimate ep guidance band share support continue operate margin expansion align long term goal outlook represent ep growth report basis zack consensus estimate earning reflect increase year quarter moreover management be upbeat rise sale force market other area third quarter flip side foreign currency fluctuation be major headwind concern company be high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also company be expose higher operate expense pertain increase head count higher investment target portfolio development geographic expansion unite state internationally also competitive landscape domestic overseas market weigh idexx performance struggle gain market traction prove be drag third quarter result here be quantitative model predict idexx do not have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp idexx be uncover best stock buy sell re report earning esp filter zack rank idexx carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank buy see complete list today zack rank strong buy stock here thermo fisher scientific inc tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
246,TMO,expect align technology inc algn free report beat expectation report third quarter earning oct market close last quarter company post positive earning surprise align technology have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement likely positive surprise proven model show align technology be likely beat earning have perfect combination key ingredient zack esp align technology have earning esp most accurate estimate be cent zack consensus estimate be peg cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank align technology currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination align technology zack rank esp make reasonably confident earning beat align technology inc price ep surprise align technology inc price ep surprise align technology inc quotewhat drive better expect earning be upbeat align technology strategic initiative international expansion ensure invisalign treatment grow base patient also be upbeat international case grow year year last report quarter reflect grow demand quarter company reach new benchmark patient have adopt invisalign treatment management anticipate consistent growth asia pacific region bid grow region company open new invisalign treatment plan facility china be upbeat management expectation continue strong performance international market be report quarter invisalign volume be likely grow sequentially reflect continue strong growth apac however summer holiday emea partially mar performance notably expand invisalign brand align technology introduce patient friendly solution invisalign mandibular advancement teen certain market canada emea apac march accord company advancement help offer more option treatment boost top line yet be report quarter company announce receipt patent align technology smarttrack aligner material be exclusively used invisalign aligner treatment recently company expand work flow option lead itero scanner context align technology recently sign distribution agreement patterson dental business unit patterson company inc pdco free report exclusive agreement effective september align technology itero element intraoral scanning system be available part patterson dental cad cam portfolio unite state canada latest development boost itero scanner customer base start third quarter moreover company see increase adoption itero scanner invisalign case submission instead pvs impression especially north america thereby drive invisalign utilization management expect bullish trend continue yet be report quarter notably third quarter company project ep cent revenue company also expect invisalign case shipment band same period year flip side unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion portfolio expansion other stock considerhere be few other medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
247,TMO,thermo fisher scientific inc tmo free report base medical instrument manufacturer be expect beat expectation report second quarter result jul market open last quarter company post earning share surpass zack consensus estimate fact thermo fisher earning outpaced zack consensus estimate past quarters average beat let see thing be shape prior announcement thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc quotewhy likely positive surprise proven model show thermo fisher be likely beat earning have right combination key ingredient zack esp earning esp represent difference most accurate estimate zack consensus estimate be be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank thermo fisher currently carry zack rank buy note stock zack rank have significantly higher chance beating estimate sell rate stock never be consider go earning announcement combination thermo fisher favorable zack rank positive esp make confident look earning beat time be drive better expect earning company focus boost growth implementation strategy strengthen product offering be encourage initiative be likely help post solid result first quarter company have already spend research development same trend be expect year too recently introduce noteworthy product include new icap triple quad mass spec system clinical research pharma quality assurance quality control mass spectrometry chromotography platform cloud base application connect electronic pipette individual user laboratory laboratory product assay microarray base solution detect genomic variation associate inherited disease genetic science also introduce new target assay cancer research run ion torrent next generation sequence instrument new test autoimmune disease drug abuse new clariom pico assay more effective biomarker discovery notably last month fda have grant premarket approval company oncomine dx target test expect innovation product launch significantly contribute company top line second quarter company aim expand capability fast grow asia pacific zone well emerge market also lead impressive result standout contributor recent time be china india south korea strategic investment support key customer application thermo fisher hope maintain bullish momentum rest growth be likely be see apply market such environmental food safety apart life science apart company be currently bet key focus area enormous opportunity be advance precision medicine mass spectrometry target gene sequence structural biology acquisition fei have already start generate synergy largely contribute company analytical instrument portfolio last quarter be also highlight quarter be report thermo fisher anticipate realize total synergy approximately end year follow deal closure cost synergy roughly adjust operate income benefit revenue related synergy get reflect second quarter performance however be apprehensive thermo fisher cite foreign exchange headwind tune revenue impact cent adjust ep also unfavorable macroeconomic condition continue weigh heavily thermo fisher stock stiff competition continue threat stock value stock considerhere be company consider model show have right combination element come earning beat upcoming quarter dextera surgical inc have earning esp zack rank see complete list today zack rank strong buy stock here teleflex incorporate tfx free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
248,TMO,waltham base thermo fisher scientific inc tmo free report be scientific instrument maker world leader serve science company be healthy growth trajectory late andha rally past month ahead gain stock have market cap company have also considerably outperformed zack categorize medical product sub industry gain notably zack rank buy company estimate revision trend current year be favorable last day estimate have moved revision opposite direction magnitude estimate revision increase share company deliver quarter positive average earning surprise earning surprise last report first quarter strong growth prospect thermo fisher be attractive pick present growth catalyststhermo fisher continuous effort drive growth inorganically acquisition activity have be generate lot enthusiasm investor company have announce agreement acquire netherlands base patheon global provider high quality drug solution pharmaceutical biopharma sector thermo fisher expect derive lot synergy buyout help expand biopharma offering europe combination be anticipate strengthen thermo fisher foothold pharmaceutical biotech market add highly complementary service portfolio also acquisition fei have already start generate synergy contribute largely company analytical instrument portfolio have turn boost market optimism stock market be also upbeat company focus gain traction high potential emerge geography china thermo fisher have be deliver solid result market biopharma healthcare environment order meet rise demand clinical trial south korea company recently launch biopharma service unit significantly thermo fisher be continuously work cash opportunity biopharma healthcare food safety market india other key picksother top rank medical stock be mesa laboratory inc mlab free report edward lifescience corp ew free report align technology inc algn free report mesa laboratory edward lifescience sport zack rank strong buy align technology carry zack rank see complete list today zack rank stock here mesa laboratory deliver positive earning surprise last quarters stock add roughly last month edward lifescience have long term expect earning growth rate stock surge last month align technology have expect long term adjust earning growth almost stock jump nearly last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
249,TMO,abbott laboratory free report be schedule report second quarter result open bell jul last quarter company earning exceed zack consensus estimate remarkably also company post average beat trail quarters let sneak peek thing be shape prior announcement factor playabbott have be healthy growth trajectory establish pharmaceutical division epd business deliver encourage operational sale growth trail few quarters major part growth be stimulate series strategic action include sale abbott develop market business acquisition cfr pharmaceutical latin america veropharm russia however absence substantial advancement division recent past have compel company maintain low expectation high single digit growth yet be report quarter abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quoteon positive note strong market position several geography include china latin america several market southeast asia epd be well position sustain market growth largest fastest grow pharmaceutical market world abbott initiate implementation operational model epd space first quarter plan model company focus selling highly diversify line product core therapeutic area treat local health condition turn allow company widen customer base create unique relationship physician retailer pharmacy also abbott plan strengthen developmental capability expand epd innovation center india have be slew development medical device well market be upbeat abbott freestyle libre flash glucose monitoring system prospect post receipt full partial reimbursement french health ministry platform company also announce health canada license freestyle libre jun notably development be expect drive company traction diabetes care segment see sale growth last report quarter continue consumer acceptance freestyle libre internationally apart market be bullish abbott confirm rx insertable cardiac monitor receive ce mark post approval product have see strong consumer acceptance implant take place country europe company announce ce mark tacticath contact force ablation catheter be key positive continue trend extensive research new product developmet company launch science base nutrition drink better recovery surgery ensure surgery immunonutrition shake ensurepre surgery clear nutrition drink apr be also bullish ongoing synergy acquisition st jude medical jan comprehensive combine portfolio be quite promising notably abbott project annual pre tax synergy include revenue expansion opportunity well operational sg efficiency overall second quarter company forecast adjust earning share cent cent comparable operational sale growth quarter be project low mid single digit earning whispersour proven model do not conclusively show abbott be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp abbott be most accurate estimate zack consensus estimate be cent uncover best stock buy sell re report earning esp filter zack rank abbott have zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here dextera surgical inc have earning esp zack rank telefex incorporate tfx free report have earning esp zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
250,TMO,pacific bioscience california inc pacb free report recently form alliance genomic datum drive medicine company bluebee develop advanced assembly pipeline integrate company technology combine solution be introduce american society human genetic ashg annual meeting be hold next week orlando fl announcement menlo park base pacific bioscience assembly pipeline now be integrate bluebee genomic analysis platform integration offer simplified fully automate end end datum analysis solution allow assembly genome size include human variety also include guarantee turn time enable better plan improve productivity grow demand single molecule real time smrt sequence genomic community company expect huge customer adoption new cloud base analysis option pacific bioscience end end solution integrate downstream datum analysis bluebee high security regulatory compliant compute center pacific bioscience global customer notably smrt sequence provide complete accurate picture genome courtesy superior performance sequence accuracy uniformity coverage extremely long read length ability characterize dna base modification be perfect tool investigate high sequence genetic complexity otherwise difficult resolve used short read technology industry prospect significantly prospect long read sequence market pacific bioscience be lead name be grow leap bound recent report decisive bio insight next generation sequence ngs manufacturer market size reach grow annum rate touch primarily drive adoption worldwide clinical customer believe pacific bioscience slew latest development be well time industry price performance past month stock have surge more compare favorably broader industry gain roughly zack rank key pickspacific bioscience currently carry zack rank hold few better rank stock medical sector be abbott free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report stock carry zack rank buy see complete list today zack rank stock here abbott have long term expect earning growth rate stock have rally roughly last month thermo fisher have long term expect earning growth rate stock have gain last year idexx laboratory have long term expect earning growth rate stock have surge last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
251,TMO,qiagen qgen free report have be hog limelight recent partnership co marketing agreement centogene ag partnership aim deliver complete sample insight research clinical testing solution end user field rare genetic condition collaboration agreement qiagen integrate bioinformatic suite centogene highly develop centomd rare disease variant database goal improvise test understand notably integration centomd phenotype genotype database be expect considerably enhance qiagen knowledge base qiagen clinical insight qci bioinformatic solution co marketing agreement qiagen now act authorize exclusive international commercial distribution partner centomd also qiagen bioinformatic solution be license centogene support latter extensive rare disease diagnostic testing service bid grow bioinformatic portfolio offer valuable observation complex biological datum qiagen announce acquisition omicsoft corporation january acquisition qiagen gain access omicsoft powerful multus omic datum management infrastructure solution well omic datum bank believe company latest partnership centogene be strategic take consideration huge prospect bioinformatic globally accord market market report global bioinformatic market be project reach worth cagr believe increase spending healthcare government private organization rise awareness trigger need nucleic acid protein sequence technological innovation development back successful partnership company research institutes continue drive growth bioinformatic market thus latest development help qiagen cash bountiful opportunity niche market share price have be gain investor confidence consistently encourage result last month company share price have outperformed broader industry stock have gain compare broader industry gain company have also surpass gain market same time frame zack rank other key picksqiagen currently carry zack rank buy other top rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
252,TMO,oct issue update research report illumina inc ilmn free report stock currently carry zack rank hold last month san diego base company provide tool integrate system analysis genetic variation function have be trading broader industry stock have gain period higher broader industry gain past few quarters company have deliver promising top line performance primarily banking strong product launch latest list include launch veriseq nipt solution europe also overall strong uptake novaseq be encourage moreover rate nipt adoption be rise outside unite state be also upbeat illumina partnership telegraph hill partner set independent company verogen inc independent company be expect boost illumina next generation sequence ngs business forensic genomic market have global commercial right product illumina be only provider miseq fgx forensic genomic system include miseq fgx sequencer forenseq dna signature prep kit forenseq universal analysis software be encourage development clinical market demand customer undergo oncology test remain robust moreover investor be await response extend ra panel be slate launch third quarter june company announce receipt fda approval extend ra companion diagnostic kit class iii pma be also look forward grail illumina own develop company focuse cancer screening market flip side weak margin due novaseq launch higher array service revenue product mix sequence consumable continue raise concern also national institutes health nih funding issue tough competitive landscape be few challenge deal key picksa few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report zack rank buy see complete list today zack strong buy rank stock here abbott have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
253,TMO,oct issue update research report lead medical device company boston scientific corporation bsx free report past month boston scientific have be trading broader industry stock have improve compare broader industry gain period recent upside worth mention be company acquisition symetis bid fortify european structural heart business be also encourage company secure multiple product approval domestic well overseas market notably company receive fda approval resonate family icd crt system additionally market hold optimism stock follow company recent release outline sustain growth strategy focuse plan expansion new market consolidate product line business segment company particularly plan launch product high growth adjacent market strong potential reap incremental market opportunity boston scientific corporation price consensus boston scientific corporation price consensus boston scientific corporation quotewhile adverse foreign exchange continue challenge be concern company recall prime product lotus range heart device be important note last quarter foreign exchange headwind affected company top line adjust gross margin basis point also dull defibrillator sale core cardiac rhythm management crm continue remain drag overall growth wo challenge economy competitive landscape persistently burden stock however give company bullish second quarter result several recent development find quite few positive factor rely company be leave stone unturned reinforce core business invest more global market zack rank key picksboston scientific carry zack rank hold few better rank stock medical sector be orthofix international ofix free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report orthofix international sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month thermo fisher have long term expect earning growth rate stock have gain last year idexx laboratory have long term expect earning growth rate stock have surge last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
254,TMO,major setback company investor medtronic mdt free report recently foresee significant impact hurricane marium second quarter fiscal sale have acquire category status hurricane marium have be place top most intense atlantic hurricane record thus hit company business puerto rico quite hard add wo company have level manufacturing setup business group viz cardiac vascular group cvg minimally invasive therapy group mitg restorative therapy group rtg diabetes group puerto rico facility be gradually get operative oct site be only partially active present power supply back generator considerable repair do company expect normal manufacturing process get fully restore come week financial have provide statement company financial health badly hurt marium further affect overall business notably line business continuity protocol company be utilize exist inventory level increase manufacturing process location outside puerto rico multiple product medtronic project fiscal second quarter revenue adjust net earning show impact extent more specifically mitg rtg group be expect be worst hit notably quarter close oct significantly company forecast recur expense directly related recovery effort puerto rico be exclude adjust earning however expense related effect outside puerto rico be consider operate expense incidentally medtronic be lack enough visibility impact marium post second quarter however forecasting strong new product demand particularly cvg diabetes group company continue expect mid single digit revenue growth comparable constant currency basis second half fiscal marium related impact company reaffirm fiscal second quarter full year fiscal guidance company many support disaster management medtronic foundation have direct disaster relief date be match employee contribution authorize agency price performance last month medtronic have be observed underperform broader industry stock have decline versus broader industry gain period sad true gloomy scenario be likely continue company latest financial prediction due marium zack rank key picksmedtronic currently carry zack rank sell few better rank stock medical sector be orthofix international ofix free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report orthofix international sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month thermo fisher have long term expect earning growth rate stock have gain last year idexx laboratory have long term expect earning growth rate stock have surge last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
255,TMO,expand tissue technology portfolio integra lifescience holding corporation iart free report recently announce launch collagen matrix revize revize plastic reconstructive surgery available solid mesh configuration revize revize collagen matrix be derive fetal bovine dermis contain high level type iii collagen company revize revize aid implant strengthen weak soft tissue surgical repair damage rupture soft tissue membrane solidify footprint plastic reconstructive surgery global medical technology company recently announce launch collagen matrix surgimend prs mesh feature meshing pattern parallel release integra announce launch surgimend prs mesh pre sub pectoral breast reconstruction europe company launch surgimend mp collagen matrix complex abdominal hernia repair feature highly macroporous design enable fluid drainage same month company announce european launch dermal regeneration template single layer thin dermal repair defect reconstruction step procedure interestingly company orthopedic tissue technology segment account company total revenue last report quarter latest launch be expect boost segment scontribution integra effort grow plastic reconstructive surgery market seem be strategic technavio datum publish business wire report global plastic surgery product market be expect reach value cagr believe grow consciousness appearance individual increase awareness rise expenditure healthcare technological advancement be likely drive demand cosmetic surgery thus latest launch help integra cash opportunity niche market share price performancein last month integra have be consistently trading broader industry date stock have rally higher gain broader industry zack rank key picksintegra currently carry zack rank hold few better rank stock medical sector be orthofix international ofix free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report orthofix international sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
256,TMO,thermo fisher scientific inc tmo free report report better expect performance second quarter adjust ep come beating zack consensus estimate year quarter figure report basis second quarter ep marked year year rise revenue quarter come year year sale also exceed zack consensus estimate quarter detailorganic revenue second quarter grow year year back acquisition total revenue grow offset currency translation thermo fisher currently operate business segment life science solution analytical instrument specialty diagnostic laboratory product service revenue life science solution segment improve year year analytical instrument segment sale grow reflect acquisition fei company revenue laboratory product service segment grow specialty diagnostic segment record increase thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc quotegross margin second quarter be basis point bps year year rise gross profit adjust operate margin expand approximately bps rise selling general administrative expense increase research development expense company exit second quarter cash cash equivalent compare end previous quarter year date net cash provide operate activity be compare year period guidance raisedbacked solid second quarter performance less adverse foreign exchange environment forecast thermo fisher raise full year financial guidance revenue guidance have be raise range growth previous year earlier band current zack consensus estimate be close low end guide range company have also raise adjust ep guidance range reflect growth previous year earlier prediction be zack consensus estimate share be also low end band patheon acquisition dealin parallel announcement company inform enter definitive agreement acquire patheon thereby pave way contract development manufacturing organization cdmo market total transaction value be estimate be roughly include assumption approximately net debt apart strengthen offering management deal be also expect be immediately considerably accretive thermo fisher adjust ep first full year close bottom linethermo fisher end second quarter promising note adjust earning revenue beating zack consensus estimate be encourage company series product launch major progress precision medicine initiative thermo fisher acquisition fei company have already start boost analytical instrument portfolio company also open center excellence electron microscopy saudi arabia management be upbeat company gain entry cdmo market agreement acquire patheon raise guidance be more encourage indicate fact overall bullish trend continue zack rank other key pickscurrently thermo fisher carry zack rank buy other top rank stock worth consider broader medical sector be petm express inc pet free report becton dickinson company bdx free report quest diagnostic inc dgx free report notably petm sport zack rank strong buy becton dickinson company quest diagnostic carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have gain last month becton dickinson company have long term expect earning growth rate stock have gain last month quest diagnostic have long term expect earning growth rate stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
257,TMO,involved scientific research then have hear base thermo fisher scientific inc tmo free report lead scientific instrument manufacturer world interestingly acquisition friendly company latest buy life technology be expect give birth unrivaled market leader serve research specialty diagnostic apply market currently thermo fisher have zack rank buy change follow promising second quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning current zack consensus estimate be peg share thermo fisher adjust earning share year year report quarter beat estimate revenue thermo fisher post second quarter revenue have also surpass zack consensus estimate revenue key stat business segment report quarter thermo fisher deliver revenue life science solution analytical instrument specialty diagnostic laboratory product service respectively however full year basis segment have see increase year year major factor management seem upbeat impressive secondquarter result company deliver robust performance top bottom line back successful execution growth strategy plan thermo fisher be currently work innovation launch new product laboratory market company also make major progress precision medicine initiative thermo fisher also open center excellence electron microscopy saudi arabia company gain entry contract development manufacturing organization cdmo market announce agreement acquire patheon check back later full thermo fisher earning report later hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
258,TMO,henry schein inc hsic free report be expect report second quarter result aug last quarter renown healthcare product service distributor deliver positive earning surprise encouragingly henry schein earning surpass zack consensus estimate past quarters average let see thing be shape prior announcement factor playhenry schein first quarter result be quite impressive record growth segment dental animal health medical technology value add service geographically company gain traction north america overseas market expect similar trend second quarter well henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quotenotably be report second quarter henry schein animal health open new national distribution service center ndsc columbus brookhollow neighbourhood have enabled company be complete solution provider veterinary practice country expect boost top line yet be report quarter company strategy expand digital dentistry globally be also encourage regard note management expect least mid single digit growth north america dental equipment market second quarter company be currently banking digital dentistry be part strategic plan henry schein be thus busy promote digital workflow general dentistry well dental specialty flip side henry schein year year deterioration gross operate margin past few quarters due higher cost sale expense be matter concern meanwhile management solid sale second quarter be likely be partially offset timing good friday year notably international holiday have fall second quarter year compare last year timing be first quarter apart currency fluctuation tough competitive landscape add wo also advent group purchasing organization gpos add competitiveness market overall company reaffirm ep guidance reflect growth year period second quarter have be change estimate revision last day same have be observed magnitude estimate revision earning estimate remain same time frame earning whispersour proven model do not conclusively show earning beat henry schein quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp henry schein have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank henry schein zack rank increase predictive power esp however company esp make surprise prediction difficult meanwhile caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
259,TMO,investor be always look stock be poise beat earning season thermo fisher scientific inc tmo free report be such company firm have earning come pretty soon event be shape quite nicely report be thermo fisher scientific inc be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface tmo report fact most accurate estimate current quarter be currently share tmo compare broader zack consensus estimate share suggest analyst have very recently bump estimate tmo give stock zack earning esp head earning season thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give tmo have zack rank buy esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead thermo fisher scientific inc beat be card upcoming report more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
260,TMO,rise yield have somewhat dull appeal dividend investing stock consistently pay higher dividend be still vogue dividend growth focusstock have strong history dividend growth generally act hedge economic political uncertainty mature company be less susceptible large swing market simultaneously offer downside protection consistent increase payout stock have superior fundamental opposed traditional dividend counterpart such sustainable business model long track record profitability rise cash flow good liquidity strong balance sheet value characteristic have history outperformance long term not necessarily high dividend yield make dividend growth quality promising investment metric long term further history strong dividend growth indicate dividend increase future be likely make portfolio healthy safe stock have long history outperformance compare broader stock market other dividend pay stock do not necessarily mean have highest yield result pick dividend growth stock appear winning strategy other parameter be also include year historical dividend growth greater select stock solid dividend growth history year historical sale growth greater represent stock strong record grow revenue year historical ep growth greater represent stock solid earning growth history next year ep growth rate greater represent rate company earning be expect grow improve earning help company sustain dividend payment price cash flow less industry ratio less industry indicate stock be undervalue industry investor need pay less better cash flow generate company week price change greater market weight ensure stock appreciate more past year top zack rank stock have zack rank strong buy buy generally outperform peer type market environment vgm style score better be simply weight combination value growth momentum combine zack rank offer best upside potential here be stock fit bill owen corning inc oc free report ohio base company be world leader build material system composite solution stock deliver average positive earning surprise past quarters company witness earning estimate revision past day year have expect earning growth rate have vgm style score sport zack rank see complete list today zack rank stock herethermo fisher scientific inc tmo free report massachusett base company be provider analytical instrument equipment reagent consumable software service research manufacturing analysis discovery diagnostic worldwide see positive earning estimate revision cent year past day expect growth rate thermo fisher have zack rank vgm style score huntington ingall industry inc hii free report virginia base company be engage design build overhaul repair ship primarily navy coast guard company see positive earning estimate revision cent past day year have expect earning growth rate have zack rank vgm style score royal caribbean cruise ltd rcl free report florida base company be global cruise vacation company operate royal caribbean international celebrity cruise royal celebrity tour have see positive earning estimate revision penny year past day expect earning growth rate stock have zack rank vgm style score mks instrument inc mksi free report massachusett base company be lead worldwide developer manufacturer supplier instrument component subsystem used measure control analyze gase semiconductor manufacturing similar industrial manufacturing process company have see solid earning estimate revision cent past day year have expect earning growth rate have zack rank vgm style score get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
261,TMO,co base davita healthcare partner inc dva free report lead provider dialysis service patient suffering chronic kidney failure be expect report second quarter fiscal result aug market close last quarter company deliver earning cent share miss zack consensus estimate cent last quarters company witness average earning beat let see thing be shape prior quarter factor playdavita kidney care business be expect perform well quarter review due continuous investment capital efficient technology steady overseas expansion strategic alliance acquisition dialysis center have play key role boost davita growth believe davita constant effort upgrade quality service global expansion active acquisition be key positive operate cash flow be expect remain strong quarter due improve performance kidney care business capitated care business overall management project davita operate income fiscal range company expect operate income kidney care business operate cash flow projection fiscal be expect flipside escalate expense be concern management expect significant decrease operational income especially pharmacy business fiscal davita expect hike dialysis related lab service quarter indicate probability increase general administrative expense company plan improve information technology infrastructure support certain regulatory compliance legal matter be likely drive expense quarter furthermore uncertainty associate possibility repeal affordable care act president trump add company concern come estimate revision zack consensus estimate current quarter earning have be stable cent share last month davita healthcare partner inc price ep surprise davita healthcare partner inc price ep surprise davita healthcare partner inc quoteearning solid prospect quantitative model doesn conclusively point earning beat quarter stock be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp davita be be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank davita carry zack rank sell please note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considerhere be company want consider proven model show have right combination element post earning beat quarter thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here dextera surgical inc have earning esp zack rank telefex inc tfx free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
262,TMO,sep market broadest benchmark home crucial mark relatively quiet session trading be second successive record close feat match other primary gauge market performance course cautious optimism wariness term pullback continue linger however analyst independent broker lpl financial believe month streak win be track mop further profit month further index have nearly always gain year period immediately follow winning streak make imperative pick stock have mop strong gain period third strongest bull run gain sep end only marginally short mark march index have gain stunning eclipse increase record bull run extend increase make current bull run third strongest ever record insight be reveal datum bloomberg dow jone index extent increase raise selloff fear investor such alarm be unwarranted be stretch gain lose luster consider annualize return measure come only fourth poorest consider such period reason such dismal show be not difficult course half year be second longest bull run time month stretch gain power future march lose have now gain straight month row fact index have now gain month last take total return account include impact dividend index have increase single month october even large swathe investor worry pricey valuation long streak gain serve ease fear analyst lpl financial have state such month stretch gain be usually follow year year increase nearly time average increase record period stand have gain successive month period stretch march july last year july index gain consider shorter time frame also increase month follow such winning streak opine lpl financial company datum such gain have occur time past month immediately month winning stretch index have increase average level incidentally have already gain now month linger mark market naysayer be already raise specter pullback however long term trend show month winning streak be usually follow strong year year gain further such stretch increase usually lead gain month immediately follow such period pick stock have notch strong gain period make profitable option however pick winning stock be difficult be vgm score come here stand value growth momentum score be weight combination score such score allow eliminate negative aspect stock select winner however be important keep mind style score carry different weight arrive vgm score have narrow search follow stock base good zack rank vgm score boee company ba free report be premier jet aircraft manufacturer largest defense contractor unite state boee have zack rank buy vgm score company have expect earning growth current year earning estimate current year have improve last day stock have gain last week caterpillar inc cat free report be world lead manufacturer construction mining equipment diesel natural gas engine industrial gas turbine caterpillar have vgm score company have expect earning growth current year earning estimate current year have improve last day stock have gain last week stock have zack rank strong buy see complete list today zack rank stock here estee lauder company inc el free report be world lead manufacturer marketer skin care makeup fragrance hair care product estee lauder have zack rank vgm score company have expect earning growth current year earning estimate current year have improve last day stock have gain last week total system service inc tss free report provide electronic payment process merchant service related service financial financial institution unite state internationally total system service have zack rank vgm score company have expect earning growth current year earning estimate current year have improve last day stock have gain last week thermo fisher scientific inc tmo free report be scientific instrument maker world leader serve science thermo fisher scientific have zack rank vgm score company have expect earning growth current year earning estimate current year have improve last day stock have gain last week trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
263,TMO,underlie strength earning growth prospect make thermo fisher scientific inc tmo free report solid bet now factor drive stock higher include impressive organic growth well growth acquisition solid balance sheet position company have impressive earning surprise history have surpass zack consensus estimate trail quarters average have also be successful gain analyst confidence analyst revise current year earning estimate upward past day estimate rise share justify stock zack rank buy share thermo fisher have gain past month compare industry gain act favor stock revenue strength company have be witness consistent improvement revenue last year total revenue see cagr project revenue growth rate be peg compare industry average steady addition capacity company have be steadily add capacity enhance exist one acquisition regard acquisition fei have already start generate synergy contribute largely company analytical instrument portfolio have turn boost market optimism stock moreover be look forward company latest patheon buyout thermo fisher forayed high potential contract development manufacturing organization cdmo space solid prospect high potential emerge market massachusett base medical instrument manufacturer plan continue strengthen foothold emerge market such china india translate success other high priority opportunity region such south korea russia brazil second quarter company record solid contribution china india middle east be also upbeat company recently open center excellence electron microscopy saudi arabia earning share growth thermo fisher have record earning growth rate last year compare index further earning momentum be likely continue long term year reflect company project earning share growth rate compare index superior return equity thermo fisher have return equity compare industry average indicate company be efficient utilize shareholder fund strong cash position thermo fisher exit last report second quarter cash cash equivalent moreover company record year date net cash operate activity believe company strong cash balance enable carry strategy inorganic expansion effective capital deployment company have be actively return capital shareholder regard last report second quarter company complete worth share buyback paid dividend aug company have available future repurchase exist share repurchase policy raise guidance buoy optimism backed solid second quarter performance less adverse foreign exchange environment forecast thermo fisher raise full year guidance raise guidance be suggestive brighter prospect other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
264,TMO,varian medical system inc var free report be schedule report third quarter fiscal earning jul market close last quarter company report earning cent share beat zack consensus estimate penny however adjust earning decline year year basis factor playwe be particularly upbeat varian oncology business account company total revenue second quarter notably company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space third quarter fiscal varian expect adjust earning share range cent cent revenue be expect increase year year basis further strengthen foothold oncology business company launch fda approve product halcyon also june company sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient regard note varian medical recently receive shonin approval japan market probeam system proton therapy varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc apart varian medical recently enter international agreement concern proton therapy platform bangkok base king chulalongkorn memorial hospital have select probeam compact single room proton therapy system cancer treatment thailand delray medical center florida believe western europe china africa present significant top line growth opportunity term company be open new office africa middle east show be aware opportunity region moreover varian strong product pipeline be key catalyst nevertheless increase local competition be primary headwind unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase investment target growth acceleration geographical expansion portfolio expansion earning whispersour proven model do not conclusively show earning beat varian medical quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp however company esp make surprise prediction difficult please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
265,TMO,thermo fisher scientific inc tmo free report recently complete buyout patheon notably patheon be lead contract development manufacturing organization cdmo serve pharmaceutical biotechnology sector close deal patheon be part thermo fisher laboratory product service segment thermo fisher initial tender offer patheon expire close deal share cash patheon generate approximately revenue fiscal thermo fisher collaboration significantly strengthen unique value proposition pharmaceutical biotech customer add highly complementary service thermo fisher revenue laboratory product service segment account total revenue grow second quarter company be make consistent effort drive revenue growth segment management expect realize total synergy approximately year follow close acquisition consist approximately cost synergy adjust operate income benefit revenue related synergy accord report market market global laboratory equipment service market be estimate reach cagr look bountiful opportunity niche space believe development be strategic fit be upbeat other takeover thermo fisher recent time regard note thermo fisher buyout fei company close late have help thermo fisher access fei industry lead high performance electron microscopy platform used protein study facilitate life science research company latest takeover affymetrix also deserve mention here genetic analysis affymetrix technology perfectly complement thermo fisher product target clinical apply market also take consideration other strategic purchase thermo fisher finesse solution alfa aesar advanced scientific lambda doe ingall past month thermo fisher have be trading broader industry last trading price stock have gain better broader market decline period zack rank key picksthermo fisher carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
266,TMO,follow strong revenue performance second quarter luminex corporation lmnx free report announce plan collaborate sutter health bolster molecular diagnostic testing portfolio collaboration be expect enhance company patient care technique especially case cystic fibrosis illness respiratory tract infection meanwhile share luminex have inched follow news release however last month stock have lose almost much wider broader industry decline only term deal sutter health be leverage luminex molecular diagnostic system include xtag cystic fibrosis ary hsv verigene respiratory pathogen flex panel panel reduce diagnosis time patient help eliminate unnecessary procedure molecular testing portfolio get latest development be significant addition luminex molecular testing diagnostic portfolio company have broad product portfolio comprise advanced ary system verigene xmap xtag multicode technology more molecular diagnostic group revenue jump year year basis second quarter solid performance be drive growth automate solution verigene ary platform furthermore segment get additional momentum recently negotiate group purchasing organization agreement be add ary platform exist verigene agreement be establish new agreement company also have large install instrument base luminex lx luminex lx flexmap system magpix technology company have accelerate market acceptance xmap technology development marketing distribution partnership lead company life science market favorable global trendsreport suggest molecular diagnostic market be expect witness stellar growth long haul frost sullivan niche space be currently see cagr compound annual growth rate be estimate reach worth believe collaborative agreement expand luminex customer base bolster foothold niche space meanwhile thermo fisher scientific inc tmo free report be lead player molecular diagnostic space initiative strengthen company laboratory product service revenue segment thermo fisher recently acquire patheon lead contract development manufacturing organization favorable estimate revision company recent earning estimate have be robust current year have see estimate go higher past day next year estimate have see same time period have have significant impact consensus estimate current year consensus have rise past month next year estimate have increase owing favorable estimate revision luminex sport zack rank strong buy signify probability outperformance term other collaborative agreement glanceapart latest deal sutter health luminex have collaborative agreement several company help expand use product technology regard note luminex have earlier announce signing new supply distribution agreement bio techne corp tech luminex also enter similar deal affymetrix affx term agreement ebioscience business division affymetrix commercialize magpix luminex flexmap multiplexed assay platform select country americas asia europe key pickanother top rank stock broader medical sector be edward lifescience corp ew free report notably company sport zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate represent impressive year date return surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
267,TMO,month have go last earning report thermo fisher scientific inc tmo free report share have gain past month recent positive trend continue lead stock next earning release be due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver recent earningsthermo fisher report better expect performance second quarter adjust ep come beating zack consensus estimate year quarter figure report basis second quarter ep marked year year rise revenue quarter come year year sale also exceed zack consensus estimate quarter detailorganic revenue second quarter grow year year back acquisition total revenue grow offset currency translation thermo fisher currently operate business segment life science solution analytical instrument specialty diagnostic laboratory product service revenue life science solution segment improve year year analytical instrument segment sale grow reflect acquisition fei company revenue laboratory product service segment grow specialty diagnostic segment record increase gross margin second quarter be basis point bps year year rise gross profit adjust operate margin expand approximately bps rise selling general administrative expense increase research development expense company exit second quarter cash cash equivalent compare end previous quarter year date net cash provide operate activity be compare year period guidance raisedbacked solid second quarter performance less adverse foreign exchange environment forecast thermo fisher raise full year financial guidance revenue guidance have be raise range growth previous year earlier band current zack consensus estimate be close low end guide range company have also raise adjust ep guidance range reflect growth previous year earlier prediction be zack consensus estimate share be also low end band have estimate be move then turn fresh estimate have trend upward past month have be revision higher current quarter thermo fisher scientific inc price consensus thermo fisher scientific inc price consensus thermo fisher scientific inc quotevgm scoresat time thermo fisher stock have average growth score be do bit better momentum front stock be allocate also grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable momentum investor value growth investor stock have zack rank hold be expect inline return stock next few month
